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AMBIC ammonium bicarbonate 
Ang angiopoietins
APS ammonium persulfate 
BM basement membrane 
bp base pair 
BSA albumin from bovine serum 
CD circular dichroism
dam DNA adenine methylase
D2, D1-2, D2-3, D1-3, 
D1-4, D2-4 
domain 2, domain 1-2, domain 2-3, domain 1-3, domain 1-
4, domain 2-4 of VEGFRs 
DNA deoxyribonucleic acid 
dNTP deoxy nucleotide tri-phosphate 
DTT dithiothreitol
EBM endothelial basal medium 
E. coli Escherichia coli
EC endothelial cell 
ECL enhanced chemi-luminescence
ECM extracellular matrix 
EDTA ethylene-diamino-tetraacetic acid 
EGF epithelial growth factor 
EGM endothelial growth medium 
ESI electron spry ionization source 
FACS fluorescence activated cell sorting 
FCS fetal calf serum 
FDA Food and Drug Administration
FGF fibroblast growth factor 
FGFR fibroblast growth factor receptor
FID free induction delay 
FITC fluorescein isothiocyanate
Flt-1 fms-like tyrosine kinase-1 
F.T. flow-through
gor glutathione reductase gene 
1
GTE Glucose-Tris-EDTA
h hour
HF hypotensive factor 
HIF-1 hypoxia-inducible factor-1 
HPLC high performance liquid chromatography 
HSC haematopoietic stem cells 
HSPG heparan sulfate proteoglycan 
HSQC heteronuclear single quantum coherence 
HUVEC Human umbilical vein endothelial cell 
Ig immunoglobulin
Kd dissociation constant 
IPTG isopropyl-beta-D-thiogalactopyranoside
KDa Kilo Dalton 
KDR kinase domain region 
LB Luria-Bertani Broth (10 g/L bacto-triptone, 5 g/L yeast 
exstract, 10 g/L NaCl) 
LC-MS liquid chromatography mass spectrometry 
MCS multi cloning site 
MAPK mitogen-activated protein kinase 
min minute
MMP metalloproteinase
ms millisecond
MWCO molecular weight cut off 
NIH-3T3 Mouse embryonic fibroblast cell line 
nm nanometer
NMR Nuclear Magnetic Resonance 
NOESY Nuclear Overhauser Effect SpectroscopY
NRP neuropilin
NRTK non receptor tyrosine kinase 
Ni-NTA nickel-nitrilotriacetic acid 
O.D. optical density 
orf open reading frame 
PAI-1 plasminogen activator inhibitor 1 
PBS phosphate buffer saline 
2
PC pericyte
PCR polymerase chain reaction 
PDGF platelet derived growth factor
PDGFR platelet derived growth factor receptor
pI isoelectric point 
PlGF placenta growth factor 
PVDF polyvinylidene fluoride 
RT room temperature 
RTK receptor tyrosine kinase 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
sec second
SMC smooth muscle cells 
STD saturation transfer difference 
svVEGF snake venom vascular endothelial growth factor 
TAE Tris acetate EDTA 
TE 10 mM Tris/HCl pH 8, 1 mM EDTA pH 8 
TEMED N,N,N’,N’-tetramethyl ethylene diamine 
TEV tobacco etch virus 
TFA trifluoroacetic acid 
TIC total ion current 
TK tyrosine kinase 
TM trans-membrane domain 
TnI troponin I 
Tris Tris (hidroxy methyl) amino methane 
trxB thioredoxin reductase gene 
TrxA thioredoxin A 
TSP-1 thrombospondin-1
U units
uPA urokinase-type plasminogen activator 
UV ultra violet 
VEGF vascular endothelial growth factor 
VEGFR VEGF receptor 
VPF vascular permeability factor 
The one letter code is used for amino acids. 
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Summary
Angiogenesis is the process of remodeling of the vascular tissue characterized by the 
branching out of a new blood vessel from a pre-existing one. The angiogenesis is 
particularly active during embryogenesis, while during adult life it is quiescent and 
limited to particular physiological phenomena. In the last years, the study of 
molecular mechanisms of angiogenesis has stirred renewed interest due to the 
recognition of the role played by angiogenesis in several pathologies of large social 
impact, such as tumors and cardiovascular diseases, but also to the pharmacological 
interest rising from the possibility of modulating this phenomenon (Carmeliet, P. Nat.
Med. 9, 653-660, 2003). Antibodies, peptides and small molecules targeting active 
endothelial cells (ECs) represent an innovative tool in therapeutic and diagnostic 
fields (D’Andrea, L. D. et al., 2008, submitted). In the process of angiogenesis, 
vascular endothelial growth factor (VEGF) is essential for growth, mitogenesis, and 
tube formation of ECs. VEGF binds to two tyrosine kinase receptors, fms-like tyrosine 
receptor (Flt-1) and kinase insert domain containing receptor (KDR), on the surface 
of ECs, thereby activating signal transduction and regulating physiological and 
pathological angiogenesis. The extracellular portion of these receptors is comprised 
of 7 immunoglobulin domains; domains deletion studies on Flt-1 have shown that the 
ligand binding function resides within the first three domains (Barleon, B. et al., J.
Biol. Chem. 272, 10382-10388, 1997). Deletion experiments on KDR show that only 
domains 2 and 3 are critical for ligand binding (Fhu, G. et al., J. Biol. Chem. 273, 
11197-11204, 1998). Actually, of these receptors, are not well known structural data, 
done exception for the domain 2 of Flt-1 of which, in the literature, is reported the 
crystal structure complexed with VEGF (Wiesmann, C et al., Cell 91, 695-704, 1997) 
and PlGF (Christinger, H. W. et al., J. Biol. Chem. 279, 10382-10388, 2004) and the 
three-dimensional, uncomplexed form determined by NMR spectroscopy 
(Starovasnik, M. A. et al., J. Mol. Biol. 293, 531-544, 1999). Both VEGF and its 
receptors are overexpressed in pathological angiogenesis, so the heightened interest 
in the study of this process is due to the realization that aberrant angiogenesis 
contributes to pathology. The aim of this PhD thesis is the characterization of 
proteins involved in the angiogenesis for a better understanding of this crucial 
process. Because the angiogenic response strictly depends on VEGF and on 
functions and signaling properties of its receptors, we centred our efforts on the 
expression of some of the extracellular Ig-like domains of VEGF receptors, focusing 
the attention on their structural characterization via NMR and on their employment in 
the identification and improvement of new organic or peptide-based molecules 
targeting the protein system VEGF/VEGFRs. First of all, once expressed and purified 
Flt-1D2, it was identified by LC-MS, before and after TEV protease cleavage; then we 
used the second domain of VEGFR-1 for CD analysis. Recorded spectra showed 
that the protein assumes a ?-sheet conformation prevalently, as expected for the 
structural organization of an Ig-like domain. In addition, with Flt-1D2 was performed an 
in vitro assay on HUVEC cells. This assay verified the binding ability of Flt-1D2 to 
VEGF-biotin, delivering the growth factor from membrane receptors and acting as an 
antibody.
After these preliminary investigations, Flt-1D2 was employed in interaction studies 
with QK and MA peptides (D’Andrea et al., PNAS 102, 14215-14220, 2005 and Del 
Gatto, A. PhD thesis, 2005), in order to better understand their biological behavior as 
agonist or antagonist in angiogenesis process. This is necessary for the optimization 
and stabilization of that features which these molecules need to be used as good 
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modulators in angiogenesis. The interaction between peptides and Flt-1D2 has been 
studied through NMR techniques founded on the observation of ligand (Saturation 
Tranfer Difference) and protein (Chemical Shift Mapping). These experiments 
showed that QK is able to bind on Flt-1 receptor the same region tied by VEGF. 
Therefore, the recombinant Flt-1D2 was employed for a NMR screening of a library of 
small molecules, in order to find other VEGF agonist/antagonist and design new 
molecules more specific and selective in their targeting VEGFRs system. These are 
preliminary data. 
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6Riassunto
Scopo di questo progetto di dottorato è stata l’espressione in forma ricombinante e la 
caratterizzazione di proteine coinvolte nel processo di angiogenesi, al fine di 
impiegarle nello screening di molecole in grado di fungere da modulatori della 
crescita di nuovi vasi sanguigni. L’angiogenesi, infatti, è un processo di 
rimodellamento del tessuto vascolare caratterizzato dalla formazione di nuovi vasi 
sanguigni a partire da strutture preesistenti. La formazione di un nuovo vaso 
sanguigno, così come quella di ogni tessuto, è garantita dall’ interazione dinamica tra 
le cellule che lo costituiscono ed il loro microambiente che risulta essere 
sostanzialmente costituito dalla matrice extracellulare e da altri citotipi con i quali la 
popolazione cellulare interagisce. La matrice extracellulare è composta da proteine 
fibrose e da proteoglicani, ma in essa sono presenti anche citochine e fattori di 
crescita, generalmente associati a componenti della matrice stessa. L’angiogenesi è 
regolata prevalentemente da uno di questi fattori di crescita, il VEGF (Vascular
Endothelial Growth Factor), potente fattore angiogenico e mitogeno specifico per le 
cellule endoteliali che, insieme alla matrice extracellulare dell’endotelio vascolare, 
alla membrana basale, alle cellule muscolari lisce e a quelle di supporto, concorrono 
alla formazione dei canali che dirigono e contengono il flusso sanguigno. La funzione 
biologica del VEGF si esplica attraverso il suo legame a due recettori di membrana 
con attività tirosin-chinasica: il Kinase Domain Receptor (KDR) e l’Fms-like tyrosin 
kinase (Flt-1), entrambi presenti sulla superficie di diversi tipi di cellule endoteliali, ma 
in grado di attivare vie di trasduzione distinte, nonostante condividano un elevato 
grado di omologia (Figura R1) (Ferrara, N et al., Endocr. Rev. 18, 4-25, 1997 and 
Ferrara, N. Curr. Opin. Biotechnol. 11, 617-624, 2000).
                     
Figura R1_ Rappresentazione delle interazioni del VEGF e dei suoi
analoghi con alcuni recettori espressi sulla superficie delle cellule
endoteliali.
Per quanto riguarda la porzione extracellulare di queste proteine, attualmente, non 
sono noti dati strutturali, fatta eccezione per il dominio 2 di Flt-1 di cui, in letteratura, 
è riportata la struttura cristallografica complessata al VEGF (Figura R2) e al PlGF 
(Wiesmann, C. et al., Cell 91, 695-704, 1997 and Christinger, H. W. et al., J. Biol. 
Chem. 279, 10382-10388, 2004) e quella libera in soluzione (Starovasnik, M. A. et
al., J. Mol. Biol. 293, 531-544, 1999).
Figura R2_ Dominio 2 del recettore Flt-1 (in arancione) complessato al
VEGF8-109 (in rosso e verde). In blu sono rappresentati i residui del VEGF a
contatto con il recettore.
Studi di delezione hanno dimostrato che i maggiori responsabili del riconoscimento 
specifico per il VEGF sono i primi 3 domini extracellulari per il recettore Flt-1 
(Barleon, B. et al., J. Biol. Chem. 272, 10382-10388, 1997) e i domini 2 e 3 per KDR 
(Fhu, G. et al., J. Biol. Chem. 273, 11197-11204, 1998). Affinché l’angiogenesi possa 
svolgersi correttamente, le interazioni che hanno luogo tra le cellule endoteliali e la 
matrice extracellulare debbono svolgersi secondo una sequenza precisa ed ordinata. 
In più, l’angiogenesi, come la maggior parte dei processi biologici, è il risultato di un 
equilibrio tra fattori “pro-angiogenici” ed “anti-angiogenici”. Lo spostamento da questa 
situazione di equilibrio (noto come switch angiogenico) è alla base di manifestazioni 
patologiche di varia natura quali tumori ed ischemie (Carmeliet, P. Nat. Med. 9, 653-
660, 2003). Alla luce di queste conoscenze, lo studio del sistema costituito dal VEGF 
e dai suoi recettori risulta, pertanto, di notevole interesse. La possibilità di disporre di 
nuovi composti capaci di modulare la risposta angiogenica del VEGF avrebbe così 
numerose applicazioni in campo terapeutico e diagnostico. Difatti, negli ultimi anni lo 
studio dei meccanismi dell’angiogenesi è stato uno tra i campi maggiormente 
investigati e finanziati nell’ambito della ricerca medica. Al momento, tra gli inibitori del 
processo approvati come agenti terapeutici si annoverano l’Avastin, un anticorpo 
monoclonale contro il VEGF, usato per il trattamento del tumore del colon-retto, ed 
un suo derivato, il Lucentis, in uso per patologie oculari. Sono invece pochi i farmaci 
disponibili che stimolano l’angiogenesi VEGF-dipendente. Attualmente un solo 
composto pro-angiogenico è stato approvato, il Regranex (PDGF umano 
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ricombinante), per il trattamento delle ulcere del piede diabetico. L’utilizzo 
farmacologico di fattori di crescita come il VEGF è stato finora precluso a causa di 
numerosi effetti collaterali (Carmeliet, P. Nat. Med. 6, 1102-1103, 2000b; Lee, C. G. 
et al., Nat. Med. 10, 1095-1103, 2004; Weis, S. M. et al., Nature 437, 497-504, 
2005). Recentemente è stata riportata in letteratura la caratterizzazione strutturale e 
le proprietà biologiche di un peptide sintetico che mima il VEGF. Il peptide, QK, 
modellato sulla regione 17-25 dell’elica del VEGF, lega i recettori del VEGF, 
attivando poi il processo di proliferazione cellulare VEGF-dipendente. Tale peptide 
potenzia la risposta biologica del VEGF, e promuove la formazione di capillari in vitro
ed in vivo (D’Andrea, L. D. et al., PNAS 102, 14215-14220, 2005). Dunque, si rende 
necessario lo sviluppo di inibitori di basso peso molecolare e di nuovi agonisti in 
modo da modulare la crescita di nuovi vasi sanguigni e, in tal modo, la progressione 
di patologie derivanti da un alterato funzionamento del processo angiogenico. Nel 
caso dello sviluppo di un tumore, occorre considerare che l’angiogenesi e la 
formazione di una metastasi costituiscono due esempi paradigmatici del ruolo 
cruciale svolto dal microambiente all’interno del quale questi due processi si 
svolgono, nella dinamica spazio-temporale del loro accadere. Il microambiente 
diventa allora anche un potenziale bersaglio terapeutico per mantenere l’angiogenesi 
in un ambito fisiologico o per deregolare il potenziale metastatico di una popolazione 
cellulare. In tal senso sono tuttora allo studio molecole in grado di bloccare 
l’interazione tra i recettori e i fattori di crescita angiogenici, impedendo così a questi 
ultimi di interagire con le cellule endoteliali che esprimono sulla loro superficie i 
recettori. Tale progetto di dottorato si inserisce dunque in questo ampio discorso ed 
ha come obiettivo la caratterizzazione di proteine coinvolte nell’angiogenesi, in 
particolare, dei domini extracellulari dei recettori KDR e Flt-1. La loro espressione in 
forma ricombinante ed il loro impiego in studi condotti mediante analisi NMR, 
offrirebbe, infatti, la possibilità di uno screening di piccoli peptidi o di collezioni di 
molecole organiche al fine di trovare nuovi ligandi per i recettori e quindi probabili 
modulatori dell’angiogenesi, in qualità di antagonisti e/o agonisti del processo. La mia 
attività scientifica nell’ambito di questo progetto si è focalizzata, pertanto, sul 
clonaggio e l’espressione di alcuni dei domini extracellulari dei recettori del VEGF Flt-
1 e KDR. A tal fine sono stati utilizzati diversi vettori per il clonaggio delle sequenze 
geniche di interesse e diversi ceppi batterici per l’ottimizzazione dei livelli di 
espressione delle corrispondenti proteine ricombinanti. l sistemi di espressione scelti, 
sfruttando la presenza di un promotore forte ed inducibile qual è quello regolato dalla 
RNA polimerasi T7, sono stati in grado di fornire alti livelli di espressione delle 
proteine di interesse; essi recano marcatori di selezione costituiti da geni che 
conferiscono resistenza ad un antibiotico (Canamicina o Ampicillina), presentano 
un’origine di replicazione riconosciuta dall’ospite batterico ed un sito di policlonaggio. 
La maggior parte dei suddetti sistemi consente, inoltre, di esprimere le proteine di 
interesse con una coda di poli-istidine all’N-terminale della catena polipeptidica, 
permettendone una più efficace ed immediata purificazione dai contaminanti di E.
coli mediante cromatografia di affinità. Le sequenze geniche corrispondenti ai domini 
extracellulari di Flt-1 e KDR (flt-1D1-4, flt-1D2-4, flt-1D2-3 e flt-1D2; kdrD1-3, kdrD2-3, kdrD1-2
e kdrD2) sono state amplificate tramite PCR, utilizzando come stampo il cDNA degli 
interi recettori e come iniziatori della reazione di amplificazione a catena della 
polimerasi coppie di oligonucleotidi disegnate sulla base delle sequenze geniche in 
esame. Il DNA dei costrutti ricombinanti è stato opportunamente purificato e 
verificato tramite sequenziamento. I clonaggi di tutte le sequenze geniche amplificate 
sono riusciti con successo ed i costrutti ottenuti nei diversi sistemi di espressione 
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sono stati utilizzati per l’espressione nei ceppi di E. coli scelti per tale scopo. Tutti i 
costrutti espressi nei diversi ceppi batterici hanno prodotto proteine insolubili, il cui 
processo di rinaturazione, dopo estrazione in presenza di agenti denaturanti quali 
urea 8M o Gu-HCl 6M, non sempre è stato portato a termine con successo o ha 
permesso di ottenere quantità di proteina non sufficienti per essere impiegate in studi 
di caratterizzazione. Il nostro interesse si è pertanto focalizzato maggiormente sul 
costrutto pETM11-flt-1D2, che siamo riusciti ad esprimere a buoni livelli nel ceppo 
BL21 Codon Plus (DE3) RIL di E. coli (60 mg/L) e a rinaturare con rese 
soddisfacenti. In seguito a trasformazione chimica nel suddetto ceppo batterico, i 
cloni selezionati su piastra sono stati propagati in terreno liquido. La proteina di 
interesse è stata espressa in forma insolubile, sia a 22°C che a 37°C, pertanto è 
stata purificata in condizioni denaturanti mediante cromatografia di affinità su resina 
funzionalizzata con ioni Nickel (Ni2+-NTA resin) e sottoposta, successivamente, ad un 
protocollo di refolding su colonna, in modo tale da sottrarle gradualmente l’agente 
denaturante (urea) utilizzato per la sua estrazione dai corpi di inclusione. Terminato il 
refolding, la proteina Flt-1D2 è stata eluita con alte concentrazioni di imidazolo, 
dializzata e, mediante taglio con la proteasi TEV, è stata allontanata dalla sua 
estremità N-terminale la coda di poli-istidine con cui è stata espressa. La proteina è 
stata purificata all’omogeneità, mediante un ulteriore step su resina Ni2+-NTA per 
allontanare da essa sia la TEV che l’HIS-TAG e sottoposta ad un’ampia 
caratterizzazione. Flt-1D2 è stata infatti identificata mediante spettometria di massa 
(LC-MS) prima e dopo il taglio con la proteasi; è stata trattata con iodoacetammide 
(prima e dopo riduzione con DTT) per stabilire l’eventuale alchilazione a carico delle 
due cisteine presenti nella sequenza amminoacidica del dominio proteico; è stata 
infine sottoposta ad una proteolisi limitata con tripsina. I dati ottenuti attraverso 
queste prove ci hanno fornito informazioni utili, seppure indirette, riguardo lo stato 
assunto dalla proteina in seguito al refolding su colonna. Infatti, il trattamento con 
iodoacetammide ha lasciato invariata la massa di Flt-1D2 non ridotta, mentre ha 
alchilato la proteina precedentemente trattata con DTT. Ciò ci ha dato conferma del 
fatto che le due cisteine presenti nella sequenza di Flt-1D2 sono impegnate in un 
ponte disolfurico, così come confermato da dati strutturali (Wiesmann, C. et al., Cell
91, 695-704, 1997). In più, la reazione di proteolisi limitata, esaminata alla massa a 
tempi diversi (dopo 45 e dopo 90 minuti) ha mostrato una struttura abbastanza 
compatta, non intaccata drasticamente dalla tripsina, così come atteso per un 
dominio immunoglobulinico quale è il dominio 2 del recettore Flt-1. Di Flt-1D2 sono 
state effettuate analisi mediante dicroismo circolare e gli spettri acquisiti hanno 
mostrato che la proteina assume una conformazione prevalentemente di tipo ?-
sheet, così come atteso per l’organizzazione strutturale di un dominio di tipo 
immunoglobulinico. La temperatura di denaturazione di Flt-1D2 è stata stimata intorno 
ai 60°C ed il processo è risultato reversibile. Parallelamente, il dominio proteico è 
stato utilizzato in un saggio funzionale di fluorescenza condotto in vitro su cellule 
HUVEC (Human umbelical vein endothelial cells). Tale saggio ha dimostrato la 
capacità di legame del VEGF-biotina ai recettori di membrana presenti sulla 
superficie delle HUVEC e allo stesso tempo la capacità di Flt-1D2 di spiazzare il 
VEGF da tale interazione. In presenza di un anticorpo anti-VEGF, l’intensità della 
fluorescenza registrata inviando sulle HUVEC il solo VEGF-biotina è diminuita 
significativamente. Un decremento analogo si è osservato anche quando le cellule 
sono state incubate con VEGF-biotina pretrattato con Flt-1D2, indicando che il 
recettore è in grado di legare il VEGF e di competere per tale legame con i recettori 
di membrana, comportandosi alla stregua di un anticorpo. In seguito all’ottenimento 
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di questi dati preliminari, si è passati alla caratterizzazione vera e propria della 
proteina che, per tale scopo, è stata marcata con 15N, mediante espressione in 
terreno minimo contenente, come unica fonte di azoto, il cloruro di ammonio marcato 
(15NH4Cl). Flt-1D2 è stata espressa e purificata secondo lo stesso protocollo utilizzato 
per la proteina non marcata, quindi è stata concentrata (0.3 mM) e sottoposta a studi 
di caratterizzazione mediante NMR. L’acquisizione degli spettri protonici mono- e 
bidimensionali di Flt-1D2 ha messo in evidenza la presenza di numerosi picchi relativi 
ai protoni ammidici, con una buona dispersione dei chemical shifts, così come atteso 
per la proteina nativa (Starovasnik, M. A. et al., J. Mol. Biol. 293, 531-544, 1999). E’ 
stato pertanto possibile asserire che il dominio proteico ottenuto in forma 
ricombinante e purificato all’omogeneità dopo refolding ha una conformazione 
correttamente ripiegata. Successivamente, la proteina è stata impiegata in studi di 
interazione con due piccoli peptidi di quindici amminoacidi sintetizzati e caratterizzati 
nel laboratorio in cui è stato svolto questo lavoro di tesi; i peptidi in esame sono QK 
(Ac-KLTWQELYQLKYKGI-NH2) ed MA (Ac-KLTWMELYQLAYKGI-NH2) (D’Andrea, 
L. D. et al., PNAS 102, 14215-14220, 2005 and Del Gatto, A. PhD thesis 2005). 
Entrambi rappresentano un esempio di quello che viene definito approccio di sintesi 
mediante rational-design e riproducono l’elica 17-25 del VEGF; infatti, l’analisi 
accurata dei dati strutturali, così come gli studi di mutagenesi, hanno permesso di 
identificare i residui amminoacidici coinvolti nel legame del VEGF ai suoi recettori. 
Essi sono distribuiti su una superficie discontinua costituita appunto dall’elica 17-25 
presente all’estremità N-terminale di ciascun monomero del VEGF (Keyt, B. A. et al.,
J. Biol. Chem. 271, 5638-5646, 1996; Muller, Y. A. et al., Proc. Natl. Acad. Sci. USA
94, 7192-7197, 1997; Wiesmann, C. et al., Cell 91, 695-704, 1997). Attualmente, la 
stragrande maggioranza delle molecole peptidiche in grado di modulare l’interazione 
tra il VEGF ed i suoi recettori deriva da screening di collezioni fagiche, mentre sono 
pochi gli esempi derivanti da un approccio di tipo razionale. L’interazione dei due 
peptidi con il secondo dominio del recettore Flt-1 è stata studiata attraverso tecniche 
NMR basate sull’osservazione del ligando (Saturation Transfer Difference) e della 
proteina (Chemical Shift Mapping). Tale interazione ha permesso di identificare, sia 
per QK che per MA, le regioni impegnate nel binding con la proteina, dimostrando 
che il peptide QK lega sul recettore la stessa regione di legame del VEGF. Flt1D2 è 
stata infine impiegata in uno studio di drug discovery, attraverso lo screening di una 
collezione di piccole molecole organiche con l’intento di selezionare nuovi ligandi a 
basso peso molecolare capaci di bloccare l’interazione tra il VEGF ed i suoi recettori. 
I dati ottenuti sono del tutto preliminari. 
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Introduction
Angiogenesis is a phenomenon intimately associated with endothelial cells (ECs) 
migration and proliferation. During embryonic development, ECs rapidly proliferate, 
thereby forming new blood vessels. In adult life, however, ECs turnover is very low, 
except for physiological wound healing and female reproductive functions. 
Angiogenesis is also implicated in pathological conditions associated with tumors, 
intraocular neovascular disorders, chronic ischemia and other diseases (Carmeliet, 
P. 2003). The mediators of this process have been identified in a series of vascular 
growth factors such as the Vascular Endothelial Growth Factor (VEGF). VEGF 
represents a key regulator of angiogenesis; its biological effects are prevalently 
mediated by two receptor tyrosine kinases (RTK): VEGFR-1 and VEGFR-2 which are 
localized on the cell surface of various endothelial cell types. VEGF and its receptors 
are over-expressed in pathological angiogenesis, making this protein system a target 
for therapeutic and diagnostic applications (Ferrara, N et al., 1997 and Ferrara, N. 
2000). Therapeutic angiogenesis is sought as the ultimate intervention to solve 
chronic ischemia in those conditions that cannot be treated alternatively; its 
converse, the anti-angiogenic treatment, with the blockage of the VEGF/VEGFRs 
pathway, is a promising therapy in oncology. To date, a number of different strategies 
to inhibit VEGF signal transduction are available and they include the use of 
humanized neutralizing anti-VEGF monoclonal antibodies, receptor antagonists, 
soluble receptors and inhibitors of VEGF receptors function (Moreira, I. S. et al.,
2007). Moreover, new molecular entities as peptides have been reported to bind to 
the extracellular region of the VEGF receptors. A large number of them show an 
antagonist activity and only few behave as agonists (D’Andrea, L. D. et al., 2008, 
submitted).
The introduction is not meant to cover the VEGF/VEGFR field completely, but rather 
to emphasize selected aspects of these molecules which are important for the aims 
described in this PhD thesis.
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How does a blood vessel form? Vasculogenesis and Angiogenesis
Blood vessel formation occurs through the processes of vasculogenesis and 
angiogenesis (Folkman, J. et al., 1996; Risau, W. 1997; Beck, L. et al., 1997). 
Vasculogenesis is the differentiation de novo of vascular endothelial cells from 
precursors cells, known as angioblasts, during embryonic development. This process 
is distinct from angiogenesis, which is a remodeling process characterized by the 
sprouting of new blood vessels from pre-existing ones (Figure 1). Vasculogenesis 
was thought to occur only in early embryogenesis. The existence of endothelial 
progenitor stem cells has been established, however, and these bone marrow-
derived cells have been found in the adult, including injured corneas and tumor 
vasculature, suggesting that vasculogenesis can occur in the adult (Asahara, T. et
al., 1997; Shi, Q. et al., 1998; Takahashi, T. et al., 1999a). Although developmentally 
significant, angiogenesis is rare in the adult. One exception is the female 
reproductive system where it has been demonstrated that angiogenesis is correlated 
with vascularization of ovarian follicles, development of the corpus luteum, repair of 
endometrial vessels and implantation of embryo in utero (Shweiki, D. et al., 1993). 
Angiogenesis is involved in physiological wound healing and tissue repair. It is 
stimulated by factors such as VEGF and fibroblast growth factor (FGF), which will be 
described at greater length below. An early response to angiogenesis-stimulating 
factors is the degradation of endothelial cell basement membrane (BM) by proteases 
such as the members of the matrix metalloproteinase (MMP) family. MMPs degrade 
collagen and other extracellular matrix components, disrupting the BM barrier, 
enabling ECs to migrate from pre-existing vessels towards angiogenic stimuli and to 
proliferate (Moses, M.A. 1997). Vascular cell-adhesion molecules contribute to ECs 
migration by mediating cell-extracellular-matrix interactions. An important mediator is 
the integrin ?V?3, a receptor for proteins such as fibronectin, which is expressed at 
low levels in quiescent blood vessels (Eliceiri, B.P. et al., 1998). Antagonists of ?V?3
inhibit the growth of new blood vessels but not pre-existing ones, suggesting that cell 
adhesion is a critical step in angiogenesis (Brooks, P.C. et al., 1994). Following 
migration and proliferation, ECs assemble into tubes with a lumen (Figure 2). Lumen 
formation may be dependent on E-selectin, a trans-membrane cell-adhesion 
glycoprotein that mediates endothelial cell-cell contacts (Nguyen, M. et al., 1992). An 
important step in producing a mature blood vessel is the recruitment of mesenchymal 
cells and their subsequent differentiation into smooth muscle cells-like pericytes (PC) 
that stabilize the newly forming vasculature. Platelet-derived growth factor (PDGF) 
plays a role in pericytes recruitment, acting as a potent chemoattractant and mitogen 
for pericytes and smooth muscle cells (SMC) (Lindahl, P. et al., 1997).
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A B
Vasculogenesis
Angiogenesis
Figure 1_ A) Vasculogenesis versus angiogenesis; B) Wall composition of nascent and mature
vessels: schematic representation of cells involved in vasculogenesis and angiogenesis
(Yancopoulos, G. D. et al., 2000). 
Figure 2_ Processes in pathological angiogenesis: the various steps in blood vessel formation. 
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Promoters and inhibitors of angiogenesis 
Formation of the normal blood vasculature is thought to depend from the balanced 
secretion, in appropriate amounts and temporal sequence, of a large number of 
chemically diverse molecules (Beck, L. et al., 1997; Yancopoulos, G.D. et al., 2000; 
Carmeliet, P. 2000a). These include VEGF and other members of the VEGF/VEGFR 
family, in addition to other growth factors (e.g. PDFG, FGF, angiopoietins) and 
various endogenous inhibitors (Table 1).
Table 1: Endogenous angiogenic regulators 
Pro-angiogenic Anti-angiogenic
Acidic fibroblast growth factor 2-Methoxyoestradiol
Angiogenin Angioarrestin
Angiopoietin-1 Angiostatin
B61/LERK-1 Angiotensin
Basic fibroblast growth factor Antiangiogenic antithrombin III 
Del-1 Endostatin
Erythropoietin Fibronectin peptide 
Follistatin Gro-?
Gangliosides Human chorionic gonadotropin (hCG) 
Granulocyte colony-stimulating factor Hyaluronan
Granulocyte macrophage colony-
stimulating factor 
Interferon ?-inducible protein 10 
Hepatocyte growth factor Interferons
Hyaluronan oligosaccharides Interleukin 12 
Insulin-like growth factor Kringle 5 
Interleukin 8 Laminin peptide 
Leptin Plasminogen activator inhibitors 
Midkine Platelet factor 4 
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Monocyte chemoattractant protein 1 Prolactin 16kD fragment 
Oestrogens Proliferin-related protein 
Placenta growth factor Thrombospondin-1
Platelet-derived growth factor Tissue inhibitors of metalloproteinase 
Pleiotrophin Transforming growth factor-beta (TGF-b) 
Progranulin Tumour necrosis factor ? (high dose) 
Proliferin Tumstatin
Prostaglandin E1, E2 Vasculostatin
Transforming growth factor ??and ? Vasostatin (calreticulin fragment) 
Tumour necrosis factor ? (low dose) 
Vascular endothelial growth factor 
Promoters of angiogenesis 
Angiopoietins and Tie receptors
Tie receptors and their ligands, the angiopoietins, play a critical role in embryonic 
angiogenesis (Partanen, J. et al., 1999 and Davis, S. et al., 1999). Tie receptors, 
Tie1 and Tie2, are tyrosine kinases expressed by ECs. Mice deficient in Tie2 are 
embryonic lethal with defects in the proper development of the endothelial lining of 
the heart. Tie1 is required for the structural integrity of ECs and mice deficient in Tie1 
die by birth (Dumont, D.J. et al., 1994 and Sato, T.N. et al., 1995). Angiopoietin-1 
(Ang1) is a ligand for Tie2 (Davis, S. et al., 1996). Ang1 induces phosphorylation of 
Tie2 in ECs, but does not induce cell proliferation. Over-expression of Ang1 results in 
more numerous and more highly branched vessels. Targeted disruption of Ang1 is 
embryonic lethal and the defects in these mice resemble those in the Tie2 deficient 
mice. In addiction to heart defects, there are a reduced number of vessels and 
remodeling of the initial primary capillary network does not occur. Importantly, there is 
a lack of recruitment of periendothelial supporting cells to the ECs in Ang1-deficient 
mice, which leads to lack of blood vessels stabilization and maturation (Suri, C. et al.,
1998). Ang1 is expressed embryonically, most prominently in heart myocardium. In 
adult tissue Ang1 is constitutively and widely expressed especially in platelets, 
megakaryocytes as well as in highly vascularized tissues, but not in tissues with low 
vascularization (Thurston, G. et al., 2000). It has been suggested that mesenchymal 
cells produce Ang1, which activates Tie2 which in turn leads to the production and 
release of factors (e.g. PDGF-BB) that recruit pericytes and smooth muscle cells 
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(Folkman, J. et al., 1996). Angiopoietin 2 (Ang2) is 60% identical to Ang1, but does 
not stimulate Tie2 tyrosine phosphorylation. Ang2 might be a natural antagonist of 
Ang1 that blocks Ang1 activation of Tie2 receptor (Maisonpierre, P.C. et al., 1997). 
Neither Ang1 nor Ang2 alone could trigger an angiogenic response, but could 
enhance VEGF-induced angiogenesis, leading to the notion of an angiogenic 
balance: Ang1 signaling via Tie2 leads to vessel maturation, whereas Ang2 blocks 
the Ang1/Tie2 signal and leads to angiogenesis or vessel regression and apoptosis, 
depending on the presence of VEGF (Hanahan, D. 1997 and Asahara, T. et al.,
1998).
Platelet derived growth factor (PDGF)
PDGF has been shown to be one of the most potent angiogenesis inducers and is 
licensed for the treatment of neuropathic diabetic foot ulcers (Bennett, S.P. et al.,
2003). The Platelet-derived Growth Factor belongs to a family of structurally and 
functionally related growth factors containing cysteine knots, which includes also the 
VEGF (Fredriksson, L. et al., 2004a). The currently known PDGFs include the PDGF-
A, PDGF-B, PDGF-C, PDGF-D chains. All members harbour a growth factor core 
domain, containing a conserved set of cysteine residues, which is necessary and 
sufficient for receptor binding activation. PDGF-A and PDGF-B contain N-terminal 
pro-domains, which are removed intracellularly by furin or other convertases; 
cleavage of these domains result in protein activation and receptor binding (Heldin, 
C. H. et al., 1999 and Fredriksson, L. et al., 2004a). PDGF-C and PDGF-D instead 
are processed in the extracellular space (Fredriksson, L. et al., 2004b). PDGFs act 
through two tyrosine kinase receptors, PDGFR ? and PDGFR ?. The receptors are 
transmembrane proteins, composed of an extracellular ligand-binding domain, a 
transmembrane domain and a cytoplasmic tyrosine kinase domain (Fantl, W. J. et al.,
1993). The extracellular region contains five immunoglobulin-like domains, while the 
intracellular domain carries a tyrosine kinase domain and a unique sequence with no 
homology to kinases (Matsui, T. et al., 1989). Upon ligand binding, the PDGF 
receptors dimerize and phosphorylate each other in trans on specific tyrosine 
residues (Kelly, J. D. et al., 1991). Although in theory there are several possible 
combinations of ligand and receptors, the functional in vivo interaction has been 
proved only for PDGF-AA and PDGF-CC with PDGFR ? and for PDGF-BB with 
PDGFR ? (Andrae, J. et al., 2008) (Figure 3). PDGFR interacts with several other 
proteins involved in multiple cellular and developmental responses including integrins 
(Hynes, R.O. 2002) and transcription factors. PDGFs play key roles in embryonal 
development, being involved in the formation of blood vessels, kidney, lungs, 
connective tissues and central nervous system. Furthermore, together with other 
growth factors, PDGF regulate the wound healing process; it has been shown that 
wounds treated with PDGF exhibit an increase in the re-epithelization and 
neovascularization rates (Heldin, C. H. et al., 1999 and Sundberg, C. et al., 1997). 
Overexpression of the PDGFs has been associated with several diseases associated 
with increased cell proliferation. Experimental evidences show that PDGF is involved 
in pulmonary fibrosis (Yi, E. S. et al., 1996) and in the formation of cholesterol 
induced atherosclerosis (Rutherford, C. et al., 1997). PDGF overexpression was also 
observed in human solid tumors, as gastrointestinal stromal and central nervous 
system tumors (Heldin, C. H. et al., 1999 and Alvarez, R. H. et al., 2006).
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Fibroblast growth factor (FGF)
In the 1980s purification of pro-angiogenic proteins led to the identification, and 
sequencing of the two prototypic heparin-binding angiogenic growth factors FGF1 
(acidic FGF) and FGF2 (basic FGF) (Abraham, J. A. et al., 1986a-b). Since then the 
FGF family has increased in number and complexity as many more members of the 
family (23 in total) with a variety of biological activities, have been discovered 
(Powers, C. J. et al., 2000). Acidic and basic fibroblast growth factors (FGF-1 and 
FGF-2, respectively) are very potent inducers of EC migration, proliferation and tube 
formation in vitro and are highly angiogenic in vivo (Klagsbrun, M. et al., 1991a). All 
FGFs share 30–70% homology in their amino acid sequences and consist of two 
highly conserved core-domains that fold in 12 antiparallel ?-strands, leading to the 
formation of a cylindrical barrel (Ago, H. et al., 1991; Eriksson, A. E. et al., 1991; Zhu, 
X. et al., 1991; Zhang, J. D. et al., 1991). These domains are separated by a central 
spacer region of variable length as well as variable are the C- and N-terminal regions 
of the different FGFs (Reuss, B. et al., 2003). Many studies have shown that FGFs 
can act on different cell types inducing cell proliferation, differentiation, migration and 
survival (Ornitz, D. M. et al., 2001). All these actions are made possible through the 
dual interaction of FGFs with high-affinity tyrosine kinase receptors (FGFRs) and with 
a large number of low affinity sites on the cell surface and within the surrounding 
extracellular matrix (ECM) (Klagsbrun, T. et al., 1991b). These sites were identified 
as heparan sulfate proteoglycans (HSPGs) obligatory partners of the FGF interaction 
with FGFR (Ornitz, D. M. et al., 1992 and Mansukhani, A. et al., 1992). To date four 
FGF transmembrane receptors (FGFRs1-4) and one soluble receptor (FGFR5) are 
known (Chaffer, C. L. et al., 2007). Isolation and structural characterization in 1989 of 
a protein with high affinity for FGF1 (Lee, P. L. et al., 1989) led to the identification of 
the prototypic of all FGF receptors, which are transmembrane proteins with three 
extracellular immunoglobulin-like domains (IgI, IgII, and IgIII), an acidic box and 
heparin-binding domain between IgI and IgII, a hydrophobic transmembrane domain, 
and an intracellular region containing a split tyrosine kinase domain (Figure 4). In the 
structure of the FGF receptor gene four possible splice sites exist, generating an 
FGFR ? subtype that expresses only two Ig-like domains, and an FGFR ? subtype 
that expresses all the three Ig-like domains. Those splice events alter FGF/FGFR 
specificity by exposing or obscuring the acidic box that lies between the IgI and IgII 
domains.
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Figure 3_ Schematic representation of the PDGFs/PDGFRs interaction. Three different
PDGFR isoforms are showed: the homodimers aa and bb and the heterodimer ab. The
extracellular domains of all PDGFRs contain five immunoglobulin-like (Ig) domains which
interact with the four different homodimeric PDGF isoforms AA, BB, CC, DD, and the
heterodimeric isoform AB. PDGFRs also have a transmembrane (TM) region and an
intracellular region containing a tyrosine kinase (TK) domain. 
Figure 4_ Schematic representation of the FGFs/FGFRs interaction. The extracellular domain of
FGFRs contains three immunoglobulin-like (IgI–III) domains. FGFs interact with the second and
third of these domains, and heparan sulfate proteoglycans (HSPG) are integral to the FGF–FGFR
signaling complex. FGFRs also have a transmembrane (TM) region and an intracellular region
containing a split tyrosine kinase (TK) domain.
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Inhibitors of angiogenesis 
A large number of angiogenesis inhibitors have been described. For example, there 
are natural molecules that apparently act directly on ECs to block their migration, 
proliferation and/or their ability to form capillary-like tubes. These include proteins 
such as angiostatin, endostatin, thrombospondin-1, troponin-1 and others (Hanahan, 
D. et al., 1996). 
Angiostatin
Angiostatin is a 38 KDa internal fragment of plasminogen (O’ Reilly, M.S. et al.,
1994). Angiostatin enables micrometastasis to remain dormant by increasing the 
tumor cell apoptotic rate. Tumor cells do not synthesize angiostatin directly, but may 
instead produce and secrete an as yet an unidentified enzyme that enters the 
circulation and interacts with plasminogen to release the angiostatin portion 
(Holmgren, L. et al., 1995). 
Thrombospondin-1
A 140 KDa fragment of Thrombospondin-1 (TSP-1) was one of the first natural 
angiogenesis inhibitors to be described. TSP-1 is an inhibitor of tumor growth and 
metastasis in a number of animal models. Its expression is inversely correlated with 
angiogenic activity (Rastinejad, F. et al., 1989). In studies of fibroblasts cultured from 
patients with Li-Fraumeni disease, it was shown that TSP-1 is regulated by the p53
tumor suppressor gene. Loss of p53 results in suppression of TSP-1 and in a 
concomitant increase in angiogenic activity (Dameron, K.M. et al., 1994). 
Endostatin
Endostatin is a 20 KDa carboxy-terminal fragment of collagen XVIII. The identity of 
the enzyme that releases endostatin from collagen XVIII in unknown. Endostatin 
specifically inhibits capillary ECs proliferation in vitro and is a potent inhibitor of the 
growth of primary and metastatic tumors (O’ Reilly, M.S. et al., 1997; Dnanabal, M. et
al., 1999; Bergers, G. et al., 1999). Endostatin has several properties that suggest it 
might be of potential clinical use as an anti-angiogenic agent. One is that endostatin 
does not induce drug resistance as do conventional chemotherapy and radiation. In 
addition, in mouse tumor models, repeated cycles of administering systemic 
endostatin results in prolonged tumor dormancy without further treatment, suggesting 
that endostatin could completely suppress a tumor rather than just inhibit it transiently 
(Boehm, T. et al., 1997). 
Troponin
Troponin I (TnI) is a 22 KDa angiogenesis inhibitor isolated from cartilage (Moses, 
M.A. et al., 1999); it is an endothelial cell-specific inhibitor of FGF- and VEGF-driven 
capillary ECs proliferation in vitro and of neovascularization in cornea models. 
Interestingly, TnI is used clinically as a sensitive serum marker to asses the degree of 
myocardial damage during infarction. It is speculated that the anti-angiogenic 
properties of TnI might responsible for the difficulty in revascularizing ischemic 
myocardium following injury. 
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The vascular endothelial growth factor (VEGF) family
The VEGF family and its receptors play a central, specific role in angiogenesis, 
mediating vascular permeability, endothelial cells proliferation, migration and survival 
(Ferrara, N. 2002). New vessel growth and maturation are highly complex and 
coordinated processes, requiring the sequential activation of a series of receptors by 
numerous ligands (Ferrara, N. 1999; Yancopoulos, G.D. et al., 2000; Carmeliet, P. 
2000a). VEGF (also referred to as VEGF-A) belongs to a gene family that includes 
placental growth factor (PlGF), VEGF-B, VEGF-C and VEGF-D. Homologous of 
VEGF have also been identified in the genome of the sheep parapoxvirus and shows 
to have VEGF-like activities (Ferrara, N. et al., 1997 and Neufeld, G. et al., 1999)
(Figure 5).
MMP cleavage 
(a.a. 113) 
VEGFR-2
binding site 
Plasmin cleavage 
(a.a. 110) 
Heparin-binding site 
Neuropilin-
binding site 
VEGFR-1
binding site 
Signal
sequence
1 2 3 4 5 6a 6b 7 8EXON
2 41 3 5 6a 7 8VEGF-A189
1 2 3 4 5 7 8VEGF-A165
1 2 3 4 5 7 9VEGF-A165b
1 2 3 4 5 6a 8VEGF-A146
1 2 3 4 5 8VEGF-A121
4’1 2 3 4 5 76PlGF-4
4’1 2 3 4 5 7PlGF-3
1 2 3 4 5 76PlGF-2
PlGF-1 1 2 3 4 5 7
VEGF-ENZ-7
Figure 5_ Structure of some VEGF family members. Alternative splicing results in the generation of
several VEGF-A and PlGF isoforms. VEGF-A gene possesses eight exons, the first of which
encodes a hydrophobic leader sequence typical of secreted proteins. VEGF-A189 lacks a portion of
exon 6, whereas VEGF-A165, generally the most commonly expressed isoform, lacks all of exon 6.
VEGF-A145 lacks both exons 6b and 7, and VEGF-A121 lacks all of exons 6 and 7. VEGF-A165b is an
inhibitory form of VEGF-A that lacks exons 6 and 8 and terminates with a portion of the supposed 3’
untraslated region, here designated as exon 9 (Nagy et al. 2007). VEGF receptor and heparin-
binding sites, as well as protease cleavage sites, are shown. Viral VEGF-E and snake venom
VEGFs are encoded by one transcript.
Tfsv-VEGF
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VEGFs
A well documented in vitro activity of VEGF is the ability to promote growth of 
vascular ECs derived from arteries and veins. VEGF induces a potent angiogenic 
response in a variety of in vivo models (Leung, D.W. et al., and Plouet, J. et al.,
1989) and its delivery also induces lymphangiogenesis in mice (Nagy, J.A. et al.,
2002). VEGF is a survival factor for ECs, both in vitro and in vivo. In vitro, it prevents 
apoptosis induced by serum starvation, in vivo induces expression of the anti-
apoptotic proteins Bcl-2 and A1 in ECs (Gerber, H.P. et al., 1998 a and b). VEGF is 
known also as vascular permeability factor (VPF), based on its ability to induce 
vascular leakage (Senger, D.R. et al., 1983 and Dvorak, H.F. et al., 1995). It is now 
well established that such permeability-enhancing activity underlies significant roles 
of this molecule in inflammation and other pathological circumstances (Bates, D.O. et
al., 1997). 
VEGF-A
VEGF-A is the most comprehensively studied member of the VEGF family and has 
singular importance in vascular development (Brown, L.F. et al., 1997; Dvorak, H.F. 
2003; Ferrara, N. et al., 2003; Dvorak, H.F. 2006). Encoded by a single gene of eight 
exons separated by seven introns (Figure 5), VEGF-A is a highly conserved, 
disulfide-bonded dimeric glycoprotein. It shares low, but significant, sequence 
homology with PDGF, and, like PDGF, has cysteines that form inter- and intra-chain 
bonds. Crystal structure reveals that the two chains, that comprise VEGF-A, are 
arranged antiparallel with receptor binding sites at either end (Muller, Y.A. et al.,
1997). Upon reduction, VEGF-A separates into its individual chains and loses all 
biological activity (Dvorak, H.F. 2003). The importance of VEGF-A as a central 
regulator of angiogenesis and vasculogenesis was demonstrated in mice targeted 
gene disruption studies. Even animals that lack one of the two VEGF alleles die 
before birth because of defects in the development of the cardiovascular system 
(Ferrara, N. et al., 1996 and Carmeliet, P. et al., 1996). These observations indicate 
that the development of the cardiovascular system depends on the generation of 
precise VEGF concentration gradients and that a decrease in the amounts of the 
VEGF produced during the development of the embryo may lead to decreased 
angiogenesis with fatal consequences. The human VEGF-A gene is located on the 
short arm of chromosome 6 and is differentially spliced to yield predominant isoforms 
that encode polypeptides of 206, 189, 165, 145 and 121 amino acids in human cells; 
corresponding murine proteins are one amino acid shorter. An additional splice 
variant, 165b, has been found in normal kidneys; it is an endogenous inhibitor of 
VEGF-A165 and is downregulated in renal tumors and therefore may be 
antiangiogenic (Woolard, J. et al., 2004). All VEGF-A isoforms differ significantly in 
their binding to cells and matrices (Park, J.E. et al., 1993; Grunstein, J. et al., 2000; 
Maes, C. et al., 2002; Yu, J.L. et al., 2002; Ruhrberg, C. 2003). VEGF-A165, the most 
prominently expressed isoform in most normal tissues and in pathological 
angiogenesis, is a positively charged molecule, with an iso-electric point (pI) of 8.5, 
that binds to proteoglycans and to other negatively charged matrices (Ferrara, N. et
al., 1992); in fact, VEGF-A was originally purified on heparin affinity columns 
(Senger, D.R. et al., 1983). VEGF-A189 contains the peptides encoded by exon 6 and 
binds to heparin more strongly than VEGF-A165, whereas VEGF-A121 lacks amino 
acids encoded by exons 6 and 7 of the VEGF gene and is acidic, so does not bind to 
heparin and diffuses freely in tissues. These different properties have consequences 
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for VEGF-A function in vivo. Developing blood vessels require both long- and short-
range guidance cues for directional migration (Ruhrberg, C. 2003 and Eichmann, A. 
et al., 2005). VEGF-A165, which is both soluble and matrix bound, can supply both 
types of cues, but when only VEGF-A121 is present, ECs lack guidance over short 
distances. However, when only proteoglycan-bound VEGF-A189 is present, there is a 
deficit in long-range guidance, and migrating ECs fail to branch appropriately. It is not 
surprising, therefore, that mice engineered to express only VEGF-A164 isoform 
develop normally, whereas those engineered to express only VEGF-A120 or VEGF-
A188 develop severe anomalies (Carmeliet, P. 1997 and Yu, J.L. et al., 2002). Matrix
VEGF-A may be inactive or ineffectual and in such circumstances proteases such as 
plasmin or metalloproteinases, which cleave the C-terminal portion of VEGF-A, are 
required to generate a biologically active peptide (Park, J.E. et al., 1993). 
PlGF (placental growth factor)
PlGF is another member of the VEGF family mainly expressed in the placenta and 
tumors. It forms disulphide-linked homodimers, but can also form heterodimers with 
VEGF. PlGF exists in four splice variants that all bind to VEGFR-1, but only PlGF-2 
can also bind to heparin and to the co-receptors neuropilin-1 and 2, due to the 
insertion of a highly basic 21 amino acid sequence encoded by exon 6 of PlGF gene 
(Persico, M. G. et al., 1999). PlGF knock out studies in mice indicate that PlGF is not 
crucial in embryonic vasculogenesis but affects angiogenesis and plasma 
extravasation under pathological conditions (Carmeliet, P. et al., 2001). The 
bioavailability of VEGF and FGF-2 and therefore their capacity to induce 
angiogenesis might be controlled by PlGF-2. PlGF can induce angiogenesis in vivo to 
an extent comparable to VEGF (Bacillari et al., 1998 and Luttun, A. et al., 2002). 
VEGF-B, C and D
VEGF-B is approximately 44% identical to VEGF-A; it exists in the two isoforms 
VEGF-B167 and VEGF-B186 and can form heterodimers with VEGF. VEGF-B binds 
only to VEGFR-1, inducing expression and increased activity of urokinase-type 
plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1), 
suggesting a role in extracellular matrix (ECM) degradation and ECs migration. 
VEGF-C and VEGF-D form a subgroup within the VEGF family as they consist of a 
central VEGF homology domain with N- and C-terminal extensions that are cleaved 
during protein maturation and are not seen in the other VEGFs or PlGF. Both, VEGF-
C and VEGF-D consist of non-covalent dimers and bind to VEGFR-2 and VEGFR-3. 
VEGF-C is mainly expressed during embryogenesis, whereas VEGF-D is also 
expressed in adult heart and skeletal muscle (Jussila, L. et al., 2002). 
VEGF-E
VEGF-E is a novel VEGF variant that was found in different strains of Orf viruses 
(Lyttle, D. J. et al., 1994). Orf viruses belong to the parapox virus family and produce 
a dermatitis in sheep and humans. The lesion produced after infection show 
extensive proliferation of vascular ECs and dilatation of blood vessels. All this could 
be attributed to the presence of a gene encoding for a VEGF family member which 
was designated VEGF-E (Savory, L. J. et al., 2000). The VEGF-E genes of more 
than 20 independent parapox virus variants show an extraordinary degree of 
sequence variation (Mercer, A. A. et al., 2002). It was shown that VEGF-E variants 
exclusively bind to VEGFR-2 stimulating proliferation of human ECs in vitro and 
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vascularization of sheep skin in vivo, with potencies equivalent to VEGF-A165 (Wise,
L. M. et al., 2003). VEGF-E family members show only ~25-35% amino acid identity 
with VEGF-A; interestingly, VEGF-E variants are most closely related to VEGF-A121,
in fact there is no heparin-binding site comparable to exon 7 of VEGF-A165.
Snake venom VEGFs (vammin and VR-1)
Vammin and VR-1 are two anti-HF antiserum reactive proteins isolated from the 
venoms of Vipera ammodytes ammodytes and Daboia russelli russelli, respectively. 
Each chain of vammin contains a total of 110 amino acid residues, while the number 
of residues in each chain of VR-1 is 109 (Yamazaki, Y. et al., 2003). The primary 
structure of vammin and VR-1 shares identity with members of VEGF family, and the 
cysteine knot motif, a characteristic of the VEGF family proteins is completely 
conserved. Snake venom VEGFs (svVEGFs) specifically bind only to VEGFR-2 with 
essentially an equal affinity to VEGF-A165. In fact, most of the important residues for 
KDR binding are highly conserved in vammin and VR-1, but some critical residues 
involved in Flt-1 binding are altered to other amino acid residues (Muller, Y.A. et al.,
1997 and Pan, B. et al., 2002). 
Regulation of VEGF-A expression 
A number of factors regulate low-level expression of VEGF-A in normal tissues and 
induce its over-expression in pathological angiogenesis. One of these, hypoxia, acts 
stimulating both VEGF-A transcription and mRNA stabilization (Claffey, K.P. et al.,
1996 and Levy, A.P. et al., 1997). VEGF-A transcription is under the control of 
hypoxia-inducible factor-1 (HIF-1), a heterodimeric protein transcription factor. One 
HIF-1 subunit, HIF-1?, is constitutively expressed, while the other, HIF-1?, is rapidly 
degraded under normoxic conditions through the ubiquitin pathway. In fact, in the
presence of oxygen, proline 564 in the HIF-1? subunit is hydroxylated by a prolyl 
hydroxylase (Ivan, M. et al., 2001). Then, the product of von Hippel-Lindau tumor-
suppressor gene, pVHL, which is the main regulator of HIF-1, attaches to 
hydroxylated proline within HIF-1. Once bound, pVHL mediates the ubiquitination of 
HIF-1?, which is designated for destruction by the proteasome. Instead, in the 
absence of oxygen, stabilized by hypoxia, HIF-1? translocates into the nucleus, 
dimerizes with HIF-1? and the complex binds to and activates a hypoxia-responsive 
element in the VEGF-A promoter (Fukumura, D. et al., 2001). HIF-1 also activates 
the transcription of other hypoxia-inducible genes such as PDGF, TGF-? and 
erythropoietin (George, D. J. et al., 2003). Hypoxic regulation of VEGF-A expression 
has been demonstrated in many tumors; however, many other tumors express 
VEGF-A constitutively at high levels even under normoxic conditions. In these 
istances, regulation must be achieved by other means. One important mechanism is 
that mediated by oncogenes (i.e. ras) and tumor suppressor genes (i.e. p53). It is 
now clear that these genes, once thought to exert their effects solely on the growth 
properties of tumor cells, have an additional function, inducing VEGF-A expression 
and thereby angiogenesis (Rak, J. et al., 2004 and Mukhopadhyay, D. et al., 2004). 
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VEGF receptors 
The biological activity of the VEGF family proteins is mediated through the binding to 
three types of receptor tyrosine kinases (RTKs), VEGFR-1, -2, -3. Activation of these 
receptors by VEGFs triggers the phosphorylation of a multitude of proteins that are 
active in signal transduction cascades (Matsumoto, T. et al., 2001). Different 
members of the VEGF family show disparate receptor binding specificities and trigger 
several signaling pathways. Both VEGFR-1 and VEGFR-2 have seven 
immunoglobulin-like (Ig-like) domains in the extracellular portion, a single trans-
membrane region and a consensus tyrosine kinase sequence that is interrupted by a 
kinase insert domain (Shibuya, M. et al., 1990 and Terman, B.I. et al., 1991). 
VEGFR-3 is a member of the same family of RTKs but is not a receptor for VEGF-A, 
binding instead to VEGF-C and VEGF-D (Karkkainen, M.J. et al., 2002) In addition to 
these RTKs, VEGF interacts with a family of co-receptors, the neuropilins (Figure 6).
VEGFR-1
VEGFR-1 [also known as Flt-1 (fms-like tyrosine kinase-1) receptor] is a 180 KDa 
high affinity receptor for VEGF-A, VEGF-B and PlGF with a Kd for VEGF-A of 
approximately 10-30 pM (Park, J.E. et al., 1994 and Olofsson, B. et al., 1998) (Figure 
6). It is expressed in vascular ECs and a range of non-endothelial cells including 
haematopoietic stem cells (HSC), macrophages and monocytes. Although Flt-1 was 
Figure 6_ Schematic diagram illustrating the receptor binding specificity of VEGF family members 
and VEGFR/NRP receptors. The VEGF family of ligands and their receptor-binding patterns are 
shown at the top. The activation of downstream signal transduction molecules leads to formation of
blood and lymphatic vessels through several EC functions such as migration, vascular
permeability, survival and proliferation.
the first RTK to be identified as a VEGF receptor more than a decade ago (de Vries, 
C. et al., 1992), the precise function of this molecule is still under debate. Recent 
evidences indicate that the functions and signaling properties of Flt-1can be different 
depending on the developmental stage of the animal and the cell type. The 
mechanisms responsible for VEGFR-1 over-expression are not yet fully understood, 
but hypoxia, which stimulates the expression of VEGF may also upregulate Flt-1 by 
the HIF-1 dependent mechanism (Gerber, H.P. et al., 1997). A natural soluble Flt-1 
receptor (sFlt-1), produced by endothelial and tumor cells has been identified as an 
alternative splice product that contains the first six of the seven amino-terminal 
immunoglobulin-like domains of Flt-1 (Kendall, R. L. et al., 1996). Soluble Flt-1 binds 
to VEGF with high affinity and forms a heterodimeric complex with VEGFR-2. sFlt-1 
protein inhibits VEGF-induced endothelial cell proliferation, in fact, transfection of 
tumor cells with sFlt-1 resulted in reduced tumor growth and metastasis (Goldman, 
C.K. et al., 1998). These results suggest that sFlt-1 acts as an angiogenesis inhibitor 
by sequestering VEGF and/or by acting as a dominant negative effector by forming 
heterodimers with trans-membrane VEGFR tyrosine kinases. Therefore, sFlt-1 and 
Flt-1 receptors have been demonstrated to suppress retinal neovascularization in a 
murine model of ischemic retinopathy (Aiello, L.P. et al., 1995). Besides, gene 
targeting studies have demonstrated that Flt-1-/- mice die in utero between days 8.5 
and 9.5 due to obstruction of vessels by an overgrowth of ECs. In fact, ECs develop, 
but do not organize into vascular channels, indicating that, at least during early 
development, Flt-1 is a negative regulator of VEGF action (Fong, G.H. et al., 1995 
and Fong, G.H. et al., 1999). It was determined that the VEGF (and PlGF) binding 
site is located primarily to the first three immunoglobulin-like domains of Flt-1 and that 
two Flt-1 receptors can be linked by a VEGF bridge. It was also determined that the 
fourth immunoglobulin-like loop contains a receptor dimerization domain (Wiesmann, 
C. et al., 1997). Although Flt-1 receptor binds to VEGF with high affinity, it is a 
kinase-impaired receptor; Flt-1 is poorly tyrosine phosphorylated following ligand 
binding and expresses only weak kinase activity thereafter (Rahimi, N. 2006). The 
activation of Flt-1 receptor by VEGF in cells lacking VEGFR-2 does not induce cell 
proliferation, while activation of the VEGFR-2 receptor by VEGF in cells devoid of Flt-
1 results in a mitogenic response (Waltenberger, J. et al., 1994). However, activation 
of Flt-1 by VEGF does induce cell migration, a response that is also induced as a 
result of VEGFR-2 activation by VEGF (Yoshida, A et al., 1996). These results 
indicate that the signal transduction cascades induced by VEGFR-1 and VEGFR-2 
are somewhat different. It is not yet completely clear why VEGFR-1 does not induce 
cell proliferation in response to VEGF and VEGFR-2 does. MAP kinase was not 
activated by VEGF in cell expressing recombinant VEGFR-1 in two separate studies 
(Seetharam, L. et al., 1995). So, it is possible that VEGFR-1 does not induce cell 
proliferation, because it does not activate MAP kinase. 
VEGFR-2
VEGFR-2 [in human: KDR (kinase domain region) receptor, in mouse: Flk-1 (fetal 
liver kinase-1) receptor] is a 200-230 KDa high affinity receptor for VEGF-A, the 
processed forms of VEGF-C and –D, and VEGF-E (Figure 6). It is expressed in both 
vascular endothelial and lymphatic endothelial cells; its expression has also been 
demonstrated in several other cell types such as HSCs (Katoh, O. et al., 1995). KDR-
/-
 embryos die in utero between days 8.5 and 9.5, exhibiting defects in the 
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development of endothelial and haematopoietic precursors, indicating that the 
receptor is crucial for vascular development (Shalaby, F. et al., 1995). VEGF-A binds 
to the second and third extracellular immunoglobulin-like domains of VEGFR-2 with a 
Kd of 75-125 pM; this affinity is lower than the affinity of VEGF-A for VEGFR-1, but 
VEGFR-2 is expressed in higher copy numbers than VEGFR-1 (Waltenberger, J. et
al., 1994). VEGFR-2 is considered to be the major mediator of several physiological 
and pathological effects of VEGF-A on ECs. These include proliferation and survival, 
migration and permeability. VEGFR-2, like many other receptors, induces 
proliferation through activation of the classical extracellular regulated kinase 
pathway, leading to gene transcription (Takahashi, T. et al., 1999b). VEGFR-2 
function is modulated through co-receptors such as heparan sulfated proteoglycans, 
which interact with certain VEGF isoforms and with VEGFR-2 (Gitay-Goren, H. et al.,
1992). The functional VEGF-VEGFR-2 complex includes neuropilins (Soker, S. et al.,
1998), which are ubiquitous membrane-bound molecules also implicated in axon 
guidance by binding to the semaphorin family members (Neufeld, G. et al., 2002). 
Neuropilins might act by stabilizing the VEGF-VEGFR-2 complex. While hypoxia 
stimulates VEGF expression and upregulates Flt-1, it downregulates VEGFR-2 
(Detmar, M. et al., 1997). 
VEGFR-3
VEGFR-3 (also known as Flt-4) is a 195 KDa high affinity receptor for VEGF-C and –
D. Distinct features of VEGFR-3 includes cleavage during synthesis within the fifth 
extracellular immunoglobulin loop (Figure 6); the two regulating polypeptides are kept 
together by a disulfide bridge (Pajusola, K. et al., 1994). There are two VEGFR-3 
splice variants in humans, one short and one long. Mouse embryos lacking 
expression of VEGFR-3 die at embryonal day 9.5 due to deficient vessel remodeling. 
Larger vessels are disorganized, leading to fluid accumulation and cardiovascular 
failure (Dumont, D. J. et al., 1998). These effects might be owing to a direct loss of 
VEGFR-3 function or because of an indirect effect caused by an increased 
availability of VEGF-C and –D for activation of VEGFR-2 (Hamada, K. et al., 2000). In 
the adult, VEGFR-3 expression is detected primarily in lymphatic endothelial cells, 
where its activation induces proliferation, migration and survival. 
Neuropilins
Neuropilins (NRP-1 and NRP-2) are two non-kinase VEGF receptors possessing a 
lower mass than either VEGFR-1 or VEGFR-2 (Gitay-Goren, H. et al., 1992). These 
receptors are expressed not only on vascular endothelium, but also on many types of 
normal and tumor cells. They have long been known as receptors for the 
semaphorins/collapsin family of neuronal guidance mediators (Neufeld, G. et al.,
2002 and Eichmann, A. et al., 2005). The neuropilins have a short intracellular 
domain; gene disruption studies indicate that neuropilin-1 is probably an important 
regulator of blood vessel development as mouse embryos lacking a functional 
neuropilin-1 gene die because their cardiovascular system fails to develop properly 
(Kitsukawa, T. et al., 1997). Neuropilin-1 is a VEGF co-receptor (Figure 6); this 
assumption is supported by experiments showing that VEGFR-2 binds to VEGF more 
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efficiently in cells expressing NRP-1 (Soker, S. et al., 1998). Neuropilin-1 is not able 
to function as a VEGFR-1 co-receptor (Migdal, M. et al., 1998). 
Structure and functional analysis of VEGF receptors Flt-1 and KDR 
VEGF induces proliferation of ECs through the binding to two receptor tyrosine 
kinases, Flt-1 and KDR/Flk-1. Both receptors belong to the type III tyrosine kinases 
and are characterized by seven Ig-like loops within their extracellular domain and a 
split kinase domain within the cytoplasmatic moiety (Fantl, W. et al., 1993). Both 
VEGF receptors contain several N-glycosylation sites and the apparent molecular 
weights of the mature proteins suggest that both receptors are extensively 
glycosylated (de Vries, C. et al., 1992 and Millauer, B. et al., 1993). Since the dimeric 
structure of VEGF is a prerequisite of receptor activation, it can be speculated that 
one VEGF molecule bridges two receptors via two similar recognition sites (Herren, 
B. et al., 1993). Characterization of VEGF binding to its receptors by mutational 
analysis of the ligand supports the assumption that VEGF has two contacts sites for 
its receptors (Keyt, B. A. et al., 1996). Therefore, domain deletion studies on Flt-1 
(Barleon, B. et al., 1997) generating several soluble mutants of the extracellular 
domains of Flt-1, each consisting of a different stretch of Ig-like loops, have 
suggested that the recognition site for VEGF is located on the first three Ig-like loops, 
whereas dimerization is stabilized due to an additional domain located on Ig-like loop 
four. These studies have also demonstrated that glycosylation is not a prerequisite of 
high affinity binding of VEGF to Flt-1. Besides, deletion experiments on KDR have 
shown that only domains two and three are critical for ligand binding. KDR fourth Ig-
like loop may also function as a dimerization domain, although there is no 
experimental data as yet to prove that assumption (Fuh, G. et al., 1998). The 
receptor binding face of VEGF has been identified by mutagenesis studies (Muller, 
Y.A. et al., 1997), revealing that the binding epitope for KDR contains two “hot spots”, 
each of which extends across the dimer interface. Charge-reversal mutagenesis has 
indicated that some of these same residues are also important for VEGF binding to 
Flt-1 (Keyt, B. A. et al., 1996). The crystal structure to 1.7Å resolution of the complex 
between the receptor-binding domain of VEGF (VEGF 8-109) and Flt-1 domain 2 (Flt-
1D2) (Wiesmann, C. et al., 1997) shows that an Flt-1 construct consisting of domain 2 
binds to VEGF with affinity only about 60 fold weaker than the entire extracellular 
portion. The crystal structure of the complex is the first example of a cystine-knot 
growth factor bound to a domain of its receptor. So, the second domain of Flt-1 (Flt-
1D2) is necessary and sufficient for high affinity VEGF binding. The 1.7Å resolution 
crystal structure of Flt-1D2 bound to VEGF revealed that this domain is a member of 
the immunoglobulin superfamily, but has several unusual features, including a region 
near the N-terminus that bulges away from the domain rather than pairing with the 
neighboring ?-strands (Wiesmann, C. et al., 1997). Some of the residues in this 
region make contact with VEGF, raising the possibility that this bulge could be a 
consequence of VEGF binding and might not be present in the absence of ligand. 
But, in 1999, Starovasnik and co-workers reported the three-dimensional structure of 
Flt-1D2 in its uncomplexed form determined by NMR spectroscopy (Starovasnik, M. A. 
et al., 1999). The solution structure is very similar to the previously reported VEGF-
bound crystal structure and the N-terminal bulge is still present. 1H-15N heteronuclear 
NOEs indicate that this region is flexible in solution. Thus, VEGF-binding is not 
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accompanied by significant structural change in Flt-1D2, and the unusual structural 
features of Flt-1D2 are an intrinsic property of this domain (Starovasnik, M. A. et al.,
1999).
Structures of VEGF-A and PlGF 
Structure of VEGF-A in the free form and bound to D2 of VEGFR-1 
VEGF-A in the free form
The crystal structure of VEGF-A (residues 8-109, VEGF-A8-109) shows a homodimer, 
organized in an antiparallel arrangement with a 2-fold axis perpendicular to the plane 
of the ?-sheets (Figure 7A). The homodimer is covalently linked by 2 intermolecular 
disulfide bonds between C51 and C60. Each monomer consists of a central irregular 
antiparallel four-stranded ?-sheet with the characteristic cysteine-knot motif. The knot 
is formed by two intra-molecular disulfide bonds C57-C102 and C61-C104 which form a 
ring structure through which a third disulfide bond C26-C68 passes and connects ?1
and the end of loop 2. The cysteine-knot motif is similar to that of the related growth 
factor PDGF. Each monomer contains three solvent-accessible loop regions 
connecting the individual ? strands (Figure 7B). In addition, an ?-helix is present at 
each N-terminus. While the monomer-monomer interface is predominantly formed by 
a hydrophobic core, the ?-sheets are solvent exposed on both sides (Muller, Y.A. et
al., 1997 and Starovasnik, M. A. et al., 1999). 
PlGF). While loop 2 adopts a very similar conformation in both proteins, loop 1 and 3 show
Figure 7_ Representation of VEGF-A (A) and superposition of VEGF-A and PlGF in the
free form (B). Crystal structures form VEGF-A (green) and PlGF (blue) were superimposed
according to the C? atoms. (A) Disulfide bonds forming the cysteine-knot in monomer A are
highlighted in yellow. In addition the 2 intermolecular S-S bridges are shown. (B) Ribbon
representation: the individual ?-strands are connected by three loops (shown for monomer A of
slight deviations. 
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VEGF-A in complex with D2 of VEGFR-1
VEGF-A (VEGF8-109) adopts in the bound state a very similar conformation as in the 
free form (Figures 8A and 8B). Slight differences are only observed for loop 1 
(residues 42-48) and loop 3 (residues 85-89), which are also flexible in the free form 
(Wiesmann, C. et al., 1997). Comparison of a NMR structure of the unbound D2 
(corresponding to residues 129-229) with the crystal structure of the complex has 
shown that no structural changes are induced upon ligand binding (Starovasnik, M. 
A. et al., 1999). Each D2 is in contact with both monomers of the ligand. The contact 
surface is divided into a hydrophobic (~65%) and hydrophilic part (~35%). The only 
direct polar interaction is a bidentate set of charge-mediated hydrogen bonds 
between side chains of R224 of D2 and D63 of VEGF-A. R224 was shown to be critical 
for high affinity binding (Davis-Smyth, T. et al., 1998). The remaining polar 
interactions in the interface are mediated by water molecules that bridge between the 
ligand and the receptor. 
loop 1-3 composed from the two monomers.
Figure 8_ Superposition of VEGF-A and PlGF with D2 of VEGFR-1
Crystal structures from VEGF-A (blue) and PlGF (green) in complex with D2 (wheat) of VEGFR-1
were superimposed according to the C? atoms. A) side view and B) top view. Indicated in B are
the three loops for the upper monomer of the ligands showing that loop 1 and 3 interact with D2 on
one site while loop 2 interacts with the opposing D2. Therefore each D2 is in contact with a set of
Structure of PlGF in the free form and bound to D2 of VEGFR-1 
PlGF in the free form
PlGF (PlGF8-109) and VEGF-A exhibit a remarkable structural similarity. Differences 
are observed in the N-terminal residues, in loop 1 and loop 3 (Iyer, S. et al., 2001) 
(see Figure 7). 
PlGF in complex with D2 of VEGFR-1
As drawn in Fig. 8A and 8B, the overall binding pattern of PlGF to D2 of Flt-1 
resembles that of VEGF-A (Christinger, H. W. et al., 2004). The interface is largely of 
hydrophobic nature with three direct polar interactions; one is the hydrogen bond 
formed between the side chain of Q19 of PlGF and the main chain carbonyl of E141 of 
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D2, and two charged interactions occur between D62 of PlGF and R224 of D2 from Flt-
1. A bis-Tris propane molecule from the crystallization buffer is in contact with PlGF 
and D2 of VEGFR-1 near the interface. Presumably, this molecule greatly stabilizes 
the crystal packing arrangement. The PlGF dimer is slightly altered when bound to 
D2, mainly in the regions of loop 1 and loop 3 which results in a more open 
conformation of the ligand. Because of a dense crystal packing in this area it cannot 
be excluded that the observed interactions are influenced by packing effects. 
VEGF and the induction of pathological angiogenesis: therapeutic 
implication and perspectives 
VEGF plays a crucial role in physiological and pathological angiogenesis, including 
solid tumor growth and metastasis (Fidler, I. J. et al., 1994 and Folkman, J. 1995)
(Figure 9). As the formation of the normal blood vasculature, pathological 
angiogenesis is a multi-step process that requires ECs division, migration, 
organization into cords, lumen formation, acquisition of pericytes and degradation of 
old and synthesis of new basement membrane. In pathological angiogenesis VEGF-
A induces the formation of several distinctly different types of new blood vessels with 
respect to organization, structure and function (Nagy, J. A. et al., 2007). The 
importance of the function of VEGF suggests that blocking its function is a promising 
new therapeutic strategy for inhibiting angiogenesis and tumor growth. In the past 
years hybridization studies have shown that VEGF mRNA is upregulated in many 
human tumors (Dvorak, H.F. 1995 and Ferrara, N. et al., 1997). Even though tumors 
do not exhibit an organized structure, from the point of view of angiogenesis a 
growing tumor may be viewed as a developing new organ. Angiogenesis is as 
essential for the growing tumor as it is for a developing organ such as the corpus 
luteum, since the delivery of blood-borne nutrients to the tumor cells is essential for 
their survival (Hanahan, D. et al., 1996). When VEGF signaling is inhibited, tumor 
angiogenesis and, consequently, tumor growth are impaired (Kim, K.J. et al., 1993 
and Millauer, B. et al., 1994). Besides, as VEGF binds to Flt-1 and KDR/Flk-1, 
thereby activating signal transduction and regulating physiological and pathological 
angiogenesis, to find an agent that inhibits binding between VEGF and its receptors 
may serve as a valuable antiangiogenic and antitumor agent. Many studies reported 
that antibodies to VEGF exert a potent inhibitory effect on the growth of several 
tumor cell lines in nude mice (Kim, K.J. et al., 1993). Subsequently, many other tumor 
cell lines were found to be inhibited in vivo by this and other anti-VEGF treatments, 
including antisense oligonucleotides and antibodies to VEGFR-2 (Ferrara, N. et al.,
1997). Several studies have shown that combining anti-VEGF treatments with 
chemotherapy (Klement, G. et al., 2000) or radiation therapy (Lee, C.G. et al., 2000) 
results in a greater antitumor effect than either treatment alone. In the past years, 
clinical trials in cancer patients were carried out with several VEGF inhibitors, 
including a humanized monoclonal antibody to VEGF (rhuMab VEGF) (Presta, L.G. 
et al., 1997), an anti-VEGFR-2 antibody (Prewett, M. et al., 1999), small molecules 
inhibiting VEGFR-2 signal transduction (Wood, J.M. et al., 2000) and a soluble VEGF 
receptor (Holash, J. 2002). Phase 2 clinical data provided initial evidence that 
rhuMab VEGF, in combination with conventional chemotherapy, resulted in increase 
in time to progression and even survival in patients with metastatic colorectal 
carcinoma (Kabbinavar, F. et al., 2003). Phase 3 studies are currently under way to 
30
confirm and fully assess the benefit of these anti-VEGF treatments in patients with 
advanced cancer. Another humanized anti-VEGF-A monoclonal antibody is 
Bevacizumab (trade name Avastin), approved, in February 2004, by the US Food 
and Drug Administration (FDA) in the United States for the treatment of metastatic 
colorectal cancer, in combination with chemotherapy regimens. This followed from a 
phase 3 study showing survival benefits (Hurwitz, H. et al., 2004). The first VEGF 
receptor tyrosine kinase inhibitor, SU5416, have already been reported; it has 
produced certain clinical benefits in clinical trials involving patients suffering from 
advanced malignancies (Stopeck, A. et al., 2002). Besides, Yasuij Ueda and co-
workers, using a high throughput screening method, have found a small molecular 
compound, 5-[N-methyl-N-(4-octadecyloxyphenyl) acetil] amino-2-methylthiobenzoic 
acid (VGA1155), that was selected for its potent inhibition of binding of VEGF to its 
receptors through association with KDR/Flk-1 (Ueda, Y. et al., 2003). 
Figure 9_ Endothelial cell survival in pathological angiogenesis: tumor growth.
De novo engineered VEGF mimicking peptides 
The analysis of structural and mutagenesis data allowed to identify the residues 
involved in the binding of VEGF to its receptors. They are distributed over a 
discontinuous surface that includes residues from the N-terminal helix 17-25. KDR 
and Flt-1 share the VEGF binding region, in fact, five of the seven most important 
VEGF binding residues are present in both interfaces (Keyt, B. A. et al., 1996; Muller, 
Y.A. et al., 1997; Wiesmann, C. et al., 1997). Many approaches have been pursued 
to modulate the VEGF-receptors interaction, and new molecular entities as peptides 
have been reported to bind to the extracellular region of the VEGF receptors. A large 
number of them show an antagonist activity and only few behave as agonists 
(D’Andrea, L. D. et al., 2008, submitted). Remarkably, the peptides modulating the 
VEGF-receptors interaction are mainly derived by phage display libraries screening, 
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and only few examples of rational design approaches have been reported so far 
(Zilberberg, L. et al., 2003). In our laboratory was designed, by a structure-based 
approach, a peptide of 15 amino acid residues, QK (Ac-KLTWQELYQLKYKGI-NH2),
reproducing the VEGF 17-25 helix region (D’Andrea, L. D. et al., 2005). It is well 
known that peptide fragments spanning helices, turns and ?-hairpins of natural 
proteins show little propensity, with very few exceptions, to reproduce their natural 
secondary structure under physiological conditions (De Grado, W. F. et al., 1999). 
Nevertheless, the stabilization of suitable conformation in aqueous solutions is a 
condition to gain the binding of designed peptides to their targets. All data collected 
on the structural preferences of the QK peptide in aqueous solution strongly indicated 
that it mainly folds in helical conformation. In particular, the first indication derives 
from the CD spectrum, which is well confirmed by the H? chemical shift analysis and 
the NMR structure determination (D’Andrea, L. D. et al., 2005). The basis of the QK 
helical fold seems to reside on the presence of amino acids with intrinsic helix 
preference and on the amphipathic nature of the helix. The biological properties of 
QK were tested performing an in vitro angiogenesis assay. In this assay QK induced 
the formation of newly formed connections in a dose-dependent manner and 
enhanced the VEGF response. These results demonstrate that QK binds to VEGF 
receptors in vitro and show that it is a potential agonist for angiogenesis. QK shows 
an unusual thermal stability (D’Andrea, L. D. et al., 2005) and very recently it was 
showed to be active in gastric ulcer healing in rodents when it is administered either 
orally or systemically (Dudar G.K. et al., 2008). Although QK was designed to bind to 
KDR and Flt-1, its agonist-like activity is surprising because receptor dimerization is 
necessary for receptor activation. QK is a small peptide and probably is unable to 
induce receptor dimerization by itself. To explain the activity of QK and its additive 
effects in presence of VEGF, we can speculate that the QK binding possibly induces 
a conformational change of the receptor that either triggers, in an unknown way, the 
dimerization or induces the receptor activation through a different uncharacterized 
mechanism that may not require dimerization. Further structural and biochemical 
studies are needed to address this issue. Anyway, these data are suggestive that 
either QK or improved analogues might fulfil the request for a safer pro-angiogenic 
drug. As therapeutic angiogenesis in cardiovascular conditions such as chronic 
ischemia or heart failure is sought as a promise of modern biotechnology, potential 
applications for QK are in the diagnostic field and in therapy of cardiovascular 
disease. An analogue of QK is MA, a peptide of 15 amino acid residues (Ac-
KLTWMELYQLAYKGI-NH2) synthesized and characterized by NMR in our 
laboratory. MA-VEGF competition binding assays were carried out by FACS 
indicating that the peptide is able to bind with specificity to VEGF receptors on ECs 
surface, inhibiting VEGF anti-apoptotic activity of over 80%, thus showing an 
antagonist activity with respect to VEGF (Del Gatto, A. PhD thesis, 2005). 
The aim of the work 
In the last years, much of the basic research in angiogenesis has been focused on 
detailing the steps involved in blood vessel growth and in identifying molecules that 
play a key role in regulating this process. This heightened analysis is due in part to 
the realization that aberrant angiogenesis is involved in relevant pathological 
conditions. Over the past decade, intensive efforts have been undertaken to inhibit 
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angiogenesis in cancer, ocular, joint or skin disorders or to develop therapeutic 
strategies to promote revascularization of ischemic tissues (Carmeliet, P. 2005). 
Despite some initial setbacks and negative clinical trial results, new angiogenic 
modulators have been developed in the last years. They mainly fall in three classes: 
antibodies, peptides and small molecules. Some of these molecules have been 
approved for treatment of cancer (Avastin), or are in phase 3 of clinical trials (Ferrara, 
N. 2005). Because of VEGF’s predominant role in angiogenesis, inhibition of VEGF 
seems to be necessary but is probably insufficient to permanently halt this process in 
many disorders. Considering the anti-tumor therapy, the angiogenic inhibitors are, 
generally, more safe and less toxic than chemotherapeutic substances, but their 
exclusive administration as drugs in the treatment of tumors is rare. In fact, a wide 
range of different growth factors are involved in the stimulation of angiogenesis and 
the blockage of one factor alone  might not be sufficient to inhibit the angiogenesis 
for a prolonged time period, as tumors could compensate by overproducing other 
growth factors (Carmeliet, P. 2005). Despite the problems involved, the anti-
angiogenic therapy continues to arouse notable interest. In fact, angiogenic 
inhibitors, if used in conjunction with traditional therapies, have the ability to enhance 
therapeutic efficacy without significantly raising the risk of toxic side effects. In the 
process of angiogenesis, vascular endothelial growth factor binds to Flt-1 and KDR, 
thereby activating signal transduction and regulating physiological and pathological 
angiogenesis (Neufeld, G. 1999). Actually, of these receptors, are not well known 
structural data, done exception for the domain 2 of Flt-1 of which, in the literature, is 
reported the crystal structure complexed with VEGF and PlGF (Wiesmann, C. et al.,
1997 and Christinger, H. W. et al., 2004) and the three-dimensional, uncomplexed 
form determined by NMR spectroscopy (Starovasnik, M. A. et al., 1999). 
The aim of this PhD thesis is the expression and characterization of the extracellular 
domains of VEGF receptors, in order to find new compounds of biotechnology 
interest for modulating the angiogenesis process. Because the angiogenic response 
strictly depends on VEGF and on functions and signaling properties of its receptors, 
we centered our efforts on the characterization of the extracellular portion of Flt-1 
(VEGFR-1) and KDR (VEGFR-2) receptors. In particular, we expressed some of their 
extracellular Ig-like domains, focusing the attention on their structural 
characterization via NMR and on their employment in the identification and 
improvement of new organic or peptide-based molecules targeting the VEGF 
receptors. In fact, once expressed and purified Flt-1D2, we used the second domain 
of VEGFR-1 for interaction studies with QK (VEGF agonist) and MA (VEGF 
antagonist) peptides (D’Andrea, L. D. et al., 2005 and Del Gatto, A. PhD thesis, 
2005), in order to better understand their biological behavior in angiogenesis 
process. Therefore, the recombinant Flt-1D2 was employed for the screening of a 
library of organic molecules by drug discovery analysis, in order to find other new 
class of VEGF receptor binders.
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Materials and Methods 
Strains, enzymes and reagents 
Reagents used for preparation of buffers and growth media of Escherichia coli and
the reagents for polyacrylamide gels electrophoresis (Acrylamide, APS, TEMED, 
SDS, Tris, Glycine) were supplied by Sigma Aldrich, Euroclone, Applichem and ICN 
Biomedicals. The molecular weight markers for proteins were from Sigma Aldrich. 
The restriction enzymes and the “modification enzymes” (calf intestine phosphatase, 
T4 DNA ligase and T4 DNA polynucleotide kinase) were supplied by New England 
Biolabs (NEB) and the molecular weight markers for nucleic acids were supplied by 
NEB and Roche. The Pfu Turbo polymerase (2.5 U/µL) was supplied by Stratagene, 
while Taq DNA polymerase (5 U/µL) was from NEB. The synthesis of the
oligonucleotides was committed at Sigma-Genosys; pETM11 and pETM20 E. coli 
expression plasmids were supplied by Novagen, while the expression vector 
pPROEXHTa was supplied by Invitrogen. E. coli TOP F’10 strain, used for cloning, 
was supplied by Invitrogen; E. coli BL21 Codon Plus (DE3) RIL cells, used for 
overexpression, were supplied by Stratagene. BL21(DE3), BL21(DE3) STAR and 
JM101 strains, also used for expression, were supplied by Invitrogen while Rosetta 
GAMI (DE3) were from Novagen. Complete Protease Inhibitor Cocktail Tablets were 
supplied by Roche and used as a mixture of protease inhibitors, according to 
manufacturer’s instruction. Ethanol, isopropilic alcohol and acetic acid were supplied 
by J.T. Baker. TFA was from Fluka. Purity and identity of protein samples were 
assessed by liquid chromatography mass spectrometry (LC-MS) performed on a 
Thermo Electron Corporation mass spectrometer equipped with an ESI source. The 
analysis of proteins was carried out on a C4 column, using a method (referred to as 
“method A”) developed at 0.2 mL/min with a linear gradient of 0.1% aqueous TFA-
0.1%TFA in CH3CN, from 5% to 70% for 30 min. 
Antibiotics
Ampicillin (supplied by Sigma Aldrich as ampicillin sodium salt) and kanamycin 
(supplied by Sigma Aldrich as kanamycin sulphate) were solubilized in deionized 
water at a concentration of 1000X, filter sterilized and stored at –20°C until use. 
Ampicillin was used at a concentration of 100 µg/mL and kanamicin was used at a 
concentration of 50 µg/mL in both solid and liquid media. Chloramphenicol and 
tetracycline were solubilized in ethanol 96% and used at a concentration of 33 µg/mL
and 12.5 µg/mL, respectively.
E. coli cells transformation techniques 
Preparation of E. coli TOP F’10 cells and transformation by electroporation 
2.5 mL of an overnight culture of E. coli TOP F’10 cells were inoculated into 250 mL 
of LB medium. The cells were grown up to mid-log phase (0.6 OD600) at 37°C, stored 
on ice for 20-30 min and then harvested by centrifugation (6000 rpm, 10 min, 4°C). 
The pellet was washed in 250 mL of sterile water. After the second centrifugation the 
cells were washed in 125 mL of sterile water. The third washing was performed in 5 
mL 10% glycerol; the cells were then harvested by centrifugation and the pellet was 
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resuspended in 750 µL of 10% glycerol. Aliquots of 1010 cells/mL (40 µL) were mixed 
with 1 µL of the DNA ligase reaction, incubated for 1 min on ice and transferred into 
chilled plastic cuvettes with an electrode gap of 0.2 cm (M-Medical). High voltage 
electroporation (25 µF) was performed with a Bio-Rad Gene Pulser XcellTM at a field 
strength of 2.5 kV/cm and 200 Ohm. A shock pulse was applied to competent cells 
producing pulse length of ~5.0-5.5 ms. Immediately after electroporation cell mixtures 
were diluted to 1 mL with LB medium and incubated for ~1 h at 37°C under shacking. 
The cells were then plated onto selective solid medium supplemented with 100 
µg/mL ampicillin or 50 µg/mL kanamicin to isolate the recombinant clones. Single 
clones were inoculated in 5 mL LB medium with the same antibiotics and grown over 
night at 37°C under shaking. Finally, were harvested by centrifugation (13.000 rpm, 2 
min, 4°C) and processed  to extract plasmidic DNA by using the QIAprep Spin 
Miniprep Kit or the QIAGEN plasmid Maxi Kit (both supplied by Qiagen). 
Preparation of E. coli BL21 (DE3) competent cells and transformation by heat 
shock
Single clones of BL21 (DE3) E. coli strains, grown at 37°C in LB agar, were 
inoculated into 2.5 mL of LB medium and incubated overnight at 37°C on a shaker. 
The cells were inoculated into 250 mL of LB medium and the culture was grown up to 
mid-log phase (0.6 OD600) at 37°C, stored on ice for 20-30 min and then harvested by 
centrifugation (6000 rpm, 10 min, 4°C). The pellet was washed in 125 mL of cold 50 
mM CaCl2 and stored on ice for 30 min. Successively, the cells were harvested by 
centrifugation and the pellet resuspended in 16 mL of cold 50 mM CaCl2. Aliquots of 
200 µL of competent cells were mixed with 50 ng of plasmidic DNA and stored on ice 
for ~30 min. The cells mixtures were transferred at 42°C for 90 sec, on ice for 2 min 
(heat shock) and then diluted to 1 mL with LB medium. An incubation for ~1 h at 
37°C under shacking was performed before plating the cells onto selective solid 
medium supplemented with the opportune antibiotics, depending on the strain. 
Proteins analyses
Determination of the protein concentration 
The concentration of the proteins in solution was determined according to the 
Bradford’s method (Bradford, 1976). The Coomassie Brilliant (Bio-Rad) reagent was 
added to the samples and the absorbance at 595 nm was monitored. A solution of 1 
µg/µL of bovine serum albumin (BSA) was used as standard. Protein concentration 
was also measured by UV spectroscopy, reading the tryptophan absorbance at 280 
nm, using a Jasco V-550 UV-VIS spectrophotometer, in an 1 cm quartz cell. 
Electrophoretic analysis of proteins (SDS-PAGE) 
The electrophoresis on polyacrylamide gel in the presence of SDS (SDS-PAGE) was 
performed according to Laemmli’s protocol (Laemmli, 1970). The samples were 
denaturized at 100°C for 10 min in 1% SDS (Applichem), 5% ?-mercaptoethanol
(Sigma), 0.001% bromophenol blue (ICN Biomedicals) and 10% glycerol 
(Applichem). The samples were then loaded on a 15% or 18% polyacrylamide gel 
and electrophoresed in 0.025 M Tris-HCl, 0.2 M glycine pH 8.3 and 0.1% SDS. The 
electrophoresis was performed at 25 mA for ~1.5 hours. The proteins were then 
revealed by Coomassie Brilliant-Blue (Applichem) staining; the gel was submerged in 
the staining solution (0.1% Coomassie Brilliant-Blue R250, 25% isopropilic alcohol 
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and 10% acetic acid) for ~30 min with gentle agitation. The gel was washed in a 
solution containing 30% ethanol and 10% acetic acid to remove the excess of 
Coomassie and then stored in 10% acetic acid. Alternatively, the proteins were 
transferred by electro-blotting from gel to a polyvinylidene fluoride (PVDF) membrane 
as described in the paragraph “Western blot analysis”. For native PAGE the samples 
were not denaturized at 100°C but loaded on a 10% polyacrylamide gel in 0.001% 
bromophenol blue and 10% glycerol and electrophoresed in Tris-glycine buffer 
without SDS. The electrophoresis was performed at 15 mA for ~2 hours, after a gel 
pre-run of 30 min. The proteins were then revealed by Coomassie Brilliant-Blue 
staining, as described above. 
Bioinformatic tools 
Protein sequences were processed using the pI/Mw tool available on the ExPASy 
Server (http://www.expasy.ch), in proteomics and sequence analysis tools section. 
Compute pI/Mw is a tool which allows the computation of the theoretical pI 
(isoelectric point) and Mw (molecular weight) for a list of UniProt Knowledgebase
(Swiss-Prot or TrEMBL) entries or for user entered sequences. 
Domains cloning of human KDR and Flt-1 receptors
The genes corresponding to the extracellular domains of KDR and Flt-1 receptors 
were amplified by PCR from NIH-3T3 cDNA of the entire receptors (kindly provided 
by Dr. Nicola Normanno).
Cloning of 1-3, 2-3, 1-2 and 2 KDR receptor domains 
The amplification of domains 1, 2, 3 of KDR was performed by using the following 
couples of primers: 
kdrD1-3 gene (residues 1-335, Fuh et al., 1998) 
Forward: 5’- CGGGATCCGAAAGACATACTTACAATTAAGGCTAA -3’ 
Reverse: 5’- CCGCTCGAGCTATCATCCAAAAGCAACAAAAGGTTTTTCATG-3’
kdrD2-3 gene (residues 120-335, Fuh et al., 1998)
Forward: 5’- CGGGATCCGTACAGATCTCCATTTATTGCTTCTGTT -3’ 
Reverse: 5’- CCGCTCGAGCTATCATCCAAAAGCAACAAAAGGTTTTTCATG -3’
In this case, the reverse primer was the same used for the amplification of kdrD1-3
gene.
kdrD1-2 gene (residues1-222, Fuh et al., 1998)
Forward: 5’- CGGGATCCGAAAGACATACTTACAATTAAGGCTAA -3’ 
Reverse: 5’- CCGCTCGAGCTATCACCTATACCCTACAACGACAACTATGTA -3’
In this case, the forward primer was the same used for the amplification of kdrD1-3
gene. Finally, the PCR reaction necessary to obtain domain 2 of KDR was performed 
with the following primers: 
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kdrD2 gene (residues 120-222, Fuh et al., 1998)
Forward: 5’- CGGGATCCGTACAGATCTCCATTTATTGCTTCTGTT -3’ 
Reverse: 5’- CCGCTCGAGCTATCACCTATACCCTACAACGACAACTATGTA -3’. 
The forward primers indicated above contained the BamHI restriction site, while the 
reverse primers were designed with the XhoI restriction site (underlined in the 
sequences) positioned downstream to two stop-translation codons (in bold in the 
sequences). This cloning strategy was used to obtain the gene products fused (at the 
N-terminal) with the 6xHistidine-tag of the pPROEXHTa expression vector (see 
below, Figure 10). The pPROEXHTa plasmid is designed to allow inducible, high level 
intracellular expression of genes; it contains a tac promoter for chemical induction, a 
multiple cloning site (MCS), an internal lac Iq gene compatible to any E. coli host and 
a TEV protease recognition site for cleaving the fusion protein.
All amplification reactions were performed in a final volume of 100 µL, using 50 ng of 
template DNA. The reaction mixture contained the 2 primers (0.25 µM each), dNTPs 
(0.25 mM each) and the Pfu turbo polymerase (5U) with its buffer 1x. PCR was 
performed using an Eppendorf Mastercycler personal apparatus, following the 
procedure indicated below: 
?? Initial denaturation step 3 min at 95°C 
??Denaturation (step 2) 1 min at 95°C 
?? Annealing (step 3) 1 min at the convenient temperature for each 
gene amplified
?? Elongation (step 4) 1 min at 72°C 
for 30 cycles, from step 2. 
All amplification products were analyzed by 1% agarose (Euroclone) gel 
electrophoresis performed in TAE buffer (18.6 g/L EDTA, 242 g/L Tris base. Add 
acetic acid until pH 7.8). PCR products were purified by using the QIAquick PCR
Purification Kit (Qiagen), and digested with BamHI (20 U/?L) and XhoI (20 U/?L)
restriction enzymes. Each amplified fragment (1?g) was digested with 3U of 
restriction enzymes for 2 hours at 37ºC in a buffer containing 50 mM NaCl, 10 mM 
Tris-HCl, 10 mM MgCl2, 1 mM DTT pH 7.9 supplemented with BSA 100 µg/mL. 
Following the digestion, each fragment was cloned into the corresponding sites of the 
pPROEXHTa expression vector, downstream to the His-tag sequence. To this 
purpose, the expression vector was previously digested with the same restriction 
enzymes (3 U/?g), and treated with calf intestine phosphatase (CIP, 10U) (NEB) for 
30 min at 37ºC. CIP enzyme (10 U/?L) was then inactivated at 75°C for 10 min. After 
digestion, PCR amplifications were purified by QIAquick PCR Purification Kit 
(Qiagen), while the BamHI/XhoI pPROEXHTa was purified by QIAquick Gel 
Extraction Kit (Qiagen). For ligation reactions was used a 1:3 molar ratio 
(vector/insert DNA) for shorter fragments and a 1:6 molar ratio for the longer ones. 
The reactions were performed using 20 U/?g DNA of the T4 DNA Ligase (400 U/?L),
in a final volume of 10 ?L, for 3 hours at RT. The identity of the inserts in the resulting 
recombinant plasmids was confirmed by DNA sequencing (MWG-Biotech). E. coli 
TOP F’10 strain was used for cloning. kdrD2 gene was cloned also in pETM11 and 
pETM20 expression vectors (see Figures 11, 12). The primers used for amplification 
of the gene in these systems were:
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Forward: 5’- GCCATGGCGTACAGATCTCCATTTATTGCT -3’ 
Reverse: 5’- CCGCTCGAGCTATCACCTATACCCTACAACGACAACTATGTA -3’
where the reverse primer was the same used for the amplification of kdrD1-2 gene,
while the forward primer contained the NcoI restriction site. pETM11 and pETM20 
expression vectors contain a T7 promoter for chemical induction and overexpression 
of recombinant proteins, a multiple cloning site (MCS) and a TEV protease 
recognition site for cleaving the fusion protein.  pETM11 contains a 6xHistidine-tag, 
while the pETM20 system contains a 6xHistidine-TrxA fusion tag for the increase of 
the solubility of gene products. 
kdrD2 gene mutagenesis 
The C161 residue of domain 2 was mutated in Alanine by using the QuikChange Site 
Directed Mutagenesis Kit (Stratagene). The primers employed for mutagenesis PCR 
reaction are reported below: 
Forward: 5’- AACGTGTCACTTGCTGCAAGATACCCA -3’ 
Reverse: 5’- TGGGTATCTTGCAGCAAGTGACACGTT -3’
Codons corresponding to the mutated amino acid are underlined in primers 
sequences. The recombinant construct pETM11-kdrD2 was used as template. The 
PCR reaction was performed, according to the Kit instructions, using an Eppendorf
Mastercycler personal apparatus, following the procedure indicated below: 
?? Initial denaturation step 1 min at 95°C 
??Denaturation (step 2) 50 sec at 95°C 
?? Annealing (step 3) 50 sec at 58°C
?? Elongation (step 4) 12 min at 68°C 
for 16 cycles from step 2.
XL1-Blue supercompetent cells (supplied by the mutagenesis Kit) were used for the 
transformation of the circular, nicked dsDNA (the methylated, non-mutated, parental 
DNA from mutagenesis PCR was first digested, for 2 hours at 37°C, with the 
restriction enzyme DpnI-10 U/?L). The identity of the mutagenic insert was confirmed 
by DNA sequencing. 
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Fig.10_ Structural organization of pPROEXHTa expression vector (Invitrogen).
Fig.11_ Structural organization of pETM11 expression vector (Novagen).
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Fig.12_ Structural organization of pETM20 expression vector (Novagen). 
Cloning of 1-4, 2-4, 2-3 and 2 Flt-1 receptor domains
Domains 1, 2, 3, 4 of Flt-1 receptor gene were amplified by PCR using the following 
couples of primers: 
flt-1D1-4 gene (residues 27-428, Wiesmann et al., 1998)
Forward: 5’- GCCATGGCGTCAAAATTAAAAGATCCTGAA -3’ 
Reverse: 5’- GTGCTCGAGCTATCAGGGTTTCACATTGACAAT -3’
flt-1D2-4 gene (residues 129-428, Wiesmann et al., 1998)
Forward: 5’- GCCATGGCGAGTGATACAGGTAGACCTTTC -3’ 
Reverse: 5’- GTGCTCGAGCTATCAGGGTTTCACATTGACAAT -3’
flt-1D2-3 gene (residues 129-334, Wiesmann et al., 1998)
Forward: 5’- GCCATGGCGAGTGATACAGGTAGACCTTTC -3’ 
Reverse: 5’- GTGCTCGAGCTATCAGATGAATGCTTTATCATA -3’
flt-1D2 gene (residues 129-229, Wiesmann et al., 1998)
Forward: 5’- GCCATGGCGAGTGATACAGGTAGACCTTTC -3’ 
Reverse: 5’- GTGCTCGAGCTATCAGATTGTATTGGTTTGTCG -3’. 
The forward primers indicated above contained the NcoI restriction site, while the 
reverse primers were designed with the XhoI restriction site (underlined in the 
sequences). All amplification reactions of the genes were performed as described 
above, in a final volume of 100 µL, using 50 ng of template DNA. The reaction 
mixture contained the 2 primers (10 µM each), dNTPs (0.25 mM each) and the Pfu
turbo polymerase (5U) with its buffer 1x. PCR was performed using the same 
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apparatus, following the procedure indicated above for KDR receptor domains. flt-1D2
gene was also cloned in the pETM20 expression vector using the same primers 
employed in the cloning of the gene in pETM11. PCR products were purified and 
digested following the same procedure described above for kdr genes. 
Expression and purification of recombinant KDR and Flt-1 
extracellular domains
Expression
After a first screening of small expression cultures, performed using different strains, 
temperatures and IPTG concentration, all the recombinant constructs obtained with 
cloning of Ig-like KDR and Flt-1 receptors domains in pPROEXHTa, pETM11 and 
pETM20 were transferred into E. coli BL21 Codon Plus (DE3) RIL cells. In fact, in all 
used conditions and strains, the proteins of interest were expressed in inclusion 
bodies, so we selected E. coli BL21 Codon Plus (DE3) RIL cells that assured a better 
expression of all proteins. Single clones of RIL strain, previously transformed with 
each recombinant expression vector and grown at 37ºC on LB agar containing 
antibiotics, were inoculated in 10 mL of LB medium, containing the same antibiotics. 
The overnight cultures were inoculated into 1L of prewarmed LB medium 
supplemented with antibiotics: 100 µg/mL ampicillin (for pPROEXHTa and pETM20 
recombinant vectors) or 50 µg/mL kanamycin (for pETM11 recombinant vectors) and 
33 µg/mL chloramphenicol. Cultures were grown at 37°C under shaking until they 
reached the mid-log phase (0.7/0.8 OD600) then, they were induced with 0.7 mM 
IPTG (Inalco). After 3-4 hours the cells were harvested by centrifugation (6000 rpm, 
15 min, 4°C). Cell pellets were resuspended in 50 mM Tris–HCl, pH 8 containing 
protease inhibitors, to avoid proteins degradation, and the suspension was sonicated 
for 6 min, by using a Misonix Sonicator 3000 apparatus with a micro tip probe and an 
impulse output of 1.5/2 (=9/12 Watt). Bacterial lysates were then centrifuged (15000 
rpm, 30 min, 4°C) and the supernatant (soluble fraction) and the pellet, obtained from 
each sample, were loaded on a 15% or 18% polyacrylamide gel.
Batch purification of 6xHis-tagged proteins under denaturing conditions 
The expression of each recombinant plasmid produced insoluble proteins, so they 
were solubilized from inclusion bodies using a lysis buffer containing 50 mM Tris–
HCl, pH 8, 10 mM imidazole, 8 M urea. The cleared lysate containing the His-tagged 
proteins in 8 M urea was added to 50% Ni2+-NTA agarose slurry resin (Qiagen) for 
the affinity chromatography purification. The binding capacity of Ni2+-NTA resins is 
between 5-10 mg/mL for 6xHis-tagged proteins. Before loading the lysate, the resin 
was extensively washed with water and finally equilibrated in the lysis buffer. The 
lysate was then loaded in presence of 10 mM imidazole and 100 mM NaCl to avoid 
non-specific binding of E. coli contaminants and the column was gently shaken for 45 
min-1h. Then, the flow-through (F.T.), containing all unbound proteins, was collected 
and the resin was washed three times with the lysis buffer containing 100 mM NaCl, 
and finally the His-tagged proteins were eluted with high concentrations of imidazole 
(250/300 mM). All the proteins expressing KDR extracellular domains and Flt-1D1-4,
Flt-1D2-4, Flt-1D2-3 were eluted and then refolded by step dialysis to remove urea. Only 
Flt-1D2 was subjected to an “on column” refolding protocol. Once loaded the lysate, 
collected the flow-through and wash fractions, the bound protein was refolded by 
equilibrating the column in buffers with decreasing concentrations of urea. All 
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fractions eluted from the resin (flow-through, washes and elutions) were analyzed on 
SDS–PAGE gels and stained with Coomassie Brilliant Blue R-250. Protein samples 
were dialyzed by using Spectra/Por membranes with the appropriate MWCO.
Expression and refolding of 15N-labeled recombinant Flt-1D2 for NMR studies 
A single clone of JM101 strain was cultured for 3 h at 37°C in 5 mL of LB medium 
without antibiotics. The cells were then inoculated in M9 medium (see composition in 
tables 2 and 3), containing 15NH4Cl (1g/L) as the sole nitrogen source, and grown 
overnight at 37°C. The harvested cells were lysed with 37% HCl (100°C for 8h) to 
obtain a mixture of single 15N labeled amino acids then used to enrich M9 medium for 
the expression of Flt-1D2 in E. coli BL21 Codon Plus (DE3) RIL strain previously 
transformed with pETM11-flt-1D2 recombinant expression vector. The expression, 
refolding and protein purification were performed as described for the unlabeled 
protein.
M9 salt solution 10X 100 mL 
100 mM MgSO4 10 mL 
10 mM CaCl2 10 mL 
100 mM thiamine-HCl 10 mL 
20% glucose 10 mL 
sterile ddH2O 860 mL 
Total volume 1 L 
Table 2: M9 medium composition. 100 mM MgSO4, 10 mM CaCl2,
100 mM thiamine-HCl and 20% glucose were filter sterilized 
before use.
Na2HPO4 6 g 
KH2PO4 3 g 
NaCl 0.5 g 
15NH4Cl 1 g 
ddH2O to 100 mL 
Total volume 100 mL 
Table 3: M9 salt solution 10X composition. Autoclave before use.
Western blot analysis
After gel electrophoresis, proteins were transferred to a polyvinylidene fluoride 
(PVDF) membrane (Immobilon-P, Transfer Membrane, Millipore) in Transferring 
Buffer (25 mM Tris-HCl, pH 8.0, 190 mM Glycine and 10% methilic alcohol) at 4°C 
overnight, using a 25 V electric field. The PVDF membrane was submerged in 
methilic alcohol for 2 min before using, to eliminate the hydrophobic properties, 
washed in H2O for 5 min and equilibrated in Transferring Buffer for 5 min. After 
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overnight electro-blotting, membrane was stained with Ponceau Red to verify 
proteins transferring and incubated in the blocking solution (5% BSA in PBS buffer, 
containing 0.05% Tween 20) at room temperature for 1 hour. It was washed with 
PBS buffer (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4 pH 7.4), 
containing 0.05% Tween 20, and incubated with mouse anti-His monoclonal antibody 
(supplied by Sigma Aldrich) dilution (1:6000) at room temperature for 1 hour.
Successively, membrane was washed with PBS buffer and incubated on a shaker, 
for 1 hour at room temperature, with horseradish peroxidase-conjugated anti-mouse 
antibody (supplied by Pierce) dilution (1:10000) as the secondary antibody. 
Membrane was finally washed with PBS buffer. The detection of immunopositive 
species by enzyme-linked chemiluminescence (enhanced chemiluminescence: ECL) 
was performed according to the manufacturer’s instructions (Super Signal®West Pico 
Chemiluminescent Substrate, Pierce), using a Chemi doc XRS apparatus (Bio-Rad). 
TEV digestion of 6xHis-tagged proteins 
All 6xHis-tagged proteins, after purification by affinity chromatography and on 
column/step dialysis refolding, were dialyzed overnight against TEV buffer (50 mM 
Tris-HCl, pH 7.0/8.0 in redox buffer containing 3 mM glutathione/0.3 mM oxidized 
glutathione) at 20°C. To protein substrates was added TEV protease, using a molar 
ratio (protease:substrate) of 1:35 and the cleavage was allowed to proceed overnight 
at 20°C. Cleaved products were analyzed by 18% polyacrylamide gel electrophoresis 
performed in Laemmli buffer, then, mixture was loaded onto a Ni2+-NTA affinity 
column equilibrated in binding buffer (the same employed for digestion reaction) 
containing 10 mM imidazole; the proteins without His-tag were collected in the flow-
through, while His-tag and TEV protease remained bound to the column. TEV 
protease was expressed and purified in our laboratory, after transforming the BL21 
pLysisS cells (Invitrogen) with the pET24a-TEV recombinant vector kindly provided 
by Dr. Nina Dathan. Purity and identity of Flt-1D2 before and after the cleavage by 
TEV protease were assessed by liquid chromatography mass spectrometry (LC-MS), 
using a Phenomenex Jupiter C4 column (250x2.00 mm, 5 ?m, 300 Å) and the method 
A described in “stains, enzymes and reagents” paragraph.
Flt-1D2 alkylation by Iodoacetamide and trypsin digestion 
Cleaved and purified Flt-1D2 was dialyzed overnight, at 20°C, against 50 mM Tris-
HCl, pH 7.0 containing NaCl 100 mM and concentrated until 0.3 mM by using the 
Amicon Ultra system (5000 MWCO, Millipore). Then, the protein was alkylated by 
iodoacetamide to estimate the oxidation state of the cysteines present in its 
sequence. In fact, Flt-1D2, as attested by structural data, has two cysteine residues 
involved in the formation of a disulfide bridge (Wiesmann, C. et al., 1997). Flt-1D2 was 
diluted until 10 ?M in AMBIC buffer 100 mM, pH 8.0; then, iodoacetamide, dissolved 
in AMBIC buffer 100 mM, pH 8.0 to a final concentration of 55 mM, was added for the 
alkylation reaction. Sample was allowed to mix by vortexing and incubated for 30 min 
at RT, in the dark. As positive control, Flt-1D2 was first reduced with DTT 10 mM and 
then alkylated by iodoacetamide. The reduction reaction was allowed to proceed 45 
min at 60°C in a heating block. Purity and identity of both alkylated and reduced-
alkylated proteins were assessed by LC-MS, using a Phenomenex Jupiter C4 column 
(250x2.00 mm, 5 ?m, 300 Å) and the method A described in “stains, enzymes and 
reagents” paragraph. To estimate the globular state of Flt-1D2, was performed a 
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trypsin digestion in 50 mM Tris-HCl, pH 7.5 containing 20 mM CaCl2, adding trypsin 
with a molar ratio trypsin:Flt-1D2 of 1:100. The reaction was allowed to proceed at 
37°C and was analyzed at different times (45, 90 min) by LC-MS, using the same 
column and method described above. 
Flt-1D2 CD analysis
Flt-1D2 far-UV circular dichroism spectra were obtained using a Jasco J-715
spectropolarimeter, equipped with a PTC-423S/15 Peltier temperature controller, 
using a 0.1mm quartz cell in the far UV range 190-260 nm. Spectra were acquired 
using a band width of 1 nm, a response of 8 sec, a data pitch of 0.2 nm and a 
scanning speed of 10 nm/min. Each spectrum was the average of three scans with 
the background of the buffer solution subtracted. Spectra were performed at 20°C at 
a protein concentration of 15 ?M, in 20 mM phosphate buffer at pH 7. CD data were 
expressed as mean residue ellipticity (?). Spectra processing was obtained by using 
the Spectra Manager software, while the analysis of the secondary structure content 
of the proteins was performed following the programs Continll (Provencher, S. W. et
al., 1981), Selcon3 (Sreerama, N. et al., 2000) and CDSSTR (Manavalan, P. et al.,
1987) of the CDPro program pack (http://lamar.colostate.edu/~sreeram/CDPro/) and
one of the most widely used neural network program: CDNN (Bohm, G. et al., 1992). 
An additional method named Cluster was employed for determination of tertiary 
structure class of examined proteins (Venyaminov, S. et al., 1994). 
Flt-1D2 thermal unfolding was performed at 15 ?M protein concentration in 20 mM 
phosphate buffer, pH 7.0, using the same Jasco apparatus and the 
temperature/wavelength scan measurement program of the Spectra Manager 
software. The temperature was increased from 10°C to 100°C at a rate of 30°C/h.
The CD signals were acquired at 1°C intervals at the indicated wavelength (214 nm).
Flt-1D2-VEGF binding competition assay on ECs by Fluorescence 
Activated Cell Sorting (FACS) 
The assay was performed on HUVEC cells by using the Fluorokine Biotinylated 
Human VEGF Kit supplied by R&D System. HUVEC cells were cultured in EBM 
(Endothelial basal medium) enriched with 2% FCS (Fetal Calf Serum), 0.5 ng/mL 
VEGF, 22.5 µg/mL heparin, 0.1 ng/mL EGF, 1 ng/mL bFGF, 1 µg/mL hydrocortisone, 
50 ng/mL amphotericin B, 50 µg/mL gentamicyn to obtain the EGM (Endothelial 
Growth Medium). Both HUVEC cells and the components added to obtain the EGM 
were supplied by Cambrex. The cells were kept with 5% CO2 at a temperature of 
37°C. All the experiments (two) were conduced using sub-confluent cells cultures 
(between 5°-6° passages). Then, the cells were treated with Cell Dissociation 
Solution Non-enzymatic (Sigma) to remove them from flasks (25 cm2) without 
damaging the membrane receptors. According to the kit instructions, one cells 
sample was incubated with VEGF-biotin (positive control), another cells sample was 
treated with an aspecific biotinylated protein supplied by the kit (negative control); 
one other sample was pre-incubated with human IgG, then treated with VEGF-biotin 
in presence of anti-human VEGF IgG to block the binding of VEGF to cell surface 
membrane (specificity control). The last cells sample was treated with VEGF-biotin 
pre-incubated with Flt-1D2 (using a VEGF-biotin:Flt-1D2 molar ratio of 1:20). After one 
hour incubation at 4°C all the samples were incubated with provided FITC-avidin for 
30 min, at 4°C, in the dark; then were washed with the supplied buffer and analyzed 
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to the citofluorimeter. The signals of fluorescence were acquired at a wavelength of 
488 nm (in logarithmic scale) and analyzed with Cell Quest software (Facscalibur 
Becton Dickinson). 
NMR Spectroscopy
Preparation of NMR samples
NMR measurements were performed on a Varian Unity Inova 600 MHz spectrometer 
equipped with a cold-probe, using either unlabeled (300 ?M) or uniformly 15N labeled 
(220 ?M) Flt-1D2 protein, in 90% H2O/10% D2O (v/v), containing  50 mM Tris-HCl and 
100 mM NaCl, pH 7. 
Peptide-protein interactions 
Chemical Shift Mapping
Peptide-protein interactions were performed using QK and MA peptides and were 
monitored by identifying perturbations in 2D ?1H, 15N? HSQC spectra. 15N-Flt-1D2 was
titrated increasing QK and MA peptides concentrations. 2D ?1H, 15N? HSQC spectra 
were acquired with 32 transients per t1 value. Presaturation of water was employed 
during a recycle delay of 1.5 s. 1K complex points were acquired in t2, with an 
acquisition time of 102.5 ms, while 128 complex points were acquired in t1 with an 
acquisition time of 64 ms. 
To determine the per residue chemical shift perturbation upon binding and account 
for differences in spectral widths between 15N and 1H resonances, weighted average 
chemical shift differences, ?av(HN), were calculated for the amide 15N and 1H
resonances, using equation: 
?av(HN) = ??H2 + (?N/2)2?½
where ?H and ?N are the differences between free and bound chemical shifts. The 
weighted average chemical shift differences were mapped to the Flt-1D2 NMR 
structure (1QSV.pdb) using MOLMOL graphics program. 
Saturation Transfer Difference
Spectra of the unlabeled Flt-1D2/peptide complex were recorded with 2048 scans and 
selective saturation of the protein resonances at 12 ppm and -3 ppm. Time 
dependence of the saturation transfer was investigated using an optimized saturation 
times ranging from 0.2 to 4.0 s. STD NMR spectra were acquired using a series of 
equally spaced 50 ms Gaussian-shaped pulses for selective saturation, with 1 ms 
delay between the pulses. Subtraction of the protein FID resonance was performed 
by phase cycling. 
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Results
Domains cloning of human KDR and Flt-1 receptors 
Cloning of 1-3, 2-3, 1-2 and 2 KDR receptor domains 
One step PCR subcloning technique was used to generate bacterial expression 
vectors containing the sequences encoding an N-terminal His-Tag, a TEV cleavage 
site and the extracellular domains 1-3, 2-3, 1-2 and 2 of VEGFR-2 (KDR). First, 
sequences D1-3 (residues 1-335, Fuh et al., 1998), D2-3 (residues 120-335, Fuh et
al., 1998), D1-2 (residues 1-222, Fuh et al., 1998) and D2 (residues 120-222, Fuh et
al., 1998) were amplified by PCR from NIH-3T3 cDNA of the entire receptor using the 
primers designed on the basis of the sequence of the same domains (see Materials 
and Methods section). This cloning strategy was used to obtain the gene products 
fused (at the N-terminal) with the 6xHistidine-tag of pPROEXHTa expression vector. 
Single products were amplified by PCR, purified and digested with BamHI-XhoI
restriction enzymes. In Figure 13 are showed the products purified after digestion.
a b c d
900/1000 bp 
300 bp 
200 bp 
500/517 bp 
400 bp 
100 bp 
Figure 13_ 1% agarose-gel analysis of KDR domains PCR products. In a, b, c and d are
reported, respectively, the BamHI/XhoI digested kdrD1-2-3 (911 bp), kdrD1-2 (570 bp), kdrD2-3
(647 bp), kdrD2 (330 bp) genes amplified from NIH-3T3 KDR receptor cDNA. DNA molecular
weight marker is the Ladder 100 bp. 
pPROEXHTa expression vector was digested with the same enzymes, purified using 
the QIAquick Gel Extraction Kit and analyzed by electrophoresis on a 1% agarose 
gel (Figure 14a). kdrD2 gene was cloned also in pETM11 and pETM20 expression 
vectors. In this case, both vectors (Figure 14 b-c) and PCR fragment corresponding 
to the second domain of VEGFR-2 (Figure 15) were digested with NcoI/XhoI
restriction enzymes.
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b300 bp 
100 bp 
400 bp 
200 bp 
1517 bp 
900/1000 bp
a c
500/517 bp 
M      D UD    U MD     M     U 
Figure 14 a-b-c_ 1% agarose-gel analysis of the digested vectors. In b lane 
labelled with “D” indicates the pPROEXHTa expression vector digested with 
BamH1/Xho1 restriction enzymes, while in a and c the NcoI/XhoI digested pETM20 
and pETM11, respectively. Lanes marked with “U” indicate undigested vectors. M 
is the DNA molecular weight marker (Ladder 100 bp). 
900/1000 bp 
300 bp 
500/517 bp 
400 bp 
100 bp 
200 bp 
M
Figure 15_ 1% agarose-gel analysis of the kdrD2
gene PCR product amplified from NIH-3T3 receptor
cDNA and digested with NcoI/XhoI endonucleases.
M, Ladder 100 bp.
All amplificates obtained from PCR reactions were ligated into the corresponding 
expression vectors; then, each recombinant construct resulted from cloning, was 
transformed in TOP F’10 cells by electroporation. Plasmidic DNA was extracted from 
overnight cultures and purified using the QIAprep Spin Miniprep Kit. The identity of 
the inserts was tested with a PCR screening (Figures 16, 17) and confirmed by DNA 
sequencing.
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D2
300 bp 
100 bp 
500/517 bp 
200 bp 
900/1000 bp 
D2-3 D1-2D1-2-3
400 bp 
Figure 16_ 1% agarose-gel analysis of the PCR screening of recombinant KDR domains.
In figure are showed the PCR products resulted from recombinant plasmids after cloning
of kdrD1-2-3, kdrD2-3, kdrD1-2 and kdrD2 genes in pPROEXHTa expression vector. All
amplification products were obtained using the putative recombinant vectors as templates
and the same primers of cloning PCR reactions. In Figure is reported the Ladder 100 bp. 
a
kdrD2 gene 
330bp
b
kdrD2 gene 
330bp
Figure 17_ 1% agarose-gel analysis of the PCR
screening products amplified from recombinant
pETM11-kdrD2 (a) and pETM20-kdrD2 (b) expression
vectors. In both gels is reported the Ladder 100bp. 
Cloning of 1-4, 2-4, 2-3 and 2 Flt-1 receptor domains 
VEGFR-1 (Flt-1) domains 1-4 (residues 27-428, Wiesmann et al., 1998), 2-4 
(residues 129-428, Wiesmann et al., 1998), 2-3 (residues 129-334, Wiesmann et al.,
1998) and 2 (residues 129-229, Wiesmann et al., 1998) were amplified by 
polymerase chain reaction from NIH-3T3 cDNA of the entire receptor. Products 
obtained from PCR were ligated into the bacterial expression vector pETM11; 
domain 2 was also cloned into the pETM20 expression vector. Thus, the expression 
plasmids encoded Flt-1 domains fused, respectively, to an N-terminal 6xHis-tag 
sequence and to an N-terminal 6xHis/TrxA-tag. 
Each polymerase chain reaction amplified, with high yields, only the desired product; 
all products were then digested with NcoI-XhoI restriction enzymes, purified and 
separated on a 1% agarose gel (Figure 18).
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A B C
900/1000 bp 
flt-1D1-4
flt-1D2-4 flt-1D2-3500/517 bp 
400 bp 
300 bp 
200 bp 
flt-1D2
100 bp 
M M M
Figure 18_ 1% agarose-gel analysis of VEGFR-1 domains PCR products. In A, B and C are
reported, respectively, the NcoI/XhoI digested flt-1D2 (320 bp), flt-1D1-4 (1202 bp), flt-1D2-4 (897 bp),
flt-1D2-3 (627 bp) genes amplified from NIH-3T3 Flt-1 receptor cDNA. M, DNA molecular weight
marker (Ladder 100 bp). 
After cloning, each recombinant construct was transformed in TOP F’10 cells by 
electroporation; then, plasmidic DNA was extracted from overnight cultures and 
purified. The identity of the inserts in each resulting recombinant plasmid was tested 
with a PCR screening (Figures 19, 20) and confirmed by DNA sequencing.
a c
900/1000 bp 
flt-1D2-3500/517 bp 
100 bp 
400 bp 
300 bp 
200 bp 
flt-1D1-4
b d
flt-1D2-4
flt-1D2
Figure 19_ 1% agarose-gel analysis of the products resulted from PCR screening of the
recombinant plasmids obtained after cloning of the genes flt-1D2-3 (a), flt-1D2-4 (b), flt-1D1-4 (c) and
flt-1D2 (d) in pETM11 expression vector. All amplification products were obtained using the putative
recombinant vectors as templates and the same primers of cloning PCR reactions. The marker
loaded with the samples is the Ladder 100 bp.
49
900/1000 bp 
500/517 bp
100 bp 
400 bp 
300 bp 
200 bp 
flt-1D2 gene
320 bp 
Figure 20_ PCR screening agarose-gel analysis. The products
were amplified by polymerase chain reaction from the recombinant 
plasmids obtained after cloning of flt-1D2 gene in pETM20 
expression vector. In figure is reported the Ladder 100 bp. 
Expression and purification of recombinant human KDR and Flt-1 
extracellular domains
Expression of 1-3, 2-3, 1-2 and 2 KDR receptor domains
The recombinant pPROEXHTa and pETM11 expression vectors containing VEGFR-1 
and VEGFR-2 extracellular domains were verified by DNA sequencing and utilized to 
transform bacterial cells, in order to express the corresponding proteins. For the 
expression of all recombinant proteins was performed a screening by using different 
strains and different growing conditions (temperature and IPTG concentration). The 
host strain chosen for the expression off all recombinant proteins was the BL21 
Codon Plus (DE3) RIL strain, done exception for KDRD1-2 and KDRD1-3 that were 
expressed in Rosetta Gami (DE3) competent cells. BL21 Codon Plus (DE3) RIL 
competent cells, as Rosetta (DE3), are efficient for the high-expression of eukaryotic 
proteins in E. coli since they are engineered to contain extra copies of the genes that 
encode the tRNAs that most frequently limit translation of heterologous proteins in E.
coli. In fact, these strains supply tRNAs for AGG, AGA, AUA, CUA, CCC and GGA on 
a compatible chloramphenicol-resistant plasmid. Rosetta Gami (DE3) strain 
combines the enhanced expression of eukaryotic proteins with the enhanced 
disulfide bond formation resulting from trxB/gor mutations that are selectable on 
kanamycin (15 µg/mL) and tetracycline (12.5 µg/mL), respectively. As the proteins 
corresponding to domains 1-2 and 1-3 of human KDR contain, respectively, 7 and 9 
cysteine residues in addition to rare codons, Rosetta Gami (DE3) strain was chosen 
to create in cell milder reduction conditions, thus facilitating expression and fold of 
these proteins. Rosetta Gami (DE3) competent cells, previously transformed with 
pPROEXHTa-kdrD1-2 and pPROEXHTa-kdrD1-3 recombinant expression vectors and 
selected on solid medium, were induced overnight with 0.7 mM IPTG at 37°C and at 
22°C when cell cultures reached an OD600nm of 0.8. Non-induced samples were kept 
before adding IPTG. The cells were harvested and the pellets were resuspended in 
25 mL of 50 mM Tris-HCl, pH 7. Suspensions were sonicated and then centrifuged at 
15.000 rpm at 4°C for 30 min. Analysis by SDS–PAGE of bacterial lysates showed 
the presence of the protein KDRD1-3 in IPTG-induced cells, precisely in crude extract 
pellet (expressed at 37°C and resuspended in 50 mM Tris-HCl, pH=7) (Figure 21, 
lane 3), with a molecular weight of about 36 KDa, as expected for the protein 
corresponding to domains 1-3. Instead, for KDRD1-2 was not possible to observe any 
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induced protein with the expected molecular weight (about 24 KDa), in any tested 
condition (Figure 22). Protein concentration of each sample loaded on the gel was 
determined according to the Bradford’s method. 
175 KDa 
83 KDa
62 KDa 
47.5 KDa 
32.5 KDa 
25 KDa 
16.5 KDa
6.5 KDa 
1      2      3       M 
Figure 21_ Analysis by SDS–PAGE of recombinant KDRD1-3 expressed
overnight in Rosetta Gami (DE3) strain at 37°C. In the first lane is
reported the BSA standard (1.48 µg/µl), in lane 2 E. coli crude extract
supernatant in 50 mM Tris-HCl, pH 7 and in lane 3 E. coli crude extract
pellet in the same buffer. In the circle is shown the induced KDRD1-3. M,
Biorad molecular weight marker. 
220 KDa 
100 KDa 
60 KDa 
45 KDa 
30 KDa 
20 KDa 
12 KDa 
8 KDa N.I.    I       N.I.    I       N.I.    I       N.I.    I 
22°C
P
37°C
P
22°C
S M
37°C
S
Figure 22_ SDS-PAGE analysis of KDRD1-2 expression in Rosetta 
Gami (DE3) strain at 22°C and 37°C overnight. N.I., non induced 
samples in Tris-HCl 50 mM pH 7; I, induced samples in Tris-HCl 50 
mM pH 7. S, supernatant; P, pellet. M, Sigma pre-stained molecular
weight marker. No induced protein band, with the expected molecular
weight, is observed on the gel. 
BL21 Codon Plus (DE3) RIL cells were transformed with pPROEXHTa-kdrD2-3 and 
pPROEXHTa–kdrD2. Both proteins were expressed in inclusion bodies, in fact, 
analysis by SDS–PAGE of bacterial lysates obtained after sonicating the cells 
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showed the presence of KDRD2-3 and KDRD2 in crude extract pellets resuspended in 
50 mM Tris-HCl, pH 8 (Figures 23, 24). The protein content of each sample was 
measured using the Bradford’s method with bovine serum albumin as the standard. 
175 KDa
83 KDa 
62 KDa
47.5 KDa 
32.5 KDa 
25 KDa
16.5 KDa 
8 KDa 
1      2        3       4        5 M
Figure 23_ SDS-PAGE analysis of KDRD2-3 (26.8 KDa) expression at 37°C, in
BL21 Codon Plus (DE3) RIL strain. The gel shows the induced and not induced
samples; in the first lane is reported the BSA standard (1.48 µg/µl), in lanes 2 and
3 E. coli crude extract supernatants (not induced and induced, respectively) in 50
mM Tris-HCl, pH 8; in lanes 4 and 5 E. coli crude extract pellets (not induced and
induced, respectively) in 50 mM Tris-HCl, pH 8. In the oval there is the induced
KDRD2-3. M, NEB pre-stained molecular weight marker.
66 KDa 
45 KDa 
36 KDa 
29 KDa 
24 KDa 
20 KDa 
14.2 KDa 
6.5 KDa
   1       2         3           4
Figure 24_ SDS-PAGE analysis of KDRD2 (14.5 KDa) expression at 37°C, in 
BL21 Codon Plus (DE3) RIL strain. The gel shows the induced and not induced
samples. In the first and second lanes are reported E. coli crude extract 
supernatants (not induced and induced, respectively) in 50 mM Tris-HCl, pH 8;
in lanes 3 and 4 E. coli crude extract pellets (not induced and induced, 
respectively) in the same buffer. In the oval is circled the induced KDRD2. M,
Sigma molecular weight marker.
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The inclusion body pellet of KDRD2 was solubilized in 20 mL 8 M urea, 10 mM 
imidazole, 0.15 M NaCl, 50 mM Tris-HCl, pH 8. The denatured protein in Tris-HCl-
urea buffer was loaded onto a Ni2+-NTA agarose resin, previously equilibrated with 
the same buffer, and the His-tagged protein was in batch purified by affinity 
chromatography. Fractions eluted from the resin were collected and analyzed by 
15% SDS–PAGE gel. In Figure 25 is showed the affinity chromatography elution 
profile.
66 KDa 
45 KDa 
36 KDa 
29 KDa 
24 KDa 
20 KDa 
14.2 KDa 
6.5 KDa 
F.T.  W1    W2    W3    M     E1      E2       E3       E4     E5    E6     M    E7     E8     E9   BSA
Figure 25_ Affinity chromatography profile of the His-tagged KDRD2 purified on a
Ni2+-NTA resin. F.T., unbound proteins eluted from resin. W1-W3, wash of the resin
with Tris-HCl-urea buffer containing 20 mM imidazole. E1-E9, fractions eluted from
resin with higher concentration of imidazole: E1-E3 are the fractions eluted with 50
mM imidazole; E4-E6 with 100 mM imidazole and E7-E9 with 250 mM imidazole. M,
Sigma molecular weight marker. KDRD2 was eluted in F.T. and, in part, in wash
fractions.
As observed on the gel, the protein corresponding to the second domain of VEGFR-
2, despite loaded in urea 8 M, did not bind to the resin and probably eluted in F.T.. In 
fact, no coomassie-stained band was visible in elutions in correspondence of the 
expected molecular weight (14.5 KDa), but a band with an apparent expected 
molecular weight was found in F.T.. To assure the presence of KDRD2 in the unbound 
protein fraction, 100 µg of F.T. were separated by electrophoresis on a 15% 
polyacrylamide SDS-PAGE and transferred from gel to a polyvinylidene difluoride 
(PVDF) membrane by electro-blotting. Detected immunopositive species were 
visualized using a Chemi doc XRS apparatus and are showed in Figure 26. On the 
gel, then electro-blotted, was loaded, near the pre-stained marker, a His-tagged 
protein purified by affinity chromatography as positive control. This protein has a 
molecular weight of 11 KDa and is showed in lane 2 of Figure 26.
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positive control
KDRD2
1     M      2
Figure 26_ Western analysis of KDRD2. The first lane of the
blot was found to contain a protein that migrates with the
expected molecular weight (in the oval). In lane 2 there is
the positive control constituted by a His-tagged protein with
a molecular weight of 11 KDa. Both species were
recognized by an anti-His antibody. M, NEB pre-stained
marker.
Western blotting analysis showed the presence of the His-tagged KDRD2 in F.T., but 
did not explain the unusual behavior of the protein. The second domain of VEGFR-2 
was successively cloned in pETM11 and pETM20 expression vectors, but the 
recombinant protein was expressed in inclusion bodies and did not bind to the resin 
again (data not shown). So, its sequence was mutated and cloned again in pETM11.
kdrD2 gene mutagenesis 
As in vitro site-directed mutagenesis is an available technique for studying protein 
structure-function relationship and gene expression, we used this approach to 
change one of the three residues of cysteine (C161) of the second domain of KDR 
receptor in Alanine. Our aim was to obtain a protein capable to bind to the Ni2+-NTA
resin and to be purified by affinity chromatography as the second domain of VEGFR-
1 that has only two cysteine residues in its sequence (see below). According to the 
procedure suggested by the Quik Change Site Directed Mutagenesis Kit, we utilized 
a supercoiled double-stranded DNA (dsDNA) vector with the insert of interest and 
two synthetic oligonucleotide primers contained the desired mutation. In our case, 
was used the pETM11-kdrD2 plasmid and the oligonucleotide primers, each 
complementary to opposite strands of the vector, contained the mutation for an 
alanine in the middle. The primers were extended during temperature cycling; their 
incorporation generated a mutated plasmid containing staggered nicks. In fact, as we 
can see in Figure 27, PCR mutagenesis product (mut) is shifted on the agarose gel 
with respect to the control represented by the non mutated construct pETM11-kdrD2
(wt), as attended for a nicked dsDNA plasmid. Following PCR reaction, the product 
was treated with DpnI, an endonuclease specific for methylated and hemimethylated 
DNA, used to digest the parental DNA template and to select for mutation-containing 
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synthesized DNA. In fact, DNA isolated from almost all E. coli strains is dam
methylated and therefore susceptible to DpnI digestion. The nicked vector containing 
the desired mutation was then transformed into XL1-Blue supercompetent cells. The 
identity of the mutagenic insert was confirmed by DNA sequencing. 
mut
b
wt
a 1517 bp
900/1000 bp
300 bp 
500/517 bp 
400 bp 
100 bp 
200 bp 
M
Figure 27_ 1% agarose gel analysis of mutated kdrD2 gene.
The products derived from PCR mutagenesis were
visualized by ethidium bromide fluorescence. The reaction
(performed in double) was loaded on the gel (b) with the
control pETM11-kdrD2 (a). M, Ladder 100 bp. 
Mutated KDRD2 was expressed in BL21 Codon Plus (DE3) RIL at 22°C and at 37°C. 
Once again, the protein was expressed in crude extract pellet induced with IPTG, 
solubilized from inclusion bodies and eluted in the unbound proteins fraction when 
loaded on Ni2+-NTA resin for affinity purification (data not shown).
The other recombinant proteins expressing domains 1-3 and 2-3 of VEGFR-2, 
instead, were solubilized from inclusion bodies, purified by affinity chromatography 
on Ni2+-NTA resin and refolded by step dialysis. Refolding was performed against 
buffers containing 6, 4, 3, 2, 1, and 0 M urea successively, and each dialysis was 
carried out at 20°C for 8 h against 10 volumes of the dialysis buffer containing 3 mM 
glutathione/0.3 mM oxidized glutathione, in order to facilitate protein disulfide bond 
formation. Despite the creation of more less reducing conditions, with the last steps 
of refolding some protein for both samples precipitated, probably due to their 
aggregation or misfolding. Thus, the amount of KDRD1-3 and KDRD2-3 recovered after 
TEV protease cleavage, performed to remove the His-tag sequence from the N-
terminal of the proteins, was insufficient for structural characterization.
Expression of 1-4, 2-4 and 2-3 Flt-1 receptor domains
For bacterial expression, the recombinant pETM11 containing 1-4, 2-4 and 2-3 
VEGFR-1 extracellular domains were verified by DNA sequencing and transformed 
into E. coli BL21 Codon Plus (DE3) RIL cells carrying an inducible T7 RNA 
polymerase gene, in order to express high yields of the corresponding proteins. 
Bacterial cultures of 1L of LB medium containing 50 µg/mL kanamycin and 33 µg/mL
chloramphenicol were grown in shaking flasks at 37°C to an A600nm of 0.8. IPTG was 
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added to a final concentration of 0.7 mM and the cultures were grown for another 3 h. 
From each culture was kept a non induced sample, before adding IPTG. Analyses by 
SDS–PAGE of bacterial lysates obtained after sonicating the cells showed the 
presence of all interest proteins in IPTG-induced crude extract pellet fractions 
(Figures 28, 29, 30). 
66KDa
45KDa
36KDa
29KDa
24KDa
20KDa
14.2KDa
Figure 28_ SDS-PAGE analysis of Flt-1D1-4 (48.7 KDa) expressed in E. coli BL21
Codon Plus (DE3) RIL strain at 37°C. Gel shows the induced and not induced
samples. In the first and second lanes are reported E. coli crude extract
supernatants (not induced and induced, respectively) in 50 mM Tris-HCl, pH 8; in
lanes 3 and 4 E. coli crude extract pellets (not induced and induced, respectively)
in the same buffer. Black arrow indicates the induced protein. M, Sigma molecular
weight marker.
 1    2         M         3             4        BSA
Flt-1D2-3
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1       2      3     4    M 1        2      3      4     M 
Flt-1D2-4
Figure 29_ SDS-PAGE analysis of expressed Flt-1D2-4 and Flt-1D2-3 (respectively 37.4
and 26.8 KDa). Gels show the induced and not induced samples. In the first and second
lanes of both gels are reported E. coli crude extract pellets (not induced and induced,
respectively) in Tris-HCl 50 mM, pH 8; in lanes 3 and 4 E. coli crude extract supernatants
(not induced and induced, respectively) in the same buffer. In the ovals are reported the
induced proteins. M, Sigma molecular weight marker.
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Expression, refolding and purification of 2 Ig-like Flt-1 receptor 
domain cloned into the pETM11 expression vector 
pETM11-flt-1D2 was verified by DNA sequencing and transformed into E. coli BL21 
Codon Plus (DE3) RIL. Significant amounts of Flt-1D2 (60mg/L) were obtained upon 
induction by IPTG, but, also in this case, the protein accumulated in the form of 
inclusion bodies. The induced protein, in fact, was visible in crude extract pellet 
fraction (Figure 30, Lane 4).
1      2      M        3       4   BSA
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Figure 30_ SDS-PAGE analysis of Flt-1D2 (14.8 KDa) expressed in BL21
Codon Plus (DE3) RIL at 37°C. Gel shows the induced and not induced
samples. In the first and second lanes are reported E. coli crude extract
supernatants (not induced and induced, respectively) in 50 mM Tris-HCl, pH
8; in lanes 3 and 4 E. coli crude extract pellets (not induced and induced,
respectively) in the same buffer. In the oval is reported the induced protein.
M, Sigma molecular weight marker.
Obtaining recombinant protein in the form of inclusion bodies has its own advantages 
and disadvantages. The isolation steps for inclusion bodies are relatively simple, but 
the refolding becomes more complicated. In fact, in the refolding process, various 
factors such as protein concentration, denaturant, ionic strength, pH, temperature 
play an important role in determining protein refolding yields. Thus, the refolding 
process of Flt-1D2 has been optimized through adjusting these conditions to prevent 
auto-degradation and aggregation of the protein and performing an “on column 
refolding”. The idea was to refold the protein still bound to the resin and then elute it 
by increasing concentration of imidazole. The inclusion body pellet of Flt-1D2 was 
solubilized in 20 mL 8 M urea, 10 mM imidazole, 0.15 M NaCl, 50 mM Tris-HCl, pH 8 
and the lysate was loaded on a Ni2+-NTA agarose resin equilibrated previously with 
the same buffer. Once collected the flow-through and wash fractions, the bound 
protein was refolded by equilibrating the column in buffers containing decreasing 
concentration of urea. The protein was refolded in following six steps using buffers 
containing 6, 4, 3, 2, 1, and 0 M urea successively, and each step was carried out at 
20°C for 3 h with 20 column volumes. After refolding, Flt-1D2 was eluted in 50 mM 
Tris-HCl, pH 8 containing high concentrations of imidazole (50, 100 and 250 mM). 
Elution profile of the protein is showed in Figure 31. 
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Figure 31_ Affinity chromatography profile of the His-tagged Flt-1D2 purified on
Ni2+-NTA resin after “on column refolding”. F.T., unbound proteins eluted from
resin. W1-W4, wash of the resin with Tris-HCl-urea buffer (50 mM Tris-HCl, 8 M
urea, 0.15 M NaCl) containing 20 mM imidazole. E1-E9, fractions eluted from
resin in 50 mM Tris-HCl, pH 8 with higher concentration of imidazole: E1-E3 are
the fractions eluted with 50 mM imidazole; E4-E6 with 100 mM imidazole and
E7-E9 with 250 mM imidazole. M, Sigma molecular weight marker. 
TEV digestion and native-PAGE analysis of Flt-1D2
Fractions eluted with 50, 100 and 250 mM imidazole from Ni2+-NTA resin were 
pooled (20 mL) and dialyzed against Tris-HCl 50 mM, pH 7, in order to remove 
imidazole and prepare the protein to the TEV cleavage. Dialysis was carried out at 
20°C overnight against 2 L of the dialysis buffer. The N-terminal His-tag was 
removed from the dialyzed Flt-1D2 by recombinant TEV protease. Glutathione (3mM 
reduced/0.3 mm oxidized) was added to the partially purified protein just before 
addition of TEV protease. Cleavage reaction was performed adding TEV to protein 
substrate in a molar ratio of 1:35 and allowed to proceed overnight at 20°C. The His-
tagged TEV was expressed in BL21 pLysisS cells (transformed with pET24a-TEV 
recombinant expression vector, kindly provided by Dr. Nina Dathan) and purified in 
our laboratory by affinity chromatography, using denaturing conditions. Eluted TEV 
was refolded by one step overnight dialysis and then stored at –80°C before being 
used to digest protein substrates. TEV-cleaved Flt-1D2 was analyzed by 18% 
polyacrylamide gel electrophoresis (Figure 32). 
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BSA   TEV      1          2         M 
Figure 32_ SDS-PAGE analysis of the
cleaved Flt-1D2. Lane 1, negative
control constituted by the uncut protein;
lane 2, cleaved Flt-1D2. M, Sigma
molecular weight marker. 
Then, mixture obtained after TEV cleavage was subjected to a second step of affinity 
purification on Ni2+-NTA resin and finally concentrated until 0.3 mM by using the 
Amicon Ultra system with a molecular weight cut off of 5000. Flt-1D2 concentration 
was estimated according to the Bradford’s method and by UV spectroscopy, reading 
the tryptophan absorbance at 280 nm, and verified by SDS-PAGE analysis. As 
observed on the gel, the protein of interest resulted as a homogeneous product 
(Figure 33).
66KDa
45KDa
36KDa
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24KDa
20KDa
14.2KDa
6.5KDa
Figure 33_ SDS-PAGE analysis of Flt-1D2
after concentration in Amicon Ultra. As
visualized by comassie-staining, the
protein was purified homogeneously. Near
Flt-1D2 was loaded Sigma molecular
weight marker. 
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An aliquot of Flt-1D2 was loaded on native-PAGE for an analysis of its conformation in 
absence of denaturing detergents and reducing agents. For native PAGE the sample 
was not denaturized at 100°C but loaded on a 10% polyacrylamide gel in 0.001% 
bromophenol blue and 10% glycerol and electrophoresed in Tris-glycine buffer 
without SDS. As shown in Figure 34, the protein was able to migrate into the gel 
showing a single coomassie-stained band and suggesting its monomeric 
conformation.
Figure 34_ Native-PAGE
analysis of Flt-1D2 cleaved by
TEV and purified. As shown,
coomassie-stained protein band
entered the gel, without
remaining into the well. 
In order to obtain the second domain of VEGFR-1 in a soluble form, flt-1D2 gene was 
cloned in pETM20 expression vector. This cloning strategy allows the expression of 
the protein of interest with an N-terminal tag constituted by TrxA, a very soluble 
protein in most of cases able to solubilize its fusion partner.
In spite of this, the recombinant Flt-1D2 was again expressed in inclusion bodies (data 
not shown). 
LC-MS analyses of Flt-1D2 after TEV cleavage, alkylation and trypsin
digestion
Purity and identity of Flt-1D2 before and after TEV protease cleavage were assessed 
by liquid chromatography mass spectrometry. The analysis of proteins was carried 
out on a C4 column, using the method A described in “Strains, enzymes and 
reagents” section of Materials and Methods. In Figure 35 are reported the 
chromatogram and mass spectrum of the His-tagged protein purified by affinity 
chromatography after “on column refolding”, while in Figure 36 are showed the 
chromatogram and mass spectrum of the untagged protein. The molecular weights 
calculated from the experimental data were in accordance with theoretical ones, for 
both proteins. Successively, the protein was employed in experiments of alkylation by 
iodoacetamide, in order to determine the oxidation state of its two cysteine residues. 
In fact, as previously described, these two cysteine residues are involved in the 
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formation of a disulfide bridge (Wiesmann, C. et al., 1997). Flt-1D2 was alkylated with 
55 mM iodoacetamide in 100 mM AMBIC, pH 8 and the reaction was kept in the dark 
for 30 min. As reaction control, the protein was first reduced with 10 mM DTT (45 min 
at 37°C), then alkylated by iodoacetamide. The alkylation reaction was checked by 
LC-MS and in Figure 37 and Figure 38 are reported the chromatograms and mass 
spectra of the alkylated and alkylated/reduced proteins, respectively. In non reducing 
conditions no alkylated adducts were found, while, in presence of DTT, the main 
product presented a mass increment of 116 Da consisted with alkylation of the two 
cysteine residues. Finally, the second domain of Flt-1 receptor was subjected to a 
trypsin digestion, in order to estimate the globular state of the protein. The reaction 
was allowed to proceed at 37°C in 50 mM Tris-HCl, pH 7.5 containing 20 mM CaCl2.
Trypsin was added to the mix in a molar ratio enzyme:Flt-1D2 of 1:100. The reaction 
was analyzed by LC-MS at different times (45 min and 90 min) and showed a stable 
conformation of the protein that was not drastically digested by trypsin, as attended 
for a compact immunoglobulin-like domain. In fact, LC chromatogram and mass 
spectrum of Flt-1D2 after reaction, were similar to these of non digested protein (data 
not shown). 
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Figure 35_ LC-MS analysis of the His-tagged Flt-1D2. A, chromatogram profile revealed by Total
Ion Count; B, chromatogram profile revealed by absorbance at 210 nm; C, UV spectrum of the
peak at 28.3 min; D, ESI spectrum of the peak at 28.4 min. Deconvolution analysis of Flt-1D2
charged states (reported in box D) corresponds to a mass of 14850.8 Da that is in agreement with
the theoretical one.
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Figure 36_ LC-MS analysis of Flt-1D2 after TEV cleavage. A, chromatogram profile revealed by
Total Ion Count; B, chromatogram profile revealed by absorbance at 210 nm; C and D, ESI spectra
of the peaks at 23.33 and 28.51 min, respectively. Deconvolution analysis of Flt-1D2 charged states
(reported in box D) corresponds to a mass of 11850.6 Da that is in agreement with the theoretical
one.
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Figure 37_ LC-MS of the alkylated Flt-1D2. A, chromatogram profile revealed by Total Ion Count; B,
chromatogram profile revealed by absorbance at 210 nm; C, UV spectrum of the peak at 27.78
min; D, ESI spectrum of the peak at 27.74 min. It is the same obtained for the untreated protein
(Fig. 36, box D).
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Figure 38_ LC-MS of reduced/alkylated Flt-1D2. A, chromatogram profile revealed by Total Ion
Count; B, chromatogram profile revealed by absorbance at 210 nm; C, UV spectrum of the peak at
27.97 min; D, ESI spectrum of the peak at 28.13 min. Deconvolution analysis of the charged states
reported in box D corresponds to a mass of 11966.2 Da that is in agreement with the theoretical
one, testifying that two alchilic groups (58 Da each) were added to the protein after alkylation.
Flt-1D2 VEGF-binding competition assay by Fluorescence Activated 
Cell Sorting (FACS) 
The ability of Flt-1D2 to bind to VEGF was assessed, indirectly, by an in vitro
competition assay performed on HUVEC cells. Flt-1D2 was used as a competitor of 
the interaction between a biotin-conjugated VEGF and its receptors present on 
HUVEC membrane. The cells were incubated with VEGF-biotin that binds to the 
receptors on membrane surface, in absence or in presence of Flt1D2. The amount of 
VEGF-biotin bound to the cell surface was revealed with FITC-avidin, measuring the 
intensity of fluorescence, through cytofluorometry analysis.
The signal indicating the binding of VEGF-biotin to receptors on the surface of 
HUVEC cells (green curve in Figure 39) significantly decreases in presence of Flt-1D2
(yellow curve). The specificity of the signal was confirmed by blocking the VEGF with 
an anti-human VEGF antibody (blue curve), in fact, the intensity of fluorescence 
decreased similarly in both experiments. This experiment indicates that the 
recombinant receptor domain is able to bind to VEGF and competes with the cell 
membrane receptors in their binding the growth factor. 
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Figure 39_ Analysis of the binding of VEGF-biotin to receptors on HUVEC cell membrane. The red
curve represents the cells incubated with a not specific biotinylated protein + FITC-avidin (negative
control); the green curve shows the cells treated with VEGF-biotin + FITC-avidin (positive control);
the blue curve represents the cells incubated with VEGF-biotin + FITC-avidin in the presence of
anti-human VEGF IgG that blocks VEGF, and the yellow curve indicates the cells incubated with
VEGF-biotin + FITC-avidin in the presence of Flt-1D2.
Expression, refolding and purification of 15N-Flt-1D2
E. coli JM101 cells were inoculated in M9 medium, containing 1g/L 15NH4Cl as the 
sole nitrogen source, and grown overnight at 37°C. The harvested cells were lysed 
with 37% HCl and the mixture of single 15N labeled amino acids was used to enrich 
M9 medium for the expression of Flt-1D2 in BL21 Codon Plus (DE3) strain previously 
transformed with pETM11-flt-1D2 recombinant expression vector. Refolding and 
purification of the labeled Flt-1D2 (referred to as 15N-Flt-1D2) were successfully 
performed using the same conditions described for the unlabeled protein. The yield 
of 15N-Flt-1D2 was comparable to that obtained for the unlabeled protein. The 
homogeneous product was concentrated until 0.22 mM and employed, together with 
the unlabeled protein, in protein-peptide NMR interaction studies. 
CD spectroscopic analysis
CD spectroscopic analyses were performed on both labeled and unlabeled proteins. 
Proteins were tested at a concentration of 15 µM in 20 mM phosphate buffer, pH 7.0 
and spectra were recorded at 20°C in the range 190-260 nm. The overall far-UV CD 
spectrum of Flt-1D2 at neutral pH is shown in Figure 40. It indicates that the protein 
has high ??sheet content, with two negative bands at about 198 nm and 214 nm, 
suggesting that the protein assumes the correct fold expected for an immunoglobulin-
like domain and in agreement with data reported in the literature (Wiesmann, C. et
al., 1997 and Starovasnik, M. A. et al., 1999). 
To perform heat-denaturation experiments, the proteins under test were dissolved in 
20 mM phosphate buffer, pH 7.0 at a concentration of 15 µM. Thermal unfolding 
curve of Flt-1D2 is shown in Figure 41. The curve shows a sigmoidal behavior, with a 
single transition and a Tm of about 60°C, indicating that a two-state unfolding 
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process occurred for the protein. Moreover, thermal unfolding was found to be 
reversible when temperature was lowered again to 10°C (data not shown).
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  Figure 40_ Far-UV CD spectrum of Flt1D2 recorded at 20°C, diluting the protein in phosphate buffer 
20 mM, pH 7. 
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   Figure 41_ CD spectrum of Flt1D2 thermal unfolding analysis. The protein was tested in phosphate
buffer 20 mM, pH 7 at 214 nm, increasing the temperature from 10°C to 100°C. Estimated Tm was 
about 60°C. 
Proteins secondary structure content 
In order to assess the secondary structure of Flt-1D2 proteins, we performed far-UV 
CD analyses using different methods to analyze CD spectra and estimate their 
secondary structure content. Circular dichroism is, in fact, an excellent tool for rapid 
determination of the secondary structure and folding properties of proteins. The 
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analysis of the secondary structure composition was performed on Flt-1D2 following 
the programs Continll, Selcon3 and CDSSTR of the CDPro software package and 
one of the most widely used neural networks program: CDNN. An additional method, 
Cluster, was employed for determination of tertiary structure class. CDPro programs 
were run using different sets of model proteins, as illustrated in Table 4. All these 
analyses indicate that Flt-1D2 adopts prevalently a ??sheet structure (Tables 4-7). 
These data are consisted with the analysis by the program Cluster, that determined 
an all beta tertiary structure class for Flt-1D2, and in agreement with the DSSP 
(Kabsch, W. et al. 1983) analysis performed on X-Ray and NMR structures of the 
protein (Table 7).
Ref. Prot. 
Set.
Program % PP2 % Helix % Sheet % Turn % Unrd
SP22X
Continll
Selcon3
CDSSTR
11.2
12
10.4
3.8
7.9
4.6
28.4
24.2
27.6
12.3
12
13.5
44.3
42.6
43.1
SP37A
Continll
Selcon3
CDSSTR
9.6
10.2
8.5
3.5
5.2
1.7
25.5
24.1
27
11.6
12.6
13.4
49.8
50.3
48.9
SP29
Continll
Selcon3
CDSSTR
n.d.
4.4
7.2
4.2
38.3
36.8
36.9
21.5
21.7
24
35.8
36.4
34.9
SDP48
Continll
Selcon3
CDSSTR
n.d.
3.2
4.4
3.7
33.9
32.7
33.9
18.7
19.7
19.7
44.2
41.6
42.9
Table 4_ Predictions of Flt-1D2 secondary structure resulting from the use of different sets of proteins 
derived from different source and combined to create a large reference set of CD spectra. In this table
are reported the predictions derived from the use of Continll, Selcon3 and CDSSTR programs with 
SP22X, SP37A, SP29 and SDP48 sets consisting in reference CD spectra of 22, 37, 29 and 48 
proteins, respectively. The first three sets comprise soluble proteins, the latter also denatured proteins. 
SP29 and SP22X work in the wavelength range 178-260 nm, while SP37A and SDP48 in ranges 185-
240 nm and 190-240 nm, respectively. 
CDNN, employed in the analysis of Flt-1D2 CD spectra, is a program of artificial 
intelligence used to analyze data of interest and determine helix, ?-structure, and 
turns contents of them, reminding the information previously acquired from the 
analysis of known proteins. A neural network is, in fact, first trained using a set of 
known proteins, so that the input of the CD at each wavelength results in the output 
of the correct secondary structure. The trained network is then used to analyze 
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unknown proteins. Below, in Tables 5 and 6, are reported the results obtaining from 
Flt-1D2 CDNN analysis, starting from two sets of globular reference proteins 
consisting in 23 and 33 elements, respectively. 
Table 5_ CDNN 2.1 (Spectra basis 23) 
180-
260 nm 
185-
260 nm 
190-260
nm
195-260
nm
200-260
nm
205-260
nm
210-260
nm
Helix   n.d.   n.d.    13,1%    12,5%    12,1%    12,3%    11,0% 
Antiparallel   n.d.   n.d.    39,8%    40,6%    42,7%    41,9%    44,7% 
Parallel   n.d.   n.d.      4,4%      5,2%      5,5%      5,5%      5,3% 
Beta-Turn   n.d.   n.d.    20,9%    21,2%    21,7%    21,8%    22,1% 
Rndm. Coil   n.d.   n.d.    32,8%    33,8%    36,3%    37,1%    35,5% 
Total Sum     -     -  111,0%  113,4%  118,3%  118,6%  118,6% 
Table 6_ CDNN 2.1 (Spectra basis 33) 
180-
260 nm
185-
260 nm 
190-260
nm
195-260
nm
200-260
nm
205-260
nm
210-260
nm
Helix   n.d.   n.d.      6,8%      8,0%      8,2%      6,5%      7,0% 
Antiparallel   n.d.   n.d.    35,0%    33,3%    34,5%    34,5%    35,6% 
Parallel   n.d.   n.d.      3,4%      4,7%      5,3%      5,4%      5,4% 
Beta-Turn   n.d.   n.d.    19,7%    20,6%    21,2%    20,2%    19,4% 
Rndm. Coil   n.d.   n.d.    35,2%    35,9%    36,9%    35,2%    35,3% 
Total Sum     -     -  100,1%  102,6%  106,2%  101,7%  102,7% 
Starting from X-Ray and NMR structures of the second domain of Flt-1D2 (Wiesmann, 
C. et al., 1997 and Starovasnik, M. A. et al., 1999), the program DSSP calculated 
another set of values to describe the secondary structure content of the protein. The 
DSSP program was designed to standardize secondary structure assignments. 
DSSP is a database of secondary structure assignment for all proteins entries in the 
Protein Data Bank (PDB). In this case, we obtained a similar percentage of ??sheet
content for both crystal and in solution structures (Table 7), in agreement with data 
collected on the refolded Flt-1D2 by running CDPro and CDNN programs.
Table 7 
Program % Alpha % Beta % Random 
DSSP-NMRFlt-1D2 5 41 54
DSSP-XRayFlt-1D2 3 47 50
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NMR Characterization of Flt-1D2
The NMR characterization of Flt-1D2 and the interaction studies with peptides and 
library were performed in collaboration with Prof. Roberto Fattorusso and Dr. 
Donatella Diana (Dipartimento di Scienze Ambientali, Seconda Università di Napoli, 
Caserta).
All the analyses performed on the recombinant second domain of VEGFR-1 
expressed in BL21 Codon Plus (DE3) RIL were indicative of the correct fold assumed 
by the protein after the “on column refolding”. In Figure 42 is showed the one-
dimensional 1H spectrum of Flt-1D2, while in Figure 43 its 2D [1H, 1H] NOESY 
spectrum. Both mono- and bi-dimensional spectra are the most conclusive evidence 
that Flt1D2 adopts a globular conformation, showing good chemical shift dispersion 
and several intra- and inter-residue NOEs, according to data yet reported in the 
literature (Starovasnik, M. A. et al., 1999). In Figure 44 is reported the 1H/15N-HSQC
spectrum of 15N-Flt1D2 that shows a good chemical shift dispersion in amide region 
(6.5-9.5 ppm), suggesting that the protein folds into a unique well defined structure. 
Figure 42_ One-dimensional 1H-NMR spectrum of Flt-1D2 protein, acquired at 298 K in H2O/D2O
mixture at pH 7.0.
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Figure 43_ A section of the 2D [1H, 1H] NOESY spectrum (100 ms mixing period) recorded at 298 K
and 600 MHz is shown.
Figure 44_ 1H/15N-HSQC spectrum of 15N-Flt-1D2 protein recorded at 25°C with a spectral width of
2066 Hz.
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NMR analysis of peptide-protein interaction 
Despite their conformational similarity, QK and MA peptides show a different 
biological activity, since the first has an agonist-like activity (D’Andrea, L. D. et al.,
2005), while the second shows an interesting antagonist behavior compared with 
VEGF (Del Gatto, A. PhD thesis, 2005). QK and MA were employed in binding 
studies with Flt-1D2 aimed to investigate the nature of this interaction and to better 
understand their behavior from a molecular point of view. 
Identification of the binding site on Flt-1D2 via Chemical Shift Mapping 
To map the binding site of Flt-1D2, were used NMR titration experiments, monitoring 
the interaction between QK peptide and the protein. Upon progressive additions of 
QK to the free 15N-Flt-1D2 (Table 8), were observed continuous changes in 1H and 
15N chemical shifts for several signals of 15N-Flt-1D2 in 2D [1H, 15N] HSQC spectra. 
These chemical shifts changes indicated the formation of the complex 15N-Flt-1D2/QK
in intermediate and in fast exchange on the NMR scale. Flt-1D2 residues with the 
most significant changes in 1H and 15N chemical shifts (??>0.04 ppm) upon formation 
of the complex were mapped onto the NMR solution structure of Flt-1D2 and are 
located in the strand ?f (E201, I202, G203, L204, T205), the strand ?g (L215, Y216, K217, R219,
Y 220, L221), the loop between the strand ?a’ and ?b (K170, F172, P173, L174) and the 
region spanning the amino acid sequence Y139, S140, E141, I142, E144, as showed in 
Figure 45.
[15N-Flt-1D2]
(µM)
[QK]
(µM)
15N-Flt-1D2:QK
Ratio
220 0 1:0
220 55 1:0.25
220 100 1:0.50
220 165 1:0.75
220 220 1:1
220 440 1:2
220 660 1:3
Table 8_ Concentrations of 15N-Flt-1D2 protein and QK peptide used in the titration experiments. In the 
table is also reported the molar ratio protein:peptide determined for each concentration of both 
species.
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AB
Figure 45_ Panel A, histogram of the variations of the chemical shifts (??ppm) observed in 2D [1H, 
15N] HSQC spectra of the free Flt-1D2 and in presence of 3 equivalents of QK peptide. Panel B, the
ribbon model of the NMR structure of Flt-1D2 (1QSV.pdb). The amino acids that undergo significant 
chemical shift changes upon formation of Flt-1D2/QK complex were mapped in blue onto the ribbon
model.
Next, similar experiments were carried out for MA peptide. As observed for the 15N-
Flt-1D2/QK complex, progressive additions of MA to the sample containing the 15N-
labeled Flt-1D2 (Table 9) resulted in significant chemical shift changes (??>0.07 ppm) 
for several signals in 2D [1H, 15N] HSQC spectra of the free 15N-Flt-1D2. Again, this 
indicates formation of a complex 15N-Flt-1D2/MA.
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[15N-Flt-1D2]
(µM)
[MA]
(µM)
15N-Flt-1D2:MA
Ratio
220 0 1:0
220 55 1:0.25
220 100 1:0.50
220 165 1:0.75
220 220 1:1
220 440 1:2
Table 9_ Concentrations of 15N-Flt-1D2 protein and MA peptide used in the titration experiments. In the 
table is also reported the molar ratio protein:peptide determined for each concentration of both 
species.
When mapped onto the solution structure of the free Flt-1D2, the residues of the 
refolded protein, upon formation of the complex with MA peptide, displayed 
significant chemical shift changes. They are located on a discontinuous surface 
defined by strands ?b (L169, K170, P172), ?f (E208, A209), ?g (V211, L215, K217, N219), and 
on a flexible region localized at the N-terminus (R133, P135, Y139, S140), as shown in 
Figure 46. 
changes upon formation of Flt-1D2/MA complex were
mapped in blue onto the ribbon model. 
A
Figure 46_ Panel A, histogram of the variations in
chemical shifts (??ppm) observed in 2D [1H, 15N]
HSQC spectra of the free Flt-1D2 and in presence of 2
equivalent of MA peptide. Panel B, the ribbon model
of the NMR structure of Flt-1D2 (1QSV.pdb). The
amino acids that undergo significant chemical shift
B
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Epitope Mapping of QK and MA peptides bound to Flt-1D2 via Saturation 
Transfer Difference 
To provide additional information regarding the interaction between peptides and Flt-
1D2, at atomic resolution, STD (Saturation Transfer Difference) NMR experiments
were performed. Without the unlabeled protein, STD spectra did not contain ligand 
signals because saturation transfer does not occur. The sample containing Flt-1D2
protein was the only one to show saturation transfer from the protein to their ligands 
in STD spectra. 
STD NMR studies provided peptide’s binding epitope for both QK and MA and were 
used to classify the residues relevant for the interaction with Flt-1D2. STD spectra 
were recorded studying the unlabeled Flt-1D2/peptide complex and, in the case of 
QK, clearly demonstrate the involvement of the aromatic region protons of the 
residues such as W4, Y8, Y12. For the side chain of Q5 and Q9 the signal of N?H
protons has similar large intensities (Figure 47). 
W4
(H?1)
E6
(HN) Y8/Y12
(QD)
Y8/Y12
(QE)
Q5
(H?21)
W4
(HN) Q9
(H?22)
W4
(HH2/
QZ2)
Q5
(H?22)
W4
(H?1)
Q9
(H?21)
b
a
Figure 47_ a) expansion of the amide and aromatic region of 1H NMR spectrum of QK alone. b)
expansion of the region containing resonances of the amide and aromatic protons of STD
spectrum for a QK:Flt-1D2 ratio of 1:20. In red is showed the backbone of the QK representative
structure; side chain of the interacting residues with the Flt1D2 are shown. 
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For MA peptide, the strongest interactions are attributed to the aromatic protons of 
W4, Y8 and Y12 and to N?H protons of the residue Q9. Expansions of the region 
containing resonances of the amide and aromatic region are shown in Figure 48. 
expansion of the region containing resonances of the amide and aromatic protons of STD
spectrum for a MA:Flt-1D2 ratio of 1:20.
b
Y8/Y12
(QD)
Y8/Y12
(QE)
W4
(QZ) Q9
(HE22)Q9
(HE21)W4
(HE1)
W4
(HD1)
a
Figure 48_ a) expansion of the amide and aromatic region of 1H NMR spectrum of MA alone. b)
Flt-1D2 was also employed in the screening of a small organic molecules library, but 
data obtained are preliminary. Seven compounds (3% of the library) were selected 
after two screening cycles, but the work is in progress to improve these molecules. 
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Discussion
In recent years the study of the mechanisms of angiogenesis and the research of 
new molecules able to modulate this process have been among the most well funded 
fields of the medical research. A strong clinical interest has emerged in developing 
anti-angiogenesis agents as therapeutic strategies for inhibiting tumor growth and 
metastasis, as well as a variety of other pathologies. Progresses towards a 
therapeutic treatment culminated, in 2004, in the approval of the first antiangiogenic 
agents for gastrointestinal cancer (Hurwitz, H. et al., 2004). On the other hand, 
therapeutic angiogenesis, consisting in promoting new vessel growth to treat 
disorders, such as ischemia, is an exciting frontier of cardiovascular medicine.
The aim of this work is the expression of the extracellular domains of VEGF receptors 
KDR and Flt-1, in order to characterize them via NMR studies. Structural data on the 
extracellular portion of the receptors are, in fact, still very limited. The only structural 
data about Flt-1 receptor regards the domain 2 of the extracellular region that has 
been described in the free form (Starovanik, M. A. et al., 1999), bound to VEGF 
(Wiesmann, C. et al., 1997) or PlGF (Christinger, H. W. et al., 2004). So far, no 
structural data have been reported for Flt-4 and the extracellular domains of KDR. 
Instead, KDR intracellular kinase domain has been described (McTigue, M. A. et al.,
1999). A partial characterization of NRP-1 and NRP-2 receptors has been performed 
(Pellet-Many, C. et al., 2008) and, very recently, the complex between VEGF and the 
extracellular Flt-1 domain has been observed by electron microscopy (Ruch, C. et al.
2007). Hence, to extend the structural information about VEGF receptors is a very 
attractive goal. Besides, our intention is to test the binding capacity of the 
recombinant domains in interaction experiments with small synthetic peptides to 
understand the molecular bases of the interaction between VEGF receptors and its 
selected agonists/antagonists. This represents, in fact, an important step towards the 
designing of therapeutic approaches aimed at the treatment or prevention of 
angiogenic diseases. Finally, our aim is to employ the recombinant domains in drug 
discovery studies by targeting phage or small organic molecules libraries since, to 
date, no small organic molecules have been identified to target VEGF receptors in 
their extracellular portion. 
Flt-1 and KDR extracellular domains have been cloned successfully in several 
expression systems and expressed in Escherichia coli. E. coli is a very suitable host 
for the over-expression of heterologous proteins whose activity does not request 
post-translational modifications and allows achieving greater efficiency, 
reproducibility and convenience than mammalian cells. VEGF receptors contain 
several putative N-glycosylation sites and the mature proteins are extensively 
glycosylated, but this post-translational modification is not a prerequisite of high 
affinity binding of receptors to VEGF (Barleon, B. et al., 1997). Besides, in spite of 
mammalian cells, it is possible to grow E. coli strains in minimum medium, in order to 
express labeled proteins for characterization studies, without affecting physiology of 
bacterial cells. In addition, most of the commercially available receptors are Fc-IgG 
chimeras, resulting impossible to study via NMR because of their dimension and 
costs. Instead, the bacterial expression systems designed for the expression in E.
coli enable to produce the recombinant proteins fused to a convenient tag which can 
be removed. 
Thus, the different constructs introduced in bacterial host cells allowed, for most of 
them, achieving high yields of recombinant receptors domains. In some cases, 
however, the limiting step was just the expression, as, for example, for KDRD1-2.
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Despite different cloning strategies and the optimization of their expression 
conditions, the first two domains of KDR receptor have never been expressed. The 
domain 2, instead, was expressed, but was not possible to purify it, because, either 
under native or denaturing conditions and, in spite of its N-terminal 6xHis-tag, it did 
not bind to the Ni2+-NTA resin. In addition, even if for each recombinant construct 
have been tested several conditions to optimize the expression of proteins of interest 
and try to get them in soluble form, no domain of both receptors was soluble 
expressed, but all proteins were extracted with denaturing agents from inclusion 
bodies and refolded. On the other hand, refolding was not always successfully and 
the difficulty to obtain a refolded protein from inclusion bodies in sufficient amount 
made so far impossible further structural and functional studies for their 
characterization. These negative results make clear how difficult is to express these 
proteins and reflect the absence, in the literature, of extensive structural information 
on KDR and Flt-1 extracellular domains. 
Instead, it was developed an experimental protocol for refolding and purification of 
the second domain of VEGF Flt-1 receptor. The structure of Flt-1D2 has been solved 
either by X-Ray (complexed with VEGF) (Wiesmann. C. et al. 1997) or by NMR 
studies (Starovasnik, MA et al. 1999). In both cases, the protein was cloned and 
expressed in E. coli as inclusion bodies and refolded. Despite these available 
protocols, we were not able to purify the protein as a homogeneous product. In fact, 
according to Wiesmann et al., the construct comprising residues 129-229 was 
expressed as an insoluble protein in E. coli and inclusion bodies were treated with 6 
M urea in 20 mM Tris-HCl, pH 7.5. Flt-1D2 was then refolded in two step dialysis by 
diluting the above solution in 6 M urea to 0.05 mg/mL. But in the last step Flt-1D2
precipitated. On the other hand, Starovasnik et al. proposed first the purification of 
the protein by affinity chromatography under denaturing conditions, then by reversed-
phase HPLC, in order to separate the folded Flt-1D2 from the unfolded form 
(Starovasnik, M. A. et al., 1999). Consequently, the case would have requested an 
additional refolding step, but, also this method failed. Our protocol consists of the 
expression of the recombinant 6xHis-tagged Flt-1D2 in E. coli BL21 Codon Plus (DE3) 
strain. The protein, expressed as inclusion bodies, is refolded by an “on column 
refolding” protocol which resulted determinant for succeeding in the production to 
homogeneity of the second domain of VEGF Flt-1 receptor. The protein was, in fact, 
first refolded, still bound to the resin Ni -NTA, and then eluted in Tris buffer 
containing high concentration of imidazole. This strategy allowed making refolding in 
relatively shorter time than step dialysis and with less amount of urea. Besides, only 
two purification steps of affinity chromatography occurred, after which the 
homogeneous Flt-1D2 was concentrated to 3.5 mg/mL. Hence, the final product was 
analyzed to investigate its conformational and functional properties using a 
multidisciplinary approach. 
2+
Protein Alkylation was performed to analyze the oxidation state of its two cysteine 
residues on both reduced and not reduced samples and showed that, in non 
reducing conditions, no alkylated adducts were found, while, in presence of DTT, the 
main product presented the two cysteine residues alkylated with an increment of 58 
Da for each thiol group derived from reduction reaction. This experiment shows that 
in the refolded Flt-1D2 the two cysteine residues are involved in the formation of a 
disulfide bridge, as expected from literature data (Wiesmann, C. et al., 1997). 
Besides, the partial digestion with trypsin demonstrated the compact structure of the 
Ig-like domain, suggesting again the correct fold of the refolded protein.
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Conformation preference of the recombinant Flt-1D2 was inspected by circular 
dichroism analyses. The content in secondary structure derived from the CD spectra 
analysis was in agreement with X-Ray data reported for Flt-1D2 (Wiesmann, C. et al.,
1997), prevalently folded in a ??sheet structure. Thermal unfolding analysis showed 
a sigmoidal curve, with a single transition (Tm of about 60°C), indicating that a two-
state unfolding process occurred. Moreover, thermal unfolding was reversible. 
In addition, the functionality of Flt-1D2 was assessed with a competition assay 
performed on HUVEC cells. The experiment verified the capability of the Flt-1 second 
domain to bind to VEGF, interfering with the interaction VEGF/receptors on HUVEC 
membrane.
The results were fully confirmed by NMR studies conduced on both 15N-labeled and 
unlabeled proteins. Protonic mono- and bi-dimensional spectra of the unlabeled 
protein show the same strong signal dispersion of chemical shifts reported in the 
literature (Starovasnik, MA et al. 1999). The 1H/15N-HSQC spectrum of the uniformly 
15N-labeled sample indicates that the global fold of the refolded Flt-1D2 is very similar 
in that reported by Starovasnik and in the crystalline state complexed to VEGF 
(Wiesmann, C. et al., 1997). We used the protein in order to understand the 
molecular bases of the interaction with two rationally designed peptides: QK and MA 
(D’Andrea, L. D. et al., 2005 and Del Gatto, A. PhD thesis, 2005). This would be the 
start point for the optimization and stabilization of that features which these 
molecules need to be used as good modulators in angiogenesis. 
QK and MA differ in their sequence for only two amino acid residues, but the first acts 
as an agonist of VEGF (D’Andrea, L. D. et al., 2005), while MA is a VEGF antagonist 
(Del Gatto, A. PhD thesis, 2005). In the literature are reported evidences that QK 
competes with VEGF for a binding site on endothelial cells expressing both KDR and 
Flt-1 receptors (D’Andrea, L. D. et al., 2005). The peptide binds to and activates both 
receptors similarly to VEGF and its agonist-like behavior is confirmed by in vitro and 
in vivo cell proliferation experiments. Although QK was designed to bind to KDR and 
Flt-1, its agonist-like activity is surprising because receptor dimerization is necessary 
for receptor activation and QK is a small peptide, probably unable to induce receptor 
dimerization by itself. Maybe, QK binding induces a conformational change of the 
receptor that either triggers, in an unknown way, the dimerization or induces the 
receptor activation through a different, previously uncharacterized mechanism that 
may not require dimerization. To address this issue, further structural and 
biochemical studies are needed.
The interaction with peptides occurred following two approaches: one based on 
ligand observation, through Saturation Transfer Difference experiments, the other on 
observation of the protein, with Chemical Shift Mapping analysis. 
The interaction studies with QK peptide identified the binding site on protein surface 
through analysis of chemical shift perturbations of 15N-Flt-1D2. For this purpose were 
recorded 2D [15N, 1H] HSQC spectra of the protein, adding increasing amounts of 
peptide.
From variations in chemical shifts induced by QK on 15N-Flt-1D2, significant changes 
in the fast exchange regime, in respect to the time scale of NMR, are identified for 
the strand ?f (E201, I202, G203, L204, T205), the strand ?g (L215, Y216, K217, R219, Y220,
L221), the loop between strand ?a' and ?b (K170, F172, P173, L174) and the region 
comprising residues Y139, S140, E141, I142, E144.
On the other hand, STD experiments have identified peptide’s binding epitope, 
confirming the involvement of side chains of amino acids W4, Q5, Y8, Q9, Y12 in 
interacting with the receptor.
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Similar experiments were carried out for MA peptide. Progressive additions of MA to 
the sample containing the 15N-labeled Flt-1D2 result in significant chemical shift 
changes for several signals in the [1H, 15N] HSQC spectra of the free 15N-Flt-1D2,
indicating, again, the formation of a complex 15N-Flt-1D2/MA. When mapped onto the 
solution structure of the free Flt-1D2, the residues displaying significant chemical shift 
changes are mapped on a discontinuous surface defined by strands ?b (L169, K170,
P172), ?f (E208, A209), ?g (V211, L215, K217, N219), and  on a flexible region localized at 
the N-terminus (R133, P135, Y139, S140). For MA peptide, the strongest interactions are 
attributed to the aromatic protons of W4, Y8 and Y12 and to N?H protons of the residue 
Q9.
Although peptides binding epitopes are clearly overlapping, NMR data indicate that 
QK and MA bind Flt-1D2 in distinct ways. In fact, on protein surface, QK induces 
chemical shift changes that are not observed in the case of the interaction with MA. 
On the basis of the chemical shift analysis, QK interacts with Flt-1D2 through ?-
strands ?g and ?a’ and ?c- ?c’ loop region, whereas MA interacts more extensively 
with the residues located on the strands ?c and ?f. However, it is evident that both 
peptides bind to a region of Flt-1D2 protein known to contain the contact surface for 
VEGF. This region comprises highly positively charged residues, suggesting that 
ionic interactions play an important role in the binding, as well as hydrophobic 
interactions.
On the other hand, STD NMR studies of QK and MA peptides in the presence of Flt-
1D2 show that the aromatic protons of the residues Trp4, Tyr8 and Tyr12 interact with 
the receptor. In addition, the HN side chain of the residues Gln5 (only for QK) and 
Gln9 are recognized, whereas the HN backbone amide protons are less implicated.
The second domain of Flt-1 receptor was also used in the screening of a library of 
small organic molecules, in order to find new compounds of biotechnology interest for 
modulating the angiogenesis process. Seven compounds (3% of the library) were 
selected after two screening cycles, but the work is in progress to improve these 
molecules.
In conclusion, in this work we cloned and expressed different portions of the 
extracellular region of KDR and Flt-1 receptors. Only the second domain of Flt-1 
receptor was refolded and purified using effective and reliable conditions to produce 
the protein at NMR concentration, developing an experimental protocol for the “on 
column refolding” resulted fast, cheap and efficient for our purpose. The protein, even 
when 15N-labelled expressed, was obtained as a homogeneous product (3.5 mg/mL), 
without adding VEGF or other cofactors that in the literature are reported to facilitate 
its concentration (Wiesmann, C. et al. 1999). Its proper folding was verified by 
nuclear magnetic resonance, biochemical and functional analyses. The protein was 
used in NMR interaction studies with two bioactive peptides and in a drug discovery 
analysis with the screening of a library of organic compounds. Our next perspective 
is to deepen the interaction studies with peptides, in order to obtain the dissociation 
constants of their binding to the second domain of Flt-1 receptor and try to explain 
their agonist or antagonist activity from a molecular point of view. Regarding the 
screening of the library, the obtainment of seven compounds to be improved is a very 
satisfactory result. To date, there are no small organic molecules able to target VEGF 
receptors in their extracellular portion and to identify new low molecular weight 
compounds able to act in this way, modulating the interaction between VEGF and its 
receptors, could be very exciting. 
Finally, our intention is to express and refold the other domains of VEGF receptors, in 
order to characterize them by NMR studies. 
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INTRODUCTION
R
adiopharmaceuticals are widely employed in nuclear
medicine for the diagnosis and therapy of different
diseases. In the last years, many new radiopharma-
ceuticals have been developed using a target speciﬁc
approach. In fact, in some diseases, such as cancer,
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ABSTRACT:
The development of receptor targeting radiolabeled
ligands has gained much interest in recent years for
diagnostic and therapeutic applications in nuclear
medicine. Cholecystokinin (CCK) receptors have been
shown to be overexpressed in a subset of neuroendocrine
and other tumors. We are evaluating binding and
biodistribution properties of a CCK8 peptide derivative
labeled with 99mTc(I)-tricarbonyl. The CCK8 peptide was
modiﬁed at its N-terminus by adding to its N-terminus
two lysine–histidine modules (KH), where histidine is
coupled to the side chain of the lysine ((KH)2-CCK8).
99mTc(I)-tricarbonyl was generated with the IsoLinkTM
kit. A431 cells stably transfected with a cDNA encoding
for the human CCK2 receptor were utilized to determine
binding afﬁnity, internalization, and retention of the
labeled peptide, in comparison with wild-type A431 cells.
A nude mouse tumor model was obtained by generating
A431-CCK2R and A431-control tumors in opposite
ﬂanks of the animals. High speciﬁc activity labeling with
99mTc was achieved. In A431-CCK2R cells, speciﬁc
saturable binding was observed as well as evident
internalization of the radiolabeled peptide after binding.
Biodistribution experiments showed rapid, speciﬁc
localization of (KH)2-CCK8 on A431-CCK2R xenografts
compared with control tumors, although absolute uptake
values were not markedly higher compared with
background activity. Clearance of unbound radioactivity
was both urinary and hepatobiliary. In imaging
experiments, while targeting to CCK2R positive tumors
could be appreciated, there was poor contrast between
target and nontarget areas. (KH)2-CCK8 shows adequate
in vitro and in vivo properties for CCK2R targeting
although improvement of biodistribution warrant further
development. # 2008 Wiley Periodicals, Inc. Biopolymers
(Pept Sci) 90: 707–712, 2008.
Keywords: technetium; radiopeptide; imaging; organome-
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cells may express on their surface, speciﬁc receptors; mole-
cules capable of targeting these receptors can discriminate
between normal and cancer cells lowering the toxicity and
the side effects of the drug. These radiopharmaceuticals are
mainly designed by the following two approaches: integrated
and bifunctional. The latter approach is generally accom-
plished by assembling a targeting molecule, a linker, a chela-
tor, and the radionuclide.1
Antibodies and peptides are the two classes of compounds
widely used as targeting molecules in receptor imaging. In
particular, peptides, which recognize the cognate receptor
with high binding afﬁnity and speciﬁcity, present some
advantages over antibodies such as: they are easily synthe-
sized and modiﬁed, are relatively inexpensive, have rapid
blood clearance, and high tumor to background ratios.1–3 A
successful example is represented by the radiolabled somato-
statin analog 111In-octreotide widely used in cancer imaging
(octreoscan).4 After the FDA approval of octreoscan, many
other peptides are being investigated.5
A well-characterized molecular target for imaging is repre-
sented by the cholecystokin (CCK) receptors.6 CCK recep-
tors, CCK1R and CCK2R, are membrane bound receptors
belonging to the superfamily of G-protein-coupled receptors
(GPCRs) and are predominantly located in the gastrointesti-
nal tract and the central nervous system.7 They differ in the
afﬁnity for gastrin; CCK1R has low afﬁnity, whereas CCK2R
binds both gastrin and cholecystokinin (CCK) with high
afﬁnity. CCK2R is overexpressed in a variety of tumors such
as medullary thyroid carcinoma, small cell lung cancer, astro-
cytomas, stromal ovarian tumors, and some gastroentero-
patic tumors.8 Several CCK and gastrin derivatives have been
characterized over the past years for the purpose of in vivo
receptor targeting, and the feasibility of using CCK8-based
peptides to target CCK2R in vivo has been shown.6,9,10 The
C-terminal sequence of cholecystokinin, CCK8, is capable of
binding both CCK receptors, but shows higher afﬁnity and
selectivity for CCK2R9 and has been extensively used for
imaging with different chelators.9–17
Several radionuclides are being used in nuclear medicine,
and 99mTc(I) is rapidly gaining in popularity since the intro-
duction by Alberto and coworkers18,19 of a one-pot proce-
dure to synthesize stable organometallic Tc(I)-complexes
[99mTc(OH2)3(CO)3]
+ (TcCO). 99mTc(I) presents very favor-
able physical properties for application as radiopharmaceuti-
cals. Its half-life (t1/2 ¼ 6 h) is long enough to carry out
chemical synthesis and get useful images after administration
to the patient. At the same time, it is short enough to permit
administration of relatively high amounts of 99mTc radioac-
tivity without exposing the patient to excessive radiation
doses. The 140 keV photons are ideal for nuclear imaging
applications, and 99mTc isotope is readily available from
commercial 99Mo-99mTc generetors.1,20
In the TcCO complex, the water molecules can be
replaced by ligands to obtain very stable d6 low-spin com-
plexes. Preferred ligands are molecules possessing, as coordi-
nating atoms, sp2 nitrogens such as present in the side chain
of the amino acid histidine.19 Ligands replacing all the three
water molecules can form very stable complexes, avoiding
trans-chelation reactions, which may occur in vivo, and the
generation of free Tc. Recently, Alberto et al. reviewed the
ligands (mono-, bi-, and tridentate) available for peptide
labeling with TcCO.21 Histidine is a convenient ligand to
functionalize peptides because of its small dimension, and it
can be easily introduced during chain assembly on the resin.
When His is inserted in a peptide chain, it can act as mono-
dentate ligand for TcCO, but when positioned at the N-ter-
minus, it acts as bidentate ligand. The a-NH2 group and the
d-N aromatic amine are efﬁcient chelators for the fac-
[99mTc(CO)3]
+ core under formation of a six-member ring.
Several articles have been reported the utility of histidine and
histidine-based ligand labeled with TcCO for imaging appli-
cations.22–28
Aim of this work was to characterize the in vitro and in
vivo properties of CCK8 tagged with a chelator composed of
two N-terminal His-like residues and labeled with 99mTc(I)-
tricarbonyl. The presence of multiple His units could favor
the metal complexation and allow to achieve higher speciﬁc
activities. This in turn would allow targeting of higher
amounts of radioactivity per unit of peptide molecule, a fea-
ture that may prove advantageous for therapeutic applica-
tions using 186/188Re(I)-tricarbonyl.
EXPERIMENTAL SECTION
All amino acids and coupling reagents (HOBT and HBTU) were
purchased from Novabiochem (La¨ufelﬁngen, Switzerland), N,N-
dimethylformamide (DMF) from Lab-Scan (Dublin, Ireland),
DIPEA and triﬂuoroacetic acid (TFA) from Romil (Cambridge,
UK), acetic anhydride from Applied Biosystem Dichloromethane,
Piperidine, 1,2-ethandithiol (EDT) from Fluka (Steinheim,
Germany), and triisopropylsilane from Aldrich (Steinheim,
Germany). Acetonitrile HPLC grade was from Riedel-de Hae¨n
(Schnelldorf, Germany).
Peptide Synthesis
Peptide amide was synthesized using ABI 433 peptide synthesizer
(Applied Biosystem) on solid phase using Rink Amide MBHA resin
(Novabiochem) and standard Fmoc (N-(9-ﬂuorenyl)methoxycar-
bonyl) chemistry. All the amino acids presented standard protection
group on the side chain except for the lysines, which were protected
with methyltrytil group (Mtt) to allow selective deprotection.
Lysines were selectively deprotected with a solution of 1% TFA, 5%
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TIS in DCM, and after neutralization (20% DIPEA in DMF) Fmo-
cHis(Trt)-OH was coupled to the resin. After Fmoc deprotection
with piperidine the peptide was cleaved from the resin, and removal
of side-chain protecting groups was achieved by treatment with a
mixture of TFA, water, EDT, TIS (94:2.5:2.5:1) at room temperature
for 3 h. Then the peptide ((KH)2-CCK8) was precipitated with ethyl
ether and liophylized. Crude peptide was puriﬁed by HPLC on a
C18 Column (Juppiter, Phenomenex) using a linear gradient of ace-
tonitrile/water (0.1% TFA) from 5 to 40% in 25 min. Purity and
identity of the synthesized peptide was assessed by HPLC (Agilent
1100 series) and MALDI-ToF mass spectrometry (Voyager DE-Per-
septive Biosystem).
Radiolabeling
Carbonyl aquaion [99mTc(OH2)3(CO)3]
+ was prepared from a com-
mercial kit (ISOLINK, Mallinckrodt, Petten) according to the man-
ufacturer’s instructions (1 ml volume; 200–1000 MBq 99mTc). Small
aliquots of the 99mTc-CO complex (100–150 lL) were incubated
with the peptide (10–50 nmol) at room temperature. Complex for-
mation was veriﬁed by RP-HPLC. Final speciﬁc activities of the
radiolabeled peptide used in the experiments were 1850–3700
GBq/mmol.
In Vitro Cellular Assays
All in vitro cellular assays were performed on A431 cells overex-
pressing CCK2R receptor (A431-CCK2R).10 Cells were plated at a
density of 1–200,000 cells/well in 12-well multiwell plates, 2 or 3
days prior to the experiments. These conditions allowed for the cells
to be almost conﬂuent at the time of the assay.
To assess binding afﬁnity of the compound, duplicate wells were
incubated with serial dilutions of [TcCO](KH)2-CCK8 in culture
medium at 48C for 1 h, with concentrations ranging from 0.05 to
120 nM. To assess nonspeciﬁc binding, 100- to 1000-fold excess
unlabeled peptide was added to some of the wells. At the end of
incubation period free radioactivity was recovered, wells washed
with two rapid rinses in PBS and bound activity recovered by solu-
bilization cells in 0.1N NaOH. Radioactivity was measured with a
Wallac Wizard gamma counter (Wallac Oy, Turku, Finland). The
amount of bound compound was normalized for protein content
that was determined by utilizing a commercially available kit (Bio-
Rad Laboratories, USA).
Binding curves were analyzed using a Macintosh computer and
Kaleidagraph software (Abelbeck Software, Version 3.0.5, distrib-
uted by Synergy Software, Reading, PA). Dissociation constants
(Kd) and apparent number of binding sites per cell (Bmax) were
derived by ﬁtting the data to the following equation:
Bound ¼ Bmax
½½TcCO KHð Þ2CCK8
Kd þ ½½TcCO KHð Þ2CCK8
:
Cellular internalization was determined by comparing differences in
accumulation of the compound incubated with A431-CCK2R cells
at 48C, temperature at which most metabolic processes are blocked,
and at 378C, where all metabolic processes including receptor inter-
nalization are active. Cells were incubated with 20 nM
[TcCO](KH)2-CCK8 at the two temperatures, for 60 and 120 min.
After 120 min of incubation some wells were rinsed with PBS to
remove unbound radioactivity and were subsequently incubated for
an additional hour at 48C with 30 lM unlabeled peptide, in order to
displace any surface bound radioactivity. Radioactivity associated to
cells was determined after washing away unbound radioactivity and
subsequently normalized for protein content, as described earlier.
In Vivo Studies
Mice bearing xenografts of A431-CCK2R and A431-control cells
were generated by injecting 100 lL of the respective cell suspensions
at a density of 2 3 107 ml1 in PBS in opposite ﬂanks of 6-week-old
CD-1 nude mice (weight 17–23 g). Tumors were allowed to grow
for 10–14 days. Final tumor weight was between 0.5 and 1 g at the
time of the biodistribution and imaging experiments.
Biodistribuition Studies. The time course of tissue and tumor
distribution of [TcCO](KH)2-CCK8 was determined following
injection of * 3.7 MBq/mouse (0.2–0.5 nmol peptide) of labeled
peptide in the lateral tail vein. At least ﬁve animals per time point
were used. The animals were killed 30 and 120 min after injection.
Blood, lungs, liver, spleen, kidneys, stomach, intestines, muscle, and
xenograft samples were weighed and radioactivity determined in the
gamma counter. Dilutions of the injected compound were simulta-
neously counted for accurate determination of the injected dose.
The relative amount of radioactivity in the organs was calculated
and expressed as percentage of the injected dose/gram tissue (%ID/
g) normalized to a 20 g mouse. In some animals, gamma camera
imaging was performed after sacriﬁcing the mouse to assess visual-
ization of CCK2R positive tissues.
Metabolite Analysis. To test stability of [TcCO](KH)2-CCK8,
the compound was injected into a nude mouse and a blood sample
was recovered 120 min postinjection. The blood samples were cen-
trifuged to recover serum and then CH3CN was added to precipitate
high molecular weight proteins. The resulting soluble fraction was
subjected to RP-HPLC and radioactivity assessed by collecting 1
min fractions that were subsequently measured in a gamma counter.
Similarly, experiments aimed at determining tissue metabolism of
the compound were carried out on homogenates obtained from
mouse tissue samples and xenografts that were freshly prepared as
previously described.10 Aliquots of [TcCO](KH)2-CCK8 were incu-
bated with the homogenates for times ranging from 0 to 60 min,
extracted with CH3CN and analyzed with RP-HPLC as above.
RESULTS AND DISCUSSION
Peptide Design and Synthesis
The synthesis of the CCK8 peptide, (KH)2-CCK8, tagged
with the multiple bifunctional ligand based on histidine as
chelator agent, was entirely carried out on solid phase. The
bifunctional ligand is composed of two lysines, spaced by a
b-alanine, each bearing a His residue on its side chain. In
this way the two His assume a N-terminal-like position. The
b-alanine acts as spacer, in order to reduce electrostatic and
steric repulsions between the chelator groups. b-alanine was
chosen as spacer because of its conformational preference:
the dihedral angle l (N-Cb-Ca-C0) can adopt only the trans
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(1808) and/or gauche (+608) conformations29 keeping the
two His residues far away from each other. The peptide
sequence is reported in Figure 1.
The peptide and the ligand are entirely synthesized in
solid phase, this is an advantage over peptide-chelate conju-
gates that need to be prepared coupling in solution the che-
lating units. The product is obtained with high yields and
can be puriﬁed by HPLC yielding a high homogeneous prod-
uct. Moreover, the modular composition of the chelating
unit allows the design of a class of ligands in which the physi-
cochemical properties of the whole molecule, such as hydro-
philicity, could be easily modulated.
Radiolabeling and Quality Control
The puriﬁed peptide was efﬁciently labeled using the isolink
kit at high speciﬁc activity starting from the carbonyl aqua-
ion [99mTc(OH2)3(CO)3]. The reaction was followed by
reverse phase HPLC and a mixture, most presumably, of
mono and double labeled species, were obtained. There were
no puriﬁcation steps for the radiolabeled material prior to
experimental use.
Receptor Binding and Internalization
Initially, we tested whether [TcCO](KH)2-CCK8 was capable
of binding A431 cells overexpressing the CCK2R in vitro.
Figure 2 shows data from a saturation binding experiment
with increasing concentration of peptide [TcCO](KH)2-
CCK8. The experiment shows rapid initial binding of the
compound to the CCK2R expressing cells and a slight increase
in cell associated activity over time suggesting that part of the
radioactivity is internalized. Nonspeciﬁc binding, as assessed
by incubation of the compound with nonreceptor expressing
cells or in receptor expressing cells in the presence of 100-fold
excess unlabeled peptide, was very low. These experiments
were performed at 48C, in order to block receptor internaliza-
tion and thus measure only ligand-receptor interaction. The
peptide binds to the CCK2 receptor with a dissociation con-
stants (Kd) of* 30 nM and with an apparent receptor num-
ber (Bmax) of 5.8 pmol/mg protein. The binding was saturable.
All parameters were in agreement with previously character-
ized CCK8-based molecules10 and are in the range useful for
receptor-binding of radiopharmaceuticals.30 This data show
that the introduction of the bis-His chelating unit does not
affect the binding of the targeting molecule to the receptor.
The CCK receptors, such as GPCRs, internalize after the
ligand binding event. A radiopharmaceutical targeting the
CCK2R can take advantage of this biological mechanism
because the receptor turn over always recycle free receptor on
the cell surface, and the segregation of the peptide in the
cytosol shift the ligand-binding equilibrium toward the
receptor-ligand complex formation. To evaluate if the pep-
tide was being internalized by the cells, we performed parallel
experiments in which A431-CCK2R cells were incubated
with 20 nM [TcCO](KH)2-CCK8 at 48C (internalization
blocked) or 378C (internalization active). The results are
reported in Figure 3. The radioactivity is progressively accu-
mulated in cells incubated at 378C with labeled peptide alone
(60 min vs. 120 min), whereas the levels of cell-associated
radioactivity are constant in cells incubated at 48C at 60 and
120 min, suggesting that internalization is occurring to some
extent at 378C. Again, the presence of the multifunctional
ligand does not appear to alter the biological activity of the
CCK8 peptide portion.
In Vivo Characterization
The in vivo characterization was carried out in nude mice
bearing xenografts of A431-CCK2R and A431-control cells.
FIGURE 1 Schematic representation of the labeled peptide
(KH)2-CCK8. The amino acid sequence of CCK8 is: Asp-Tyr-Met-
Gly-Trp-Met-Asp-Phe-amide.
FIGURE 2 Receptor binding. A431 cells overexpressing CCK2R
were incubated with increasing concentration of TcCo labeled pep-
tide. The radioactivity of bound compound was normalized for pro-
tein content.
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With this approach, two xenografts displaying identical prop-
erties regarding to blood ﬂow, vascular permeability, etc. are
used, and the two tumors differ only in the ability to express
CCK2 receptors. As we have previously shown,10 this model
allows an accurate assessment of speciﬁc and nonspeciﬁc
interactions of the ligand and the evaluation of its imaging
properties. We have evaluated the biodistribution (Figure 4),
metabolite analysis (Figure 5), and the imaging properties
(Figure 6) of the peptide [TcCO](KH)2-CCK8.
The uptake of [TcCO](KH)2-CCK8 in the A431-CCK2R
xenografts was higher than in A431-control tumors with a
target to nontarget ratio (receptor positive vs. receptor nega-
tive tumor) of 2.3:1 at 120 min postinjection indicating a
good uptake, retention and that the binding speciﬁcity is
maintained in vivo. The route of clearance of radioactivity
was mostly through the kidneys, although a signiﬁcant por-
tion of radioactivity showed hepatobiliary clearance. In gen-
eral, the clearance was rapid and evident by the 30 min time
point. Retention in all organs (see Figure 4) was lower than
4% ID/g after 2 h except for the kidney (7.35% ID/g); blood
FIGURE 3 Peptide internalization. A431-CCK2R cells were incu-
bated with 20 nM [TcCO](KH)2-CCK8 at 48C and 378C for 60 and
120 min. An additional incubation of one hour at 48C with 30 lM
unlabeled peptide was performed in order to displace any surface
bound radioactivity. Radioactivity associated to cells was normal-
ized for protein content. NSB. Nonspeciﬁc binding was assessed by
incubating control A431 cells at 378C for 120 min with tracer
amounts of labeled peptide or by incubating A431-CCKBR cells at
48C with the radiolabeled peptide in the presence of excess (30 lM)
cold peptide.
FIGURE 4 Peptide biodistribution. Analysis of peptide organ
distribution 30 or 120 min after injection. ID/g, injected dose/gram
tissue.
FIGURE 5 Metabolite analysis. RP-HPLC traces of (A)
[TcCO](KH)2-CCK8 peptide control, (B) serum at 120 min post
injection, (C) liver homogenates after 1 h incubation at 378C, and
(D) kidney homogenates after 1 h incubation at 378C.
FIGURE 6 c-camera images. Animals were sacriﬁced 2 h after
injection of [TcCO](KH)2-CCK8 peptide. Accumulation of the pep-
tide was seen in a CCK2R-positive xenograft (right thigh) but not in
the control tumor (left thigh). Hot spots in the abdomen are con-
sistent with liver and kidney accumulation.
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levels of 0.75% ID/g at 2 h indicate fairly rapid plasma clear-
ance. We also evaluated the stability of the peptide conjugate
under different conditions (see Figure 5). The compound
was injected into a nude mouse, and a blood sample was
recovered 120 min postinjection. HPLC analysis showed deg-
radation of the starting compound to hydrophilic byproducts
and the starting material was no longer detectable (Figures
5A and 5B). As previous experience with CCK8-based
ligands10 indicate that metabolism in the organs rather than
in serum plays a major role, the compound was incubated
with tissue homogenates obtained from liver and kidney
(Figures 5C and 5D). In both cases, rapid degradation of the
compound to very hydrophilic byproducts was observed;
however, in kidney extracts the degradation was more com-
plete, whereas in the liver we could still observe a signiﬁcant
amount of the starting material.
Imaging properties of [TcCO](KH)2-CCK8 were assessed
by performing gamma camera images 2 h after injection (see
Figure 6). Concentration of the compound in the CCK2R pos-
itive tumor can be appreciated; however, the image also shows
high-level background activity in kidney, liver, and gastroin-
testinal tract as expected from the biodistribution data.
CONCLUSIONS
We have reported the chemical synthesis, in vitro and in vivo
biological properties of a new molecule, [TcCO](KH)2-
CCK8, based on CCK8 peptide as targeting agent bearing an
amino acid-based chelator and labeled with the techne-
tium(I) carbonyl. The compound shows speciﬁc binding to
CCK2R receptors with high afﬁnity, low nonspeciﬁc binding,
and cellular internalization. The speciﬁcity of compound-
receptor interaction is maintained in vivo. However, imaging
applications of this compound could beneﬁt from reduction
of the relatively high-background radioactivity levels, likely
linked to signiﬁcant hepatobiliary clearance. The ease of syn-
thesis and the modular design of this class of ligands allow
their modiﬁcation and further development with the aim of
favoring renal clearance through increased hydrophilicity.
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A vascular endothelial growth factor mimetic accelerates gastric ulcer healing
in an iNOS-dependent manner
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Dudar GK, D’Andrea LD, Di Stasi R, Pedone C, Wallace JL. A
vascular endothelial growth factor mimetic accelerates gastric ulcer
healing in an iNOS-dependent manner. Am J Physiol Gastrointest
Liver Physiol 295: 374–381, 2008. First published June 26, 2008;
doi:10.1152/ajpgi.90325.2008.—Angiogenesis is crucial to all types
of wound healing, including gastric ulcer healing. The most potent
promoter of angiogenesis is vascular endothelial growth factor
(VEGF). We hypothesized that a 15-amino acid peptide designed to
mimic the angiogenic action of VEGF would accelerate gastric ulcer
healing. Gastric ulcers were induced in mice by serosal application of
acetic acid. Treatment with the VEGF mimetic accelerated gastric
ulcer healing when administered orally or intraperitoneally, at a dose
of 50 ng/kg or greater. Such healing was not observed when the
reverse sequence pentadecapeptide or the full-length VEGF protein
was administered. Contrary to our hypothesis, the VEGF mimetic did
not signiﬁcantly increase angiogenesis in the ulcerated stomach. The
enhancement of ulcer healing by the VEGF mimetic occurred inde-
pendently of cyclooxygenase-2 (COX-2) activity but was blocked by
inhibitors of inducible nitric oxide synthase (iNOS). These results
demonstrate that a VEGF mimetic is a potent stimulus for gastric ulcer
healing, even when given orally. The effects of the mimetic were
independent of stimulatory effects on angiogenesis and COX-2 activ-
ity but were dependent on iNOS-derived NO production.
stomach; nitric oxide; cyclooxygenase; angiogenesis; prostaglandin;
gastric mucosa
CHRONIC GASTRIC ULCER HEALING involves epithelial cell migration
and proliferation, matrix remodeling, and angiogenesis. These
processes can be modulated by a plethora of transcription
factors, growth factors, and cytokines (36). Growth factors that
inﬂuence angiogenesis have been of particular interest to many
investigators (13, 23, 31). Vascular endothelial growth factor
(VEGF), a 46-kDa homodimeric glycoprotein, is the most
potent stimulator of angiogenesis (31). It is produced by a
variety of cell types including macrophages, smooth muscle
cells, ﬁbroblasts, megakaryocytes, and neoplastic cells (2, 17).
Several studies have provided evidence for a role of VEGF
in gastric ulcer healing. For example, expression of VEGF was
detected in the margins of human gastric ulcers (32). The same
group observed that rat gastric ﬁbroblasts could express VEGF,
and this expression was enhanced when the ﬁbroblasts were
exposed to growth factors that stimulated ulcer healing (e.g.,
epidermal growth factor and hepatocyte growth factor) (33).
Expression of VEGF was observed to be elevated following
induction of gastric ulcers in rats, in parallel with increases in
angiogenesis (29).
There is also a link among prostaglandin synthesis by the
gastric mucosa, VEGF expression, and angiogenesis. Although
indomethacin suppressed ulcer healing and angiogenesis in
rats, it did not affect gastric VEGF expression (29). It has been
known for several years that cyclooxygenase-2 (COX-2) makes
an important contribution to the healing of ulcers throughout the
gastrointestinal tract (15, 20, 25, 28). Again, this may be linked to
the role of VEGF in ulcer healing. COX-2 and VEGF have been
colocalized in ﬁbroblasts in the ulcer bed (19). A selective COX-2
inhibitor suppressed VEGF release from human gastric ﬁbro-
blasts, and this could be reversed by addition of prostaglandin E2
(PGE2) to the culture medium (19).
The possibility that VEGF can be exploited therapeutically
to improve gastric ulcer healing has been investigated. Jones
et al. (10) observed enhanced ulcer healing in rats following a
single injection of naked DNA encoding VEGF. This effect
was signiﬁcantly reduced by cotreatment with an antibody
directed against VEGF. We exploited the platelet as a rich
source of VEGF to examine its effects on gastric ulcer healing.
Ulcer healing could be substantially accelerated by oral treat-
ment with a suspension of human platelets, and this effect was
reversed by immunoneutralization of VEGF (40).
In the present study, we have examined the effects of a
15-amino acid peptide that adopts a helical conformation in
aqueous solution that resembles the -helical region (17–25) of
the VEGF protein (4). This peptide has been shown to bind to
both the VEGF-1 and VEGF-2 receptors and to induce endo-
thelial cell proliferation, activate the same signaling cascades
as VEGF, and stimulate capillary formation in vitro (4). We
have examined the ability of this VEGF mimetic to inﬂu-
ence experimental ulcer healing and characterized the de-
pendence of such effects on angiogenesis and on COX-2 and
nitric oxide synthase (NOS) activity.
MATERIALS AND METHODS
Animals. All experiments were approved by the University of
Calgary Animal Care Committee. Male Wistar rats weighing 150–
175 g and male C57BL/6 mice weighing 20–25 g were obtained from
Charles River Laboratories (Montreal, Quebec, Canada). The animals
had free access to a standard laboratory chow and were housed in a
room with a 12-h:12-h light-dark cycle.
Peptides. The VEGF mimetic used in these studies is a 15-amino
acid peptide (KLTWQELYQLKYKGI), synthesized as described by
D’Andrea et al. (4). The NH2 terminus of the peptide is acetylated,
whereas the COOH terminus is capped with an amide group. The
effects of a peptide with the reverse sequence of the VEGF mimetic
(IGKYKLQYLEQWTLK) were also assessed. As with the VEGF
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mimetic, the NH2 terminus of the reverse peptide is capped with an
acetyl group and the COOH terminus ends in an amide group.
Gastric ulcer induction. Gastric ulcers were induced in mice accord-
ing to the method outlined by Wang et al. (45), with slight modiﬁca-
tions (41). In brief, a laparotomy was performed under halothane
anesthesia, and the stomach was externalized. A 1-ml syringe, with its
barrel cut and ﬁled smooth, was placed ﬁrmly against the serosal side
of the stomach. Acetic acid [200 l of 20% (vol/vol)] was added to the
syringe such that it was in contact with the serosal surface for 1 min.
The acetic acid was removed from the syringe by aspiration and
replaced with several rinses of sterile saline. The stomach was then
placed back to its original anatomical position, and the midline
incision was closed with sutures.
The procedure used to induce gastric ulcers in rats was similar to
that employed for mice, with a few differences. The rats were fasted
overnight before the surgery. Acetic acid (80% vol/vol) was applied to
the serosal wall of the stomach for 1 min with the barrel of a 3-ml
syringe.
Measurement of gastric ulcer area. In each experiment, a group of
mice or rats was euthanized on day 3 after ulcer induction. This
provided data on the size of ulcers before treatment. Groups of
animals were similarly euthanized at various times after beginning
treated with test drugs. In all cases, the stomach was excised and
pinned out (mucosal surface up) onto a wax block. A 25-mm2 paper
grid was placed adjacent to the ulcer, and a photograph was taken. The
photograph was then enlarged and used for planimetric measurement
of the ulcer area (performed by an observer unaware of the treatments
the animals had received). The area of ulceration was then converted
into units of mm2 using the paper grid as a reference. In some
experiments, samples of gastric tissue were processed for further
evaluation (e.g., immunohistochemistry).
Effects of the VEGF mimetic on ulcer healing. The ability of the
VEGF mimetic to accelerate ulcer healing was ﬁrst examined in the
mouse. Beginning 3 days after ulcer induction, mice were treated
twice-daily intraperitoneally with the VEGF mimetic (100 ng/kg) or
vehicle (sterile 0.9% saline). Groups of 5–7 mice were euthanized on
days 5, 7, and 10 after ulcer induction, and gastric ulcer areas were
measured.
Next, the ability of different doses of the VEGF mimetic to enhance
gastric ulcer healing was assessed. Beginning on day 3 after ulcer
induction, mice were treated intraperitoneally with vehicle (n 16) or
the VEGF mimetic at 25 ng/kg (n  4), 50 ng/kg (n  13), or 100
ng/kg (n  4). The mice were euthanized on day 7 after ulcer
induction for measurement of ulcer area.
Whether or not the VEGF mimetic would be effective when
administered orally was then examined. Groups of mice were treated
twice daily with vehicle or the VEGF mimetic (50 ng/kg), each being
given either intraperitoneally or orally (n  5–9 per group). The mice
were euthanized on day 7 for measurement of gastric ulcer area.
A series of experiments was performed to determine whether the
beneﬁcial effects of the VEGF mimetic on ulcer healing could be
observed with the full-length VEGF protein. Groups of 6–9 rats were
treated twice daily with VEGF (1 g/kg) or vehicle, given either
orally or intraperitoneally, beginning on day 3 after ulcer induction
and continuing until day 7. The mice were then euthanized, and ulcer
areas were measured. The dose of VEGF used in this experiment
represents an equimolar dose to 50 ng/kg of the VEGF mimetic.
The effects of the VEGF mimetic on gastric ulcer healing were then
compared with the effects of a peptide with the same length as the
mimetic but with the reverse sequence. Twice daily intraperitoneal
treatment with vehicle (n  6), the VEGF mimetic (50 ng/kg, n  6),
or the reverse sequence peptide (50 ng/kg ip, n  7) was conducted
over a 3-day period beginning on the third day after ulcer induction.
The mice were then euthanized, and ulcer areas were determined.
The experiments described above all involved the use of mice. The
following experiment was performed to determine whether the VEGF
mimetic could inﬂuence ulcer healing in rats. Beginning on day 3 after
ulcer induction, groups of 5 rats each were treated twice daily
intraperitoneally with the VEGF mimetic (50 ng/kg) or vehicle. The
rats were euthanized on day 7 after ulcer induction for measurement
of gastric ulcer area.
Gastric acid secretion. Since agents that suppress gastric acid
secretion can accelerate ulcer healing in this model (9), we examined the
possibility that the VEGF mimetic might suppress gastric acid secre-
tion in the mouse. Mice were fasted overnight and anesthetized with
halothane. The pyloric sphincter was ligated, and the mice were
allowed to recover consciousness. The mice were then treated intra-
peritoneally with vehicle (n  4) or the VEGF mimetic (100 ng/kg,
n  5). Three hours later, the mice were anesthetized with halothane,
the lower gastro-esophageal junction was clamped, and the stomach
was carefully excised. The contents of the stomach were collected into
a tube and the volume of the ﬂuid determined gravimetrically. The pH
and the titratable acidity of the gastric juice were determined, as
described previously (1).
Angiogenesis. Gastric tissues harvested at the end of some of the
above-described experiments were assessed for the extent of angio-
genesis occurring in the ulcer bed and at the ulcer margin. Microves-
sels were visualized via immunohistochemical staining of CD31, an
endothelial cell-speciﬁc marker (18). Tissue samples were immersed
in formalin-free zinc ﬁxative and embedded into parafﬁn blocks.
Sections (7 m) of the tissues were then cut and placed onto
positively charged glass slides, heated overnight at 60°C, and stored
until further processing.
The sections were deparafﬁnized and rehydrated using an ethanol
gradient and then boiled in citrate buffer for 10 min to achieve epitope
retrieval. The tissue was blocked with normal rabbit serum blocking
solution for 1 h before overnight incubation at 4°C with rat anti-mouse
CD31 antibody (Pharmingen, San Diego, CA). Afterward, an endog-
enous peroxidase-blocking step was performed with the use of 3%
hydrogen peroxide in 0.01 M PBS (pH 7.4) solution for 10 min at
room temperature. The primary antibody that bound to the tissue
sections was detected using the horseradish peroxidase-Streptavidin
method (Vector Laboratories, Burlington, ON, Canada). The mi-
crovessels were detectable once the tissue underwent a reaction with
diaminobenzidine. The stained microvessels in the granulation tissue
were counted in a blind manner under a microscope at a magniﬁcation
of 400. The results were reported as the number of microvessels per
mm2 of tissue.
Role of COX-2. COX-2 plays an important role in the healing of
ulcers in mice and rats (15, 19) and has also been shown to regulate
release of VEGF from gastric ﬁbroblasts (19). We therefore investi-
gated the possibility that COX-2 activity may be necessary for the
enhancement of ulcer healing by the VEGF mimetic. Groups of mice
with gastric ulcers were treated twice daily, from day 3 to day 7, with
a selective COX-2 inhibitor (lumiracoxib, 10 mg/kg po, n  8), with
the VEGF mimetic (50 ng/kg ip, n  14), or with both the VEGF
mimetic and lumiracoxib (n  9). An additional group of mice was
treated with the vehicles for lumiracoxib and the VEGF mimetic (1%
carboxymethylcellulose and 0.9% saline, respectively). On day 7, the
mice were euthanized and ulcer areas were measured. Lumiracoxib is
a selective inhibitor of COX-2 (8). We conﬁrmed that the 10-mg/kg
dose of lumiracoxib produced a selective inhibition of COX-2 in mice.
As described in detail elsewhere (38, 46), injection of carrageenan or
zymosan into an air pouch on the rat or mouse results in a marked
stimulation of PGE2 synthesis, with this synthesis occurring almost
exclusively via COX-2. Oral pretreatment with lumiracoxib (10 mg/
kg) reduced zymosan-induced PGE2 synthesis by 90% (P  0.01)
while not signiﬁcantly affecting whole blood thromboxane synthesis
[the latter occurring exclusively via COX-1 (37)].
Role of NOS. NO contributes signiﬁcantly to gastric mucosal
defense (42, 44) and has been shown to contribute signiﬁcantly to
experimental ulcer healing (12, 14). Expression of inducible NOS
(iNOS) has been noted in inﬂammatory cells at the base of gastric
ulcers in rodents (14). NO has also been reported to be a crucial
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mediator of VEGF-dependent angiogenesis (22, 47). Indeed, there is
evidence of reciprocal regulation between NO and VEGF in the
context of angiogenesis (11).
We performed studies to determine whether NOS activity was
required for the enhancement of ulcer healing by VEGF and further
examined whether selective inhibition of the inducible isoform of
NOS (iNOS) contributed to VEGF mimetic-induced ulcer healing.
Beginning 3 days after the ulcer induction, groups of mice were
treated twice daily intraperitoneally with saline (n  7), the VEGF
mimetic (50 ng/kg, n  7), nitro-L-arginine methyl ester (L-NAME)
(15 mg/kg, n  4), both the VEGF mimetic and L-NAME (15 mg/kg,
n 5), N6-(iminoethyl)-L-lysine (L-NIL) (3 mg/kg, n 5), or both the
VEGF mimetic and L-NIL (n  5) . On day 7, the treated mice were
euthanized, and ulcer areas were determined. L-NAME is a nonselec-
tive inhibitor of NOS (24); that is, it inhibits all three of the identiﬁed
isoforms of this enzyme. L-NIL is a selective inhibitor for the
inducible isoform of NOS (21).
Materials. Indomethacin was purchased from Sigma Chemicals
(St. Louis, MO) and was dissolved in 5% sodium bicarbonate.
Lumiracoxib was purchased from SynphaBase AG (Muttenz, Swit-
zerland) and was suspended in 1% carboxymethylcellulose sodium.
L-NAME (Sigma) and L-NIL (Sigma) were dissolved in 0.9% saline.
VEGF was purchased from Chemicon International (Temecula, CA)
and was dissolved in sterile distilled water.
Statistical analysis. All data are expressed as the means  SE.
Comparisons of data among multiple groups were performed with
one-way ANOVA followed by Dunnett’s multiple comparison test.
Comparisons between two groups were conducted using the unpaired
Student’s t-test. An associated probability of less than 5% was
considered signiﬁcant.
RESULTS
Enhancement of gastric ulcer healing by a VEGF mimetic.
Gastric ulcers were clearly visible and of relatively consistent
size 3 days after application of acetic acid to the serosal surface
of the mouse stomach. The ulcers penetrated into the submu-
cosal layer. In mice treated twice daily with vehicle, the size of
the ulcers decreased over time (Fig. 1). A signiﬁcantly more
pronounced reduction of ulcer area was observed in mice
treated twice daily with the VEGF mimetic.
The VEGF mimetic accelerated ulcer healing in a dose-
dependent manner (Fig. 2). Intraperitoneal treatment at a dose
of 25 ng/kg did not signiﬁcantly affect gastric ulcer healing
compared with that in mice treated with vehicle. However, at
doses of 50 and 100 ng/kg, the VEGF mimetic signiﬁcantly
enhanced ulcer healing.
The VEGF mimetic also signiﬁcantly enhanced ulcer heal-
ing when given orally (Fig. 3). Thus oral treatment with the
VEGF mimetic from days 3 through 7 after induction of ulcers
resulted in signiﬁcantly smaller ulcers compared with treat-
ment orally with vehicle that were not signiﬁcantly different
than what was observed in mice treated intraperitoneally with
the VEGF mimetic.
In contrast to the improved healing observed in mice treated
with the VEGF mimetic, treatment with the full-length VEGF
protein did not signiﬁcantly affect ulcer healing when given
either intraperitoneally or orally (Fig. 3). Also, intraperitoneal
treatment with a peptide with the reverse sequence of the
VEGF mimetic did not signiﬁcantly affect ulcer healing com-
pared with vehicle treatment (8.6  0.8 vs. 10.8  1.4 mm2,
respectively; n  6–7).
As in mice, the ulcers in rats were well established 3 days
after application of acetic acid to the serosal surface of the
stomach. The mean ulcer area at day 3 was 118  6 mm2. By
day 7, the mean ulcer area in rats treated with vehicle had
declined to 91  10 mm2, but a signiﬁcantly greater reduction
of ulcer area was observed in the rats treated intraperitoneally
with 100 ng/kg of the VEGF mimetic (35 15 mm2; P 0.05
vs. the vehicle-treated group; n  4 per group).
Lack of effect of the VEGF mimetic on acid secretion.
Intraperitoneal administration of the VEGF mimetic at a dose
(100 ng/kg) that had a signiﬁcant effect on ulcer healing did not
have any detectable effect on gastric acid secretion. The
Fig. 1. Time course of gastric ulcer healing in mice treated intraperitoneally
with vehicle or the vascular endothelial growth factor (VEGF) mimetic.
Treatment with vehicle or the VEGF mimetic (100 ng/kg) was initiated on
day 3 (note that the day 3 bar is indicative of the size of ulcers before initiation
of treatment). Data represent means  SE of at least 5 mice per group. *P 
0.05, **P  0.01 vs. the corresponding vehicle-treated group.
Fig. 2. Dose-dependent improvement of ulcer healing by a VEGF mimetic in
mice. The VEGF mimetic and vehicle were administered intraperitoneally
twice daily beginning on day 3. Data represent means  SE for at least 5 mice
per group. *P  0.05 vs. the vehicle-treated group.
Fig. 3. Effects of oral (po) vs. intraperitoneal (ip) administration of the VEGF
mimetic (mim) (50 ng/kg) or the full-length VEGF peptide (1 g/kg; equimo-
lar to the dose of the VEGF mimetic) on gastric ulcer healing. Twice daily
treatment was started on day 3 after ulcer induction and continued until day 7.
*P  0.05 vs. the corresponding vehicle-treated group (n  6–9 per group).
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volume of gastric juice recovered from the pylorus-ligated
stomach 3 h after administration of the VEGF mimetic did not
differ signiﬁcantly from that collected from vehicle-treated rats
(0.62  0.09 vs. 0.66  0.06 ml, respectively). The titratable
acidity in the gastric juice was also similar in the VEGF
mimetic-treated vs. vehicle-treated mice (10.4  2.7 vs.
10.1  1.3 meq, respectively).
Effects of the VEGF mimetic on ulcer healing are COX-2
independent. As in the experiments described above, mice
treated with the VEGF mimetic (50 mg/kg) from day 3 to day
7 had an average ulcer area that was signiﬁcantly smaller than
that in the vehicle-treated mice (Fig. 4). Treatment with lumi-
racoxib, a selective inhibitor of COX-2, did not affect ulcer
healing compared with vehicle-treated mice. Moreover, mice
treated with the combination of lumiracoxib and the VEGF
mimetic still exhibited a signiﬁcant improvement in the extent
of healing compared with vehicle-treated mice.
Effects of the VEGF mimetic on ulcer healing are NO
dependent. Treatment with L-NAME did not signiﬁcantly af-
fect ulcer healing (Fig. 5). However, when L-NAME was
coadministered with the VEGF mimetic, ulcer healing oc-
curred to a similar extent as was observed with vehicle treat-
ment; that is, a signiﬁcant effect of the VEGF mimetic on ulcer
healing was no longer apparent.
To determine whether selective inhibition of iNOS would
produce the same inhibitory effect on VEGF-induced enhance-
ment of ulcer healing, the effects of treatment with L-NIL were
examined. As was the case with L-NAME, treatment with
L-NIL did not inﬂuence ulcer healing compared with vehicle
(Fig. 5). However, mice cotreated with L-NIL and the VEGF
mimetic did not exhibit the extent of ulcer healing that was
observed in mice treated with the VEGF mimetic alone.
Effects of the VEGF mimetic on angiogenesis. The effects of
the VEGF mimetic on angiogenesis were examined by quan-
tifying the number of microvessels in the ulcer bed (granula-
tion tissue) and in the ulcer margin. Angiogenic microvessels
were clearly identiﬁable in the ulcer bed and ulcer margin after
staining for CD31 (Fig. 6). Little if any staining for CD31 was
detected in gastric tissue from healthy mice (i.e., no ulcers).
The number of microvessels in the ulcer margin did not change
signiﬁcantly between days 3 and 5 after ulcer induction, but
there was a signiﬁcant increase in angiogenesis in the granu-
lation tissue (Figs. 6 and 7). In mice treated with the VEGF
mimetic, the extent of angiogenesis was similar to that in the
vehicle-treated group.
Treatment with L-NIL did not signiﬁcantly affect the extent
of angiogenesis compared with vehicle-treated mice, either in
the ulcer bed or the ulcer margin (Fig. 7). However, in both
tissues, cotreatment of mice with L-NIL and the VEGF mimetic
resulted in a signiﬁcant reduction of the extent of angiogenesis
(P  0.05 compared with the vehicle-treated group and com-
pared with the group treated with the VEGF mimetic alone).
DISCUSSION
VEGF is the most potent known stimulator of angiogenesis
(31), a process integral to all types of wound healing. In the
present study, we examined the effects on gastric ulcer healing
of a VEGF mimetic modeled on a portion of the VEGF region
responsible for binding to and activating the VEGF receptors.
This pentadecapeptide signiﬁcantly accelerated gastric ulcer
healing in mice and rats. Signiﬁcant effects were observed with
a dose as low as 50 ng/kg and when given orally or intraperi-
toneally. The effect of the mimetic was speciﬁc, in that the
reverse-sequence pentadecapeptide did not signiﬁcantly affect
ulcer healing. Moreover, an equimolar dose of VEGF did not
affect ulcer healing, whether given orally or intraperitoneally.
Contrary to our hypothesis, the beneﬁcial effects of the VEGF
mimetic on ulcer healing did not appear to be due to enhance-
ment of angiogenesis.
Reconstruction of the destroyed vascular network within the
ulcerated site is integral to healing because granulation tissue
formation and tissue deposition are dependent upon nutrient
availability and nutrients are delivered to the injured site via
capillaries. As observed previously (15, 16), there was a marked
increase in microvessel density in response to the induction of an
ulcer in the stomach. However, treatment with the VEGF mimetic
did not increase the extent of angiogenesis above that observed in
vehicle-treated rats. Our hypothesis that the VEGFmimetic would
enhance angiogenesis was based on the fact that the mimetic was
designed to replicate the region of the VEGF protein responsible
for interacting with the VEGF receptors that are known to trigger
angiogenesis (4). Indeed, previous studies of the VEGF mimetic
demonstrated that this peptide can bind to the VEGF receptors,
initiate VEGF-induced signaling cascades, and stimulate angio-
genesis in vitro (4).
In considering other potential mechanisms of action of the
VEGF mimetic, we ﬁrst considered the possibility that the
Fig. 4. Effects of treatment with a selective cyclooxygenase-2 (COX-2)
inhibitor (lumiracoxib, 10 mg/kg) on the ability of a VEGF mimetic (50 ng/kg)
to improve ulcer healing in mice. Vehicle and the VEGF mimetic were
administered intraperitoneally, whereas lumiracoxib was administered orally.
Data represent means  SE, with n  8–14 mice per group. *P  0.05 vs. the
vehicle-treated group.
Fig. 5. Gastric ulcer area in mice treated with vehicle or the VEGF mimetic
(50 ng/kg ip), alone or in conjunction with a nitric oxide synthase (NOS)
inhibitor [either nitro-L-arginine methyl ester (L-NAME), 15 mg/kg ip, or
N6-(iminoethyl)-L-lysine (L-NIL), 3 mg/kg ip]. Data represent means  SE;
n  4–7 mice per group. *P  0.05 vs. the corresponding vehicle-treated
group.
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mimetic might reduce gastric acid secretion since inhibitors of
acid secretion are the mainstay of treatment of gastric ulcers
and have been shown to be effective in this model (9). How-
ever, the mimetic, when administered at a dose that was
effective in enhancing ulcer healing, had no effect on the
volume of gastric juice or its acidity.
We then examined the possibility that the beneﬁcial effects
of the VEGF mimetic were mediated via COX-2. COX-2 plays
an important role in gastric mucosal defense (43) and can be
rapidly upregulated in response to mucosal irritants, including
aspirin (6). Prostaglandins produced in the ulcerated mouse
stomach are largely derived from COX-2 (19), and inhibition
of COX-2 activity has been shown to signiﬁcantly delay ulcer
healing (15, 20, 28). Moreover, treatment with conventional
nonsteroidal anti-inﬂammatory drugs (NSAIDs) and selective
COX-2 inhibitors at doses that delay ulcer healing in rats was
also found to alter the ratios of pro- and antiangiogenic factors
(VEGF and endostatin, respectively) in serum. COX-2-derived
prostaglandins can stimulate the release of VEGF (19), whereas
NSAIDs can interfere with downstream proangiogenic signaling
of VEGF (30). In the present study, we found that treatment
with a selective COX-2 inhibitor (lumiracoxib) did not inter-
fere with the beneﬁcial effects of the VEGF mimetic on ulcer
healing in mice. Importantly, we conﬁrmed that the dose of
lumiracoxib used in these experiments produced a signiﬁcant
(90%) inhibition of COX-2 activity in the mouse.
Like prostaglandins, NO contributes signiﬁcantly to gastric
mucosal defense and healing (42, 44). Inhibitors of NO syn-
thesis have been shown to delay ulcer healing in rodent models
(12, 14), while NO donors can signiﬁcantly accelerate healing
in these models (7, 12, 15). Expression of iNOS is apparent in
inﬂammatory cells in the ulcer bed in rats (14). The delay in
gastric ulcer healing that occurs following administration of
inhibitors of NO synthesis has been associated with diminished
angiogenesis and impaired blood ﬂow at the ulcer margin (3,
12, 35). In the present study, the potential role of NO synthesis
in the actions of the VEGF mimetic was examined through the
use of a nonselective NOS inhibitor (L-NAME) and a selective
iNOS inhibitor (L-NIL). Neither of these inhibitors, alone,
signiﬁcantly affected ulcer healing when administered over a
period of 4 days. However, both inhibitors interfered with the
ability of the VEGF mimetic to enhance ulcer healing. More-
over, inhibition of iNOS activity resulted in a signiﬁcant
reduction of angiogenesis in the ulcer bed and ulcer margin of
Fig. 6. Immunohistochemical staining of the endo-
thelial cell marker CD31 in granulation tissue (A–C)
and the ulcer margin (D–F). A and D show day 3
mice, B and E show day 5 vehicle-treated mice (ip),
and C and F show day 5 VEGF mimetic-treated
mice (50 ng/kg ip).
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mice treated with the VEGF mimetic to levels even lower than
those observed in vehicle-treated rats. This is consistent with
the ﬁndings of previous studies that NO is also crucial for
VEGF-dependent angiogenesis (22, 47), but, to our knowledge,
this is the ﬁrst demonstration of a beneﬁcial effect on healing
being mediated by iNOS.
Gastrointestinal ulceration and bleeding remain signiﬁcant
clinical concerns, particularly in patients taking NSAIDs on a
chronic basis (39). Cotherapy with proton pump inhibitors is
the most common approach to preventing ulceration and pro-
moting the healing of existing ulcers in these patients. How-
ever, there is still a need for agents that will promote more
rapid and effective healing. In terms of therapeutic utility, it is
noteworthy that the VEGF mimetic was as effective in pro-
moting ulcer healing when given orally as when given system-
ically. This is in contrast to the experiments in the present
study and in a previous study (40), showing that oral (or
systemic) administration of the full-length VEGF protein did
not affect ulcer healing. Of course, it is possible that higher
doses of the full-length VEGF protein would accelerate ulcer
healing, but in the present study we tested a dose equimolar to
an effective dose of the mimetic. We previously observed that
administration of a suspension of human platelets to rats with
gastric ulcers resulted in a marked acceleration of ulcer healing
in a VEGF-dependent manner (40). We speculated that the
effectiveness of VEGF delivered in this way, vs. administration
of the VEGF itself, may indicate the need for “presentation” of
the VEGF by the platelet. For example, the release of VEGF
from platelets that have bound to damaged tissue may result in
a high local concentrations and possibly protection from pro-
teolytic actions or denaturation by luminal acid. In the case of
the VEGF mimetic, certain modiﬁcations were made to en-
hance its biological half-life; thus, the NH2- and COOH-
terminal modiﬁcations of the peptide make it more resistant
to proteolytic degradation by exopeptidases (4). Also, the
fact that the mimetic, when given orally, accelerated gastric
ulcer healing to the same extent as when given systemically
suggests that the mimetic is stable in gastric acid, at least for
a period of time sufﬁcient to affect the healing process. The
importance of VEGF in ulcer healing and/or maintenance of
mucosal integrity in humans is supported by the recent
reports of gastrointestinal ulceration occurring in patients
with colorectal cancer treated with an anti-VEGF antibody
(bevacimuzab) (27).
We utilized a mouse model of gastric ulceration that in-
volves serosal application of acetic acid for a brief period of
time. This is a clinically irrelevant means of inducing an ulcer;
nevertheless, this model has several advantages for use in a
study such as the present one. The size of the ulcers is
reproducible from animal to animal (thus facilitating studies of
rates of healing), and the ulcers are histologically similar to
human gastric ulcers (45). Importantly, a previous study using
the same model demonstrated that ulcer healing could be
accelerated by local injection of naked DNA encoding VEGF
(10), and our own studies demonstrated that ulcer healing in
this model could be enhanced in a VEGF-dependent manner by
administration of rat or human platelets (16, 40). Gastric ulcers
in humans are mainly associated with the use of NSAIDs or
with colonization of the stomach by Helicobacter pylori (H.
pylori). Unfortunately, repeated oral administration of NSAIDs
to rodents does not reproducibly result in gastric ulceration
(indeed, severe intestinal ulceration is more common, often
leading to perforation and death) (5, 26). Although there are
several animal models of H. pylori infection, gastric ulceration
is not a consistent feature of any such models.
In summary, the studies described herein demonstrate that a
15-amino acid mimetic of VEGF is a very potent stimulus for
gastric ulcer healing in rodents and is active when given orally
or systemically. The acceleration of healing by this mimetic is
dependent upon iNOS activity but not on COX-2 activity.
From the present studies, it would appear that the acceleration
of ulcer healing induced by the VEGF mimetic is not related to
an enhancement of angiogenesis in the ulcerated tissue. Given
its oral bioavailability and potency, this mimetic may have
therapeutic utility for the treatment of ulceration in the gastro-
intestinal tract.
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Fig. 7. Angiogenesis in the ulcer margin and granulation tissue (ulcer bed) of
mice treated intraperitoneally with vehicle, the VEGF mimetic (50 ng/kg), or
a selective inhibitor of inducible NOS (L-NIL, 3 mg/kg ip). Treatment was
initiated on day 3 after ulcer induction, and tissues were harvested for
determination of extent of angiogenesis (CD31-positive staining microvessels)
on day 5 after ulcer induction. Data represent means  SE, with n  12–14
mice per group. P  0.05 vs. the day 3 group; *P  0.05 vs. the
vehicle-treated group; 	P  0.05 vs. the group treated only with the VEGF
mimetic. There were no statistical differences between the vehicle and the
VEGF mimetic-treated groups.
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